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Understanding compound-induced histopathology in rat liver using 
gene expression network methods 
Summary 
 
Current drug discovery is a lengthy and costly pipeline; it takes between twelve and 
fifteen years and costs $1-2 billion (USD). As such, any compound failures represent a sunk 
cost – exacerbated if such failures occur later in the pipeline. Compound and drug induced 
liver injury is a significant cause of failures. Current progress to tackle this is based on 
systems biology, and so falls within the field of toxicogenomics. As such, the databases in the 
public domain are crucial to progress. DrugMatrix and Open TG-GATEs were identified as 
containing large, in vivo transcriptomics data with histopathological observations as 
endpoints, a proxy for toxicity. Due to the size and chemical variety of the databases, data-
driven methods led to the novel creation of histopathology signatures, which accounts for 
dependence between histopathology observations (Chapter 2). 
Six toxic groups were determined for DrugMatrix and 13 for Open TG-GATEs, and were 
analysed with a view to enable classification, namely, what is revealed in the gene expression 
profiles when the histopathology phenotype was present. This led to determining gene-
phenotype associations, both known and novel. An example of a novel association was the 
match of the histopathology signature of ‘glycogen accumulation, mixed infiltration and 
lymphocytic inflammatory cell infiltration’ to fructose metabolism, gluconeogenesis, and 
chemokine response pathways (Chapter 3). Concordance was found between 
histopathologically related toxicity groups between databases and their co-expression 
networks. 
From here, the co-expression network methods were applied to determine the 
concordance of gene expression across time (one day to four/five days), database 
(DrugMatrix and Open TG-GATEs), and toxicity group. This found underlying biological 
terms such as RNA transport, ribosome biogenesis and translation as well as toxicity-specific 
terms (aminoacyl t-RNA synthesis in metabolic processes for the histopathological 
observations of glycogen accumulation, cellular infiltrate, hepatocellular necrosis and fatty 
change in liver. Crucially, this work determined that the toxic group membership plays a 
more significant role in gene co-expression networks compared to the time point of the gene 
expression measurement (Chapter 4). 
In conclusion, data driven clustering was performed to create histopathology signatures. 
Using these, the usefulness of transcriptomics data was determined both to classify toxic state 
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(gene expression data measured when the phenotype was present) and to determine how 
consistent it is over time scales. This work provided a framework for the comparison of co-
expression networks for the deconvolution of gene expression data with respect to a 
phenotype. 
 
Benjamin Alexander-Dann 
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1. Introduction to Toxicity within Current Drug Discovery 
 
Current drug discovery is a lengthy and costly pipeline; it takes between twelve and 
fifteen years and costs $1-2 billion (USD).1–3 As such, any compound failures represent a 
sunk cost – exacerbated if such failures occur later in the pipeline. There has been a 
significant increase in the investment and technologies for drug development but these have 
failed to increase the rate of approved drugs. This is the so called “innovation gap” and has 
two main drivers: efficacy and safety.4,5 Whilst there are numerous reasons for the former, 
this work focuses specifically on the latter. 
The aim of this work is to identify biological indicators of unsafe compounds, using 
chemical structure, gene expression and biological pathways. This is two fold: to identify 
how toxic end points are reached (biological understanding) and to determine whether 
particular biomarkers can identified for effective compound screening in drug development 
(predictive toxicology). 
The toxicity of drugs is a significantly regulated area, with changes enforced regularly, 
particularly after high profile cases, such as the thalidomide scandal.6 This scandal, termed 
the “biggest medical disaster in history” lead to severe birth defects for 10,000 children.7 This 
was not an isolated incident. 462 medicinal products were removed from the marketplace 
between 1953 and 2013, with the most common reason being hepatotoxicity.8 In addition to 
these withdrawals, there were postmarketing safety events for 32% of the 222 novel 
therapeutics that were approved by the United States of America’s Food and Drug 
Administration (FDA) between 2001-2010. Furthermore, safety issues accounted for 24% of 
clinical trial failures between 2013 to 2015 – the second highest cause, behind efficacy.9 The 
issue is mirrored in a non-clinical setting: 40% of compound failures in preclinical studies 
were due to toxicity.10 From these failures (from post marketing to preclinical studies), the 
importance of safety and toxicology studies is shown to be paramount. There are four main 
types of toxicity: geno-, nephron-, cardio-, and hepato- toxicity. These are reviewed briefly in 
Table 1-1.  
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Compound- and drug-induced liver injury, a part of hepatotoxicity is of particular 
relevance for drug development, due to the liver’s function in the metabolism of xenobiotic 
substances. 
 
 
Table 1-1 The four main types of unacceptable toxicity failure: genotoxicity, nephrotoxicity, 
cardiotoxicity and hepatotoxicity. 
Type Definition 
Genotoxicity Destructive effect on a cell’s genetic material (DNA/RNA). These 
toxins are split into three main groups: carcinogens (cancer-
causing), mutations (causing mutations) or teratogens (birth defect 
causing).11 
Nephrotoxicity Damage or destruction of kidney function causing kidney-specific 
detoxification and excretion failures. These toxins are split into 
mechanism based groups: changes in glomerular hemodynamics, 
tubular cell toxicity, inflammation, crystal nephropathy, 
rhabdomyolysis, and thrombotic microangiopathy.12 
Cardiotoxicity Damage to heart muscle or heart electrophysiology dysfunction. 
These structural and functional toxicities are difficult to separate as 
structural damage often results in reduced function and vice 
versa.13 
Hepatotoxicity Injury to hepatocytes (liver cells) or bile duct cells. Main 
mechanisms include bile acid-induced hepatocyte apoptosis, 
adhesion molecules and oxidant stress in inflammatory liver 
injury, cytochrome P4502E1-dependent toxicity, peroxynitrite (its 
formation correlates with necrosis), and mitochondrial 
dysfunction.14  
 
1.1 Compound and Drug Induced Liver Injury 
 
Compound and drug induced liver injury (DILI) in human patients is a diagnosis of 
exclusion, within human patients (i.e. all other plausible causes have been ruled out).15 It 
manifests clinically as cholestasis and/or hepatocellular damage, which can include changes 
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to metabolism, transport protein function and direct hepatocellular damage.16,17 Whilst it has 
significant human implications, pre-human trials are the focus of this work. It is proposed 
that the pathogenesis of DILI is split into three main mechanisms: direct cell stress, direct 
mitochondrial stress, and immune reactions (extrinsic to cell).18 The mechanisms and 
phenotypes of DILI are discussed in the following sections. 
1.1.1. Mechanisms of drug-induced liver injury 
 
Figure 1-1 Mechanisms of drug-induced liver injury. Drugs either directly cause cytotoxicity 
or via immune response with antigen-presenting cells. The drugs, or reactive metabolites, 
can cause damage through oxidase stress, mitochondrial damage, bile acid accumulation, 
endoplasmic reticulum stress, cell death or DNA damage. Affected cells can produce danger 
signals, such as “danger associated molecular patterns” (DAMPs), which favour the release 
of cytokines. This figure was adapted from Chen et al.19 
A toxic drug (or compound) either directly causes cellular damage or indirectly, via 
activation of the immune system, as shown in Figure 1-1. The drug, or its reactive 
metabolites formed in the liver, cause either oxidase stress, mitochondrial damage, bile acid 
metabolism, endoplasmic reticulum stress, cell death or DNA damage. Antigen-presenting 
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cells (a heterogeneous group of cells that mediate immune response by processing and 
presenting antigens for lymphocytes) cause injury to hepatocytes, which in turn release so-
called “danger signals” (e.g. damage associated molecular patterns molecules, DAMPs).  
Oxidase stress occurs due to an imbalance of reactive oxygen species (ROS) formation 
(via the c-Jun N-terminal kinase, JNK) and detoxification via Nrf2/Keap1.20 More 
specifically Nrf2 plays an important part in liver injury: it both promotes the HO-1 gene 
which encourages autophagy (the act of cleaning out damaged cells) and so protects the liver, 
and it regulates antioxidant-relevant genes, However, Keap1 can bind to Nrf2 and inhibit its 
activity, resulting in liver injury via the Trx-PI3K/AKT-HIF1-HO-1/CyclinD1 signalling 
pathway. This is shown in Figure 1-2. Increased ROS has been linked to direct damage to 
DNA, lipids, proteins, enzymes, and intracellular glutathione depletion.21 
 
Figure 1-2 The role of Nrf2 in acute liver injury. Nrf2 protects the liver through regulating 
antioxidant genes including sulfiredoxin-1, glutamate-cysteine ligase, and glutathione 
peroxidase-2 (blue lines), and promoting the HO-1 gene and hence autophagy. However, 
Keap1 can bind to Nrf2 and inhibit it and the Trx-PI3K/AKT-HIF1-HO-1/CyclinD1 
signalling pathway and so promoting liver injury. This figure has been adapted from Xu et 
al.22 
Mitochondrial damage plays a critical role in both steatosis and hepatic necrosis via 
activation of cellular death pathways. Crucially, cell death here is an active process, not a 
passive biochemical overwhelming of cells.23 Bile acid accumulation occurs when bile acid 
(the production of which is one of the primary functions of the liver) is not adequately 
transported away from the liver. The inhibition of bile salt export pump, am ATP-dependant 
transporter, has been implicated in the accumulation of bile salts (which are cytotoxic), which 
in turn activate oxidative stress and FAS pathways.24 These proposed mechanisms are closely 
related to the histopathology observations associated with liver damage).  
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1.1.2  Histopathology observations to characterise drug-induced liver injury 
 
Histopathology is often used to characterise DILI (and, indeed, all forms of disease 
states). The microscopic observations can even be used in an unsupervised manner to define 
disease states.25 It is defined as “the microscopic study of animal and plant tissues by the 
staining, sectioning and examining under microscope”.26 These observations are expert based 
but  considerable work there has been done by the eTox Consortium to create the 
‘histopathology ontology’ (HPATH) which standardises terms and their relation to each 
other.27 The characteristics for DILI and liver injury more generally are summarised in Table 
1-2. These phenotypes are used to define end points in toxicity studies and so their definition 
is crucial for comparisons between different experiments. Additionally, these terms are used 
in this work to define toxic groups. 
 
Table 1-2: Histopathology observations that are common in liver injury. The observations 
are taken from Robert Maronpot28 and the descriptions from the Histopathology Ontology 
which was developed by the eTox Consortium27 
Histopathology 
Observation 
Description 
Glycogen deposition  Irregular and poorly defined clear spaces in the cytoplasm 
(rarefaction) usually with centrally located nuclei. 
Fatty change Hepatocellular vacuolation is usually lipidic in nature, 
nevertheless, vacuoles may develop from increased 
intracellular fluid contents within vesicles and/or by swelling 
of cytoplasmic organelles; Fatty change can also be observed 
in combination with other hepatotoxic injuries (e.g., chronic 
liver toxicity, degeneration, inflammation, and necrosis) or 
nutritional disturbance (e.g. diet, vitamin A excess) in both 
animals and man. 
Pigmentation Pigmentation in most tissues consists of lipofuscin and/or 
hemosiderin, usually present in interstitial macrophages. 
Nevertheless other cells are capable of accumulating 
pigments (e.g. hepatocytes, renal tubular cells). Pigments 
may also originate from specific compounds or their 
metabolites. Special stains and/or other investigations are 
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necessary to further characterize the origin of the pigments 
in a given tissue. 
Degeneration Degeneration is a deterioration of living cells following an 
insult, with the possibility to reverse after removal of the 
insult. Degenerated cells show morphological changes (e.g. 
cell swelling, increased eosinophila/basophila of the 
cytoplasm) which are in context of biochemical, metabolic 
and/or mechanical disruption of the cell physiology and 
integrity. 
Cell death Grouping of all changes affecting individual or group of 
cells, characterized by partial or total overwhelming of the 
cell capacity to maintain a biochemical and morphological 
equilibrium, resulting in various type of morphologies. 
Hypertrophy Increase in volume of a tissue or organ produced entirely by 
enlargement of existing cells, without contribution of 
generation of new cells (such as in hyperplasia). Most organs 
undergoing hypertrophy can have an increase in cell number 
as well, to a certain extent. 
Karyomegaly An increase in nuclear size and is occasionally noted in rat 
tubular epithelium. it is presumed to represent repeated 
nucleic acid replication without nuclear divisions or 
cytokinesis but its pathogenesis is uncertain. 
Inflammatory cell 
infiltrates 
When the various combinations of inflammatory cell 
infiltrates occur in the absence of other features of 
inflammation 
Proliferation response: 
non-neoplastic 
(hyperplasia) 
Nonneoplastic proliferation of hepatocytes which appear 
unaltered but may have slightly basophilic cytoplasm and/or 
prominent nuclei. An evidence of prior or ongoing 
hepatocellular damage is present. 
Proliferation response: 
neoplastic 
Neoplastic cells are said to be transformed because they 
continue to replicate, apparently oblivious to the regulatory 
influences that control normal cell growth. This is caused by 
DNA mutations that are (for the most part) acquired 
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spontaneously or induced by environmental insults. These 
genetic but also epigenetic changes alter the expression or 
function of key genes that regulate fundamental cellular 
processes, such as growth, survival, and senescence, 
resulting in an abnormal growth. 
 
 
Despite knowledge of some of the mechanisms in liver injury and the associated 
phenotype changes, liver toxicity remains an issue. A prevailing thought that has led to the 
current issues in drug development is the “target focused drug design”. The majority of drug 
development focuses on the identification of a protein target that is associated with a 
particular disease or phenotype.4 In this approach, a biologically relevant target is identified 
and modelled. Compounds are created and optimised to hit this target and modulate its 
activity towards the desired effect. Compounds are then progressed through the pipeline, but 
human toxicity is assessed later. The case has been made for the inclusion of toxicology 
studies in the exploratory phase of drug development.29,30 This relies on inherent target 
safety, chemical series safety and safety in compound lead optimisation. Inherent target 
safety is mostly concerned with novel targets. For example, anti-cancer compounds designed 
to hit proteins on the RAS-RAF-MEK-ERK pathway for anti-tumour potential result in skin 
toxicity, akin to the toxicity seen with multikinase and EGFR inhibitors.31 This is almost 
expected as RAF and MEK are major downstream mediators of EGFR signalling.32 Chemical 
series safety and safety lead optimisation relate to whether particular physiochemical 
properties that are known toxicants are included in the optimisation of target modulation.33 
However, the sole focus on physiochemical descriptors is not sufficient for improved 
compound attrition rates.10 Whilst control of these physiochemical properties is important, 
they fail to correlate well or meaningfully with the complicated and nuanced toxicity end 
points. 
The case for “systems biology” approaches and predictive models of late stage toxicity is 
clear. This is used in the field of toxicogenomics, defined as “combin[ing] toxicology with 
information-dense genomic technologies to integrate toxicant-specific alterations in gene, 
protein and metabolite expression patterns with phenotypic responses of cells, tissues and 
organisms”.34 The field of toxicogenomics is discussed in Section 1.3. A key part to 
toxicogenomics is the use of ‘omics data. 
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1.2 Measurement of gene expression data 
 
Gene expression measurement is the measurement of RNA, produced from the 
transcription of DNA and translated to create polypeptides.35 There are three main methods to 
measure this data: real-time quantitative polymerase chain reaction (RT-qPCR), microarray 
analysis and RNA sequencing (RNA-Seq). These have been recently reviewed here 36. RT-
qPCR is the most sensitive of the three but is a more intensive protocol and can only be 
performed for a limited number of genes. As such, it tends to be used to validate the 
expression measured from the other, high throughput methods. 
Microarrays were developed in the 1990s.37 A microarray is a series of wells on a chip, to 
which probes corresponding to known genomic locations of an organism of interest have 
been bound, as shown in Figure 1-3. These probes are selectively designed nucleotide 
sequences. It is to these probes that fluorescently tagged reverse transcribed sample cDNA, 
made from the sample RNA of interest, bind. The location (i.e. which probe) and intensity of 
fluorescence determine the type and amount of RNA present in the original sample.38 Due to 
the nature of the design, only known genes (i.e. those whose RNA product that binds to 
specifically designed probes) can be measured, limiting de novo studies. Therefore lncRNA 
and miRNA are not suitable for this method, as they are part of less well known genomic 
regions. Additionally, it assumes that a perfect match occurs between the probes and cDNA, 
and that no probe is saturated (i.e. no further binding possible), leading to noise in the 
measurements.39 Despite this, microarray technologies produce concordant, biologically 
relevant signals.40 It is an established technique and there are numerous computational 
packages encoding algorithms for the analysis of microarray platforms. 
In comparison, RNA-Seq does not measure fluorescence, but directly counts the amount 
of reverse transcribed cDNA. Therefore, it can detect previously unknown sequences, and so 
is more valid for determining unknown genomic sequences or novel transcripts. Additionally, 
it can measure lower levels of cDNA than microarray experiments. However, it is currently a 
more expensive method (although the cost gap is diminishing).  
The concordance between microarrays and RNA-Seq has been studied in the context of 
liver toxicity in rats.41 Compound-induced gene expression data from 5 known toxicants was 
measured using both microarray and RNA-Seq platforms. High levels of agreement were 
observed (78% overlap of differentially expressed genes) but RNA-Seq did find more 
differentially expressed genes and enriched pathways.  
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Figure 1-3 Gene expression measurement using microarray platform technology, A) shows 
the design of the platform, which is a series of wells that contain specific oligonucleotide 
sequences to match up with the DNA of chosen sample. B) shows the processes of expression 
measurement.  
 
 
 
1.3 The field of toxicogenomics 
 
The field of toxicogenomics is defined as “combin[ing] toxicology with information-
dense genomic technologies to integrate toxicant-specific alterations in gene, protein and 
metabolite expression patterns with phenotypic responses of cells, tissues and organisms”.34 
It has numerous aims, namely to predict toxic endpoints, to determine the mechanism of toxic 
action, and to identify biomarkers of toxicity.42 Data limitations have narrowed the scope of 
the field to transcriptomics data (which are more numerous and systematic).43 
A prominent, early limitation of this field was the lack of large-scale, public, suitable 
databases. However, this has changed over the last eight years, with the introduction of two 
toxicogenomics-specific databases; namely DrugMatrix44 and Open TG-GATEs.45 Both of 
these contain in vivo, compound-induced gene expression data, along with histopathology 
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annotations. Additionally, complementary transcriptomics databases provide compound-
induced gene expression data that can be integrated with toxicity-related endpoints from 
other databases. These include the cell-based Connectivity Map46 and the Library of 
Integrated Network Cellular Signatures (LINCS).47 Section 1.3.1 discusses all of the 
databases in detail. 
The field of toxicogenomics can be broadly split into method-based categories: 
differential gene expression analysis and its pathway enrichment, compound signature 
matching, protein-protein interaction networks, and the use of co-expression network 
methods. Numerous research papers involve the integration of multiple methods. 
 
1.3.1 Toxicogenomic databases 
 
Toxicogenomic databases are strictly those containing ‘omics’ data with toxicity related 
endpoints (see DrugMatrix and Open TG-GATEs section below). However, these are 
complemented by orthogonal data sources that can add mechanistic or predictive aspects to a 
study. These include the ‘Comparative Toxicogenomic Database’48 (which includes pairwise 
associations between compounds, genes, pathways, and phenotypes), pathway databases, 
Gene Ontology lists, and transcription-gene associations. There are also large, purely 
transcriptional databases (Table 1-5). 
 
1.3.1.1 DrugMatrix and Open TG-GATEs 
 
DrugMatrix was created as a commercial database in 2006, before being brought into the 
public domain in 2011. It focuses on compound induced rat data, with transcriptomics data 
from liver, kidney, heart, and thigh muscle. Crucially, it provides histopathology, 
haematology and other clinically relevant data on these rats during and post exposure. It was 
described in detail in previous work.44 Additionally, it contains a complete matrix for protein 
activities. 
Open TG-GATEs45 was published in 2012 and follows a similar protocol to 
DrugMatrix. The acronym stands for ‘toxicogenomics project-genomics assisted toxicity 
evaluation system’ and was created in Japan. It also contains compound-induced gene 
expression data and histopathology observations from rat liver and kidney. Additionally, it 
contains cell line data on rat and human primary hepatocytes. It should be noted that, while 
there are similarities with DrugMatrix, there are a few significant differences: the difference 
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in the dose that the rats were exposed to. DrugMatrix defines the maximum tolerated dose as 
‘a 5-10% reduction in weight gain over five days of daily dosing’, and an alternative dose 
that was determined from literature and expert opinion. Open TG-GATEs, on the other hand, 
has three dose levels. The highest is defined as that which induces the ‘minimum toxic effect 
over the course of a 4 weeks toxicity study’. The other two are 30% and 10% of this level. 
This level sets a lower dose, which reflects the difference in chemical spaces that these 
databases cover. DrugMatrix selected its compounds to reflect a wide area of therapeutic 
chemical space. Open TG-GATEs selected compounds that had previously been annotated as 
nephro- or hepato- toxic. Both are summarized in Table 1-3. 
These databases form the basis for hypothesis generation and validation in this work, 
and their data is reviewed in detail in Chapter 2. 
 
Table 1-3 Summary of DrugMatrix and Open TG-GATEs databases. Both contain in vivo 
gene expression data and histopathology observations, and so are suited for this study. FED 
is fully effective dose (expert defined), MTD is maximum tolerated dose (5-10% weight loss 
over a 5-day daily dosing study), ‘highest dose’ is defined as ‘minimum toxic effect over the 
course of a 4 weeks toxicity study. 
 
DrugMatrix Open TG-GATEs 
Source Iconix/National Toxicology 
Program (NTP) 
Japanese National Toxicogenomics 
Project 
Number of 
compounds 
~600 170 (156 public compounds) 
Gene 
expression 
Organ data 
4 (heart, liver, thigh muscle and 
kidney) 
2 (liver and kidney), plus cell lines 
(primary human and rat hepatocytes) 
Time points 
(days) 
0.25, 1, 5, 7,14 0.25, 1, 4, 8, 15, 29 
Dose type Single and repeat dose Single and repeat dose 
Dose level 2 levels (FED and MTD) 3 levels (ratio of 1:3:10 where 10 is 
‘highest dose’) 
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1.3.1.2 The Comparative Toxicogenomics Database (CTD) 
 
The Comparative Toxicogenomics Database (CTD) is a publicly available database, first 
created in 2004.49 It aims to understand the effect that environmental exposures have on 
human health and consists of manually curated associations between chemicals, genes, 
diseases, and phenotypes as well as inferred interactions. There are monthly data releases that 
update its known associations (ctdbase.org). The current (as of August 2019) database’s 
contents are shown in Table 1-4. 
 
Table 1-4 Curated associations within the Comparative Toxicogenomics Database (August 
2019) 
Curated Interaction type Counts 
Chemical – Gene 1,972,064 
Gene - Disease 39,276 
Chemical - Disease 216,163 
Phenotype based interactions 208,058 
 
In addition to these manually curated associations, the CTD also infers associations 
between its constituents. This is based on the hypothesis that “Chemical A is associated by 
inference with Disease B because Chemical A has a curated interaction with Gene C, and 
Gene C has a curated association with Disease B”. This increases the number of gene - 
disease associations by 26,240,322 and the number of chemical – disease associations by 
2,457,395.  
 
1.3.1.3 Transcriptomics databases 
 
Transcriptomics databases may also be used in the determination of toxic mechanisms of 
action, and so are applicable to this work. There are two groups of databases: those under the 
same/very similar experimental conditions (Connectivity Map (CMap) and LINCS), and 
those that collect a variety of gene expression data from individual scientific studies (Gene 
Expression Omnibus (GEO)50 and ArrayExpress51). These are summarised in Table 1-5 
CMap and LINCS are related databases that originated with CMap in 2006, with the gene 
expression profiles of 164 small-molecule compounds. This was upgraded to 1,309 drugs 
across five cell lines.46 To follow up on this work and to widen the chemical space of the 
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xenobiotics, LINCS was created. Whilst continually updated, it contains the gene expression 
profiles of over 20,000 compounds on up to 77 cell lines, measured on the L1000 chip. This 
chip measures 978 so called landmark genes (selected to represent the greatest proportion in 
gene expression variation) and predicts the remainder of the genome-wide expression levels. 
However, there are concerns on the internal reliability and replicability of this approach.52,53 
GEO is a repository of gene expression data, taken and uploaded from a wide range of 
experiments and so varies considerably with species, in vivo/in vitro, dose, and whether the 
profile is that of disease or compound-induced.50 ArrayExpress is almost a sub-database of 
GEO, where the gene expression data have been curated (there are a few unique 
experiments).54  
 
Table 1-5 Summary of public transcriptomic databases 
Database Source of gene 
expression 
data 
Samples Link 
Connectivity 
Map 
5 human cell 
lines 
6,400 http://clue.io/cmap  
LINCS 77 human cell 
lines 
1,328,09855 http://www.lincsproject.org/ 
GEO 16 species, 
variety of cell 
lines 
3,167,476 https://www.ncbi.nlm.nih.gov/geo/ 
ArrayExpress 16 species, 
variety of cell 
lines 
2,381,203 https://www.ebi.ac.uk/arrayexpress/ 
 
1.3.1.4 Pathway databases 
 
A biological pathway is a set of reactions that lead to the creation of a certain product or 
change in the cell. It can include altering the expression of genes or the creation of new 
proteins or fats.56 Within gene expression, pathways are considered as the set of genes that 
act together to perform a biological function. As such, there are multiple databases that bring 
together these gene sets, termed pathways. The definitions between databases change and 
may even be considered as somewhat arbitrary.57 As pathways consist of genes, they are 
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species specific, and so care must be taken in their use. Commonly used pathway databases 
are summarised in Table 1-6. When considering rat models, the ‘Rat Genome Database’ 
provides the relevant pathways.58 
 
Table 1-6 Commonly used pathway databases. Table adapted from Alexander-Dann et al.59 
Database Description Comment Link 
WikiPathways60 Integrated collection of 
different pathway 
databases 
 
Freely available, 
everyone can curate  
https://www.wikipath
ways.org/ 
Reactome61 Large database with a 
focus on signaling 
pathways 
 
Free and the largest 
database of its kind 
https://reactome.org/ 
Gene Ontology62 
Reviewed:63 
Gene product 
functional annotation 
in a hierarchically 
structured ontology  
 
Contains annotations 
at multiple levels of 
specificity 
http://www.geneontol
ogy.org/ 
Kyoto Encyclopedia 
of Genes and 
Genomes64 
One of the oldest 
pathway databases; 
content constantly 
updated 
Very good metabolic 
pathway collection, 
but became partly 
paid for use and at 
some parts the 
curation is arbitrary 
 
http://www.genome.j
p/kegg/ 
Ingenuity Pathway 
Analysis65 
A complete user-
friendly pathway 
analysis tool, which is 
even capable to predict 
causal relationships 
 
Capable of 
sophisticated 
analysis, commercial 
https://www.qiagenbi
oinformatics.com/pro
ducts/ingenuity-
pathway-analysis/ 
Molecular Signature 
Database66 
The Broad Institute’s 
pathway signature 
collection 
Different molecular 
signatures can be 
determined 
according to user, 
easy compatibility 
with GSEA 
http://software.broadi
nstitute.org/gsea/msi
gdb 
 
 
 
1.3.2 Methods used in the field of toxicogenomics 
 
The previous section focused on the different databases that find application in the field. 
The following highlights their usage and current developments. These are roughly split via 
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method type, although successful research does integrate many types. Herein, determining 
differentially expressed genes (DEGs), pathway enrichment, and co-expression network 
methods shall be discussed. These methods are not solely used in the field of toxicogenomics 
and have been used in the study of disease, compound mode-of-action and cellular biology. 
 
1.3.2.1 Differentially Expressed Genes (DEGs) 
 
Once gene expression data has been measured by microarray or RNA-seq and processed, 
it can be applied towards toxicity-related endpoints and anchoring phenotypes. The most 
common way to do this is to determine differentially expressed genes. A gene is considered 
differentially expressed if its observed expression is significantly different between two 
experimental conditions.67 This is statistically determined using fold change (expression in 
one condition divided by its expression in the other condition) which is expressed in 
logarithmic form (usually base 2). The logarithm is to ensure linear mapping when 
considering the experimental conditions in reverse: for example, if a gene is expressed four 
times more in one case, its fold change equals 4. The reverse of that (i.e. underexpressed) 
would be 0.25. Extending this means anything overexpressed is mapped between one (no 
change) and infinity (hypothetically), whereas anything underexpressed is mapped to 
between zero and one. This non-linear mapping can lead to biased weights in gene expression 
values’ importance. A corrected t-test can then be used to determine the false discovery rate 
(and so statistical significance).68  
Separately to the fold change method, methods that utilise a gene’s entire expression 
distribution have been developed (e.g. Bayesian and counting methods). ‘Limma’ is a 
commonly used computational package (in R) that determines DEGs using linear modelling 
and Bayesian estimates of a gene’s variation.69  
There are other parametric and non-parametric tests to determine DEGs, including rank 
product, t-statistics and B-statistics. A study compared these methods, quantified by their 
ability to predict rat nephrotoxicity.70 All the methods generated “reasonably performing 
classifier[s]”, however t-test and fold change were the most balanced performance in 
specificity, accuracy, and sensitivity with 83.6%, 81.0%, and 72.2% respectively. 
Interpretation and enrichment of this data give insight into the roles that PPAR, RXR, and D 
vitamin receptor play in the tubule toxicity pathways. This is illustrative of the importance 
that compound-induced gene expression data can play when determining toxic mechanisms 
of action. 
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There are limitations with solely determining differentially expressed genes: 
investigations suffer from high dimensionality (a large number of genes are being measured, 
but with a small number of repeats) and noise which masks the compound-induced signal. 
The latter is important if a compound does not have a large transcriptional level effect, so the 
gene expression profile is dominated by noise.71,72 Hence, integrating this DEGs with known 
biological pathways may help to deconvolute the signal.  
 
1.3.2.2 Pathway enrichment 
 
Pathway enrichment is split into two categories: functional class scoring (FCS) and over-
representation analysis (ORA).73 Both methods require gene sets for their enrichment, as 
reviewed in Section 3.1.1.4 and Table 1-6. 
FSC scoring is based on assessing the expression changes of genes in a list (gene set) 
between different experiments (i.e. treated vs. control). Its most common method is gene set 
enrichment analysis (GSEA).74 GSEA was used in investigations into polycyclic aromatic 
hydrocarbons in rat liver.75 It suggested the involvement of PPAR signaling pathway within 
the liver. 
Over-representation analysis determines whether a pathway (gene set) is overrepresented 
in a list of genes (usually DEGs). This is typically performed with a Fisher exact test, 
hypergeometric distribution test or Jaccard Index. A one-sided Fisher exact test is the same as 
the hypergeometric distribution test, with the null hypothesis being that there is no significant 
association of the gene set with the DEGs. The chances of this occurring are calculated using 
Table 1-7. 
Table 1-7 2x2 confusion matrix for Fisher Exact Test 
 DEG All other genes 
Genes in pathway a b 
All genes not in 
pathway 
c d 
 
The calculation for obtaining such a set is: 
 ! = 	$!"#! %$$"%$ %$!"#"$"%!"$ % = $!"## %$$"%% %$!"#"$"%#"% % = 	 (' + ))! (, + -)! (' + ,)! () + -)!'! )! ,! -! (' + ) + , + -)!  
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Where !&'" is the binomial coefficient and ! is factorial. The p-value here represents the 
probability that this association would occur by chance. Often, harsh p-value cutoffs are used 
to determine statistical significance. Pathway databases may contain thousands of gene sets 
and so using the above calculation alone would result in an unacceptable number of false 
positives (e.g. if using a cutoff of p = 0.05 to determine significance and 1,000 pathways 
being tested, 50 pathways would be incorrectly labelled as significantly associated to the 
DEGs. To get around this problem, many ‘multiple hypothesis testing’ corrections are 
available and are summarized in Table 1-8. 
 
Table 1-8 Summary of multiple hypothesis testing corrections 
Correction Method Comment 
Bonferroni Divide the computed score 
by the number of tests 
May be very stringent 
Benjamini-Hochberg P < (). where p is the p 
value, i is the rank (of the 
particular p value compared 
to all those tested), m is the 
total number of tests and Q 
is the accepted false 
discovery rate 
Less sensitive to overall 
number of tests 
Benjamini & Yekutieli P < ()	+	$()). where c(m) 
allows for dependency of 
tests. 
Incorporates the dependence 
of tests 
 
 
The main limitation to all pathway-based enrichments is the curation bias of the database; 
there is a bias towards the study of genes involved where current research is more invested 
e.g. genes implicated in cancer which then have more entries within pathway databases. 
Additionally, it cannot give entirely novel mechanisms of toxicity as the genes must be 
annotated with pathways for them to occur. However, such methods do put gene-level 
outputs into context.  
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1.3.2.3 Co-expression network methods 
 
Gene expression experiments result in high dimensional data, as previously noted. As 
such, methods can make use of the entire measured transcriptome to make use of gene – gene 
interaction behaviour, and so provide sophisticated dimensionality reduction. Co-expression 
network methods use such information, based on the hypothesis that highly correlated and 
co-expressed genes are involved in the same biological functions. They are split into two 
predominant categories: data-driven or knowledge based. They have recently been reviewed 
here.76 
Early work with co-expression networks was a method called “context likelihood of 
relatedness”.77 Here, the mutual information of genes creates a similarity network by the 
estimation of a gene-gene interaction pair against the full mutual information distribution per 
gene. This was applied to 2,4,6-trinitrotoluene (TNT) exposed human and rat hepatocytes.78 
This showed concordance between human and rat cells, an important consideration when 
determining suitable animal models for human toxicity. 
Following on from “context likelihood of relatedness”, the ‘iterative signature algorithm’ 
(ISA) was created.79 This method results in ‘modules’, which are groups of highly correlating 
genes. The method relies on starter (or input) genes, which are thought to belong to separate 
modules. These are typically generated from hierarchical clustering gene expression matrices 
or may be randomly generated. Once created, the modules are refined by adding/removing 
genes iteratively to determine correlation. Gene and condition thresholds determine the 
modules size and stringency. Such restrictions allow for genes to be in multiple modules. 
However, the starter genes may mean that the final modules are local, not global, minima and 
so the method may not find all true modules for a given simulation. 
The most prominent method is ‘weighted gene co-expression network analysis’ 
(WGNCA).80 It has been shown to be one of the most suited methods for determining the 
main expression and functional effects of samples within a dataset.76 It is non-exhaustive (i.e. 
genes do not have to fit into a module but can be left out) and, whilst two main parameters 
are required to be optimised, it is shown to be relatively (to other module determining 
methods) insensitive to parameter tuning. The method to determine modules consists of three 
main steps: (i) creation of a gene-gene correlation matrix based on gene expression 
signatures, (ii) weighting of co-expression, (iii) module determination. These are shown in 
Figure 1-4. Initially, all genes (or probes, depending in the input levels) are correlated against 
each other, resulting in a numerical matrix with values between zero and one (for an unsigned 
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network, -1 and 1 for a signed network). This is then raised to a softpower, b. This parameter 
is determined from the data to optimise the ‘scale free’ property of the network. 
 
 
Figure 1-4 The overview of weighted gene co-expression network analysis (WGCNA). 
Adapted from Alexander-Dann et al.59 
 
Scale free properties in biological networks are a controversial issue. ‘Scale free’ 
refers to the power law distribution of degree (aka some nodes in the network have many 
more connections than others, and the distribution of these connections follows a power law). 
This is modelled in Figure 1-5 where P(k) is the fraction of nodes that have k connections. It 
is a central claim in network research that “real world” networks, particularly complex, 
biological networks, obey this distribution. Whether or not the biological network truly 
follows this distribution, by raising the correlation network to the power of b, the signal to 
noise ratio is changed. The softpower is usually in the range 5 – 20, and so high correlation 
values (close to one) will be relatively unchanged. Low correlation values (near zero) are 
assumed to be noise and are reduced heavily, e.g. 0.9./= 0.35 compared to 0.3./	= 5.9	4	1001. 
 
Figure 1-5 Scale free distribution of connections in complex networks. P(k) is the proportion 
of nodes that have k connections. 
 
The result of this forms a weighted adjacency matrix for all genes (nodes) in the 
network. The next step is to use the network properties (specifically node’s connectivity) to 
further weight the matrix into a topological overlap matrix (TOM). This is done by 
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determining the pairwise topological overlap, w, of two nodes, i and j. For biological 
networks, the suitable equation for this is:81,82 6(2 = 7(2 + '(2min;<( , <2> + 1 − '(2 	 
 Where 7(2 is the connectivity between two nodes, '(2 is the adjacency weighting from the 
above matrix, and ki is the total connectivity of one node. This results in a similarity metric 
which can be convert to a dissimilarity network by simply subtracting from 1.  This network 
is complete (i.e. all genes are connected to all other genes with a non-zero weight). 
Hierarchical clustering of this dissimilarity  matrix genes defines modules, making a non-
complete network. Thus, creating the output of WGCNA. 
It is the output of WGCNA that is most useful: each module represents a sub graph of the 
original network formed of highly connected genes which can be enriched with pathway level 
annotations (in the same manner as the DEG to pathway enrichment). The modules can be 
related to external information (e.g. phenotypes) and they may be tested to determine their 
conservation in other networks.83 This has been performed in many applications, including 
non-toxicity related endpoints, to determine gene markers for diseases, weight phenotypes, 
and growth and development as endpoints.84–87 
 
Co-expression methods have significant potential in understanding and predicting 
compound-induced toxicity. However, they are reliant on correlation arguments. Correlation 
is not the same as causation and so care must be taken in the reliability of the created 
associations. As they are indeed based on correlation, there are also requirements for a larger 
number of repeats (the standard of 3 repeats is not enough for robust correlation). Co-
expression network methods are sensible data dimensionality reduction tools and represent 
the state of art. 
 
1.3.3 Developments in the field of toxicogenomics 
 
1.3.3.1 Differentially expressed genes and pathway enrichment 
 
Determining differentially expressed genes has been used to suggest hypotheses for toxic 
mechanisms of action. For example, they were used to determine the response of 
neuroblastoma cells to exposure to MPP+ (1-methyl-4-phenyl-pyridinium, a known toxicant 
and a model for Parkinson’s disease).88 Here, differentially expressed genes (DEGs) were 
defined by their fold change (greater than 1) and the microarray was confirmed by RT-qPCR. 
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This list of DEGs included two transcription factors, namely c-Myc proto-oncogene and 
RNA-binding protein 3, suggesting their involvement in toxicity development. The same 
toxicant was further examined in a time-dependant manner, which lead to the determination 
of 79 DEGs, which passed strong significance cut-offs.89,90 Histones, such as H2AFJ, H3F3B, 
HIST1H2AC, HIST1H2BD, HIST1H2BG, and HIST1H2BK, were differentially expressed 
and this suggested that the destabilization of nucleosomes occurs after initial exposure to the 
xenobiotic. These techniques help to understand the mechanisms of toxicity. Furthermore, 
DEGs can be used as biomarkers and/or variables in predictive models.91–93 
It was used in the mechanistic study of crystalline silica on human lung adenocarcinoma 
cells (A549) and rat lungs.94 Crucially, this study showed concordance between the two 
species, and it suggested novel mechanisms of silica-induced pulmonary toxicity; centred on 
different dual specific phosphatase (DUSP1 and DUSP5) and growth arrest proteins 
(GADD34 and GADD45a). The method was similarly used in melphalan-induced vascular 
toxicity.95 Here, DEGs were mapped to transcription factors, with functional modules 
indicating MYC and NF-kB1 showing significant involvement. From these, the molecular 
mechanism of melphalan-induced vascular toxicity was hypothesised and five small 
molecules were suggested to modulate the crucial transcription factors, and so overcome the 
toxicity.  
Further work, from DEGs and enriched pathways was performed on data from Open TG-
GATEs.96 Reactome pathways were used to construct a “computationally predicted adverse 
outcome pathway” i.e. a workflow describing all the key molecular and cellular steps, from a 
compound binding a molecular target all the way to the observable phenotype, for a 
compound with specific histopathology phenotype. It was exemplified with the mechanism of 
fatty liver disease, caused by exposure to carbon tetrachloride. Similarly, methods with 
pathway analysis and protein-protein interaction networks have been studied to determine 
toxic pathways in liver injuries in rat.97,98 These studies showed decreased metabolism in the 
liver, with increased inflammatory pathway activity, as well as activation of fibrosis relevant 
genes. 
Determining DEGs and pathway level enrichments forms the basis of most 
toxicogenomics analyses. However, the output of these may be hundreds of DEGs and 
pathways, with no clear way of prioritising them, so determining primary mechanisms of 
action is not always clear. To that end, further methods that use gene expression data have 
been developed, most notably, the use of co-expression network methods. 
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1.3.3.2 Co-expression network methods 
 
ISA has been applied to both DrugMatrix and Open TG-GATEs, to determine gene 
expression signatures associated with ‘chemical and drug-induced liver injuries’.99 Using 
clinical pathology, organ weight and histopathology observations, the authors generated 25 
diverse toxicity-related endpoints. Theses labels were shown to not be independent and were 
highly correlating. These labels segregated gene expression profiles, from which modules 
were created. Using ISA, hierarchical clustering, support vector machines, DEGs, and 
protein-protein interaction networks, different modules were created. ISA created modules 
with high enrichment of liver injury (taken from gene-disease relationships in the 
comparative toxicogenomic database). Specifically Sod2, Gulo and Car3 were associated 
with periportal lipid accumulation, and Obp3 and Rgn were associated with periportal 
fibrosis. Open TG-GATEs was used to validate this approach. Associations to acute kidney 
injury (AKI) have also been determined with this method.100 The created modules were used 
to determine a list of 30 genes, to be used a biomarker of AKI. They were validated against 
randomly selected genes and those from additional AKI gene expression data from GEO. 
Genes known to be involved in AKI were found, including Havcr1, Clu, and Tff3. 
Importantly, novel gene – phenotype associations were found, namely Cb44, Plk2, Mdm2, 
Hnmt, Macrod1, and Gtpbp2. These were confirmed in non-compound induced AKI models, 
implying a non-specific response to injury.  
Toxicity relevant studies have also been performed with WGCNA. The dose-dependent 
carcinogenic effect of chloroprene in mice was investigated.101 Two modules were shown to 
be important in differentiating the outcome, with seven hub genes (genes with the highest 
number of connections, quantified by degree) found critical for carcinogenesis of lung tissue. 
Numerous studies have used WGCNA in application for rat liver toxicity. Using a 
toxicity label based on the histopathology observation of ‘liver periportal fibrosis’ (with 
grade of minimal or above), relevant modules were determined.97 This was based on 
DrugMatrix data and found known, relevant genes such as TIMP1, APOA1, CTGF, 
LGALS3, TGFB1, and MMP-2, within a module annotated with ‘liver cirrhosis’ from the 
CTD (N.B. liver fibrosis is not a curated term) and the ‘extracellular matrix organization’ GO 
term. Novel associations were also determined: LGMN, a cysteine protease that functions in 
ECM remodeling, and PLIN3, which is known to be involved in the pathogenesis of steatosis. 
Interestingly and importantly in predictive toxicology, gene expression profiles of known 
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toxicants were linked to the phenotype before it was visible, showing the potential for early-
stage biomarkers. 
Sutherland et al. also used WGCNA to associate gene expression data with 
histopathology from DrugMatrix and Open TG-GATEs.102 They created one large network 
across all different compound-induced gene expression data and determined 415 specific 
modules. They then enriched these modules with particular histopathology observations 
based off their relevant correlation with a module’s eigengene (the dimensional reduction of a 
module to a vector with a value for each sample). This generated a large number of 
phenotype-gene associations, both novel and established. They suggested a mechanism of 
hepatotoxicity involving endoplasmic reticulum stress and Nrf2 activation. 
 
 
 
1.3.4 Limitations of the field of toxicogenomics 
 
Despite the advancement and progress in both methods and available data, there are 
numerous issues facing the field of toxicogenomics. Most notably, the evidence generated in 
the studies has not yet achieved regulatory approval for a new chemical entity.103 However, 
they are being used for the ‘weight-of-evidence’ evaluations for substances’ mode-of-action. 
The reliability, reproducibility and efficacy are crucial for incorporation into both drug 
development and regulatory approval. This paves the way for the work in this thesis to be 
presented. 
 
1.4 Overview of work contained in thesis 
 
This work presents an analysis of DrugMatrix and Open TG-GATEs across different data 
domains: chemical structure, physicochemical descriptors, histopathology and gene 
expression spaces. From these, the creation of histopathology signatures is performed to 
generate toxic groups (Chapter 2). 
These groups are then analysed through the use of gene expression data (via co-
expression networks) to determine gene-phenotype associations at the time point of the 
phenotype (Chapter 3) and preceding time points (Chapter 4). 
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2. Evaluation of data domains to classify toxic classes in 
DrugMatrix and Open TG-GATEs 
 
DrugMatrix and Open TG-GATEs are two large, public databases that contain data from 
various different domains: chemical structure, gene expression, histopathology, bioactivity, 
and clinical chemistry. With the wealth of data available, it is vital to determine which data is 
toxically relevant, within the domains of all the measured limitations. Herein, these domains 
are assessed with a view to determine data driven toxic groups. 
First, chemical structure and physiochemical properties are analysed. The compounds in 
the toxicogenomics databases represent at range of chemical structures, and so are compared 
to ChEMBL104 and DrugBank.105,106 used to represent known chemical space and known 
therapeutic spaces, respectively. ChEMBL contains 1,879,206 million compounds, with over 
15 million activities. DrugBank contains 13,345 chemical entitites, of which ~2,000 are 
approved small molecule drugs and ~6,000 are experimental small molecules. As such, these 
make ideal comparisons to DrugMatrix and Open TG-GATEs, on a chemical structure and 
physico-chemical property level.  
Second, the effect of primarily time point and secondarily of dose on gene expression is 
considered. Data exploration of the gene expression data available is performed, tied to time 
point, and related to histopathology observations.  
Third, histopathology data from DrugMatrix and Open TG-GATEs are analysed to 
determine their (in)dependence for the classification of toxic groups. Due to differences in 
nomenclature used, terms are mapped to the histopathology ontology HPATH. This was 
developed by the eTox consortium for the standardisation of histopathology terms between 
experiments.  
The resulting toxic groups were investigated with respect to their similarities and 
differences in terms of compounds, doses, time points and histopathology observations.  
 
2.1 Methods 
 
2.1.1 Chemical space 
 
The compounds selected for DrugMatrix and Open TG-GATEs were compared to each 
other and to ChEMBL (version 24)104 and DrugBank (version 5.0.1)105, using structural 
fingerprints and physico-chemical descriptors. Standardised SMILES were downloaded from 
each database, and processed in KNIME (version 3.7.2).107 Physico-chemical descriptors 
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were calculated for all of DrugMatrix and Open TG-GATEs, and randomly selected subsets 
of 50,000 compounds from ChEMBL and DrugBank, using the RDKit 2D “calculated 
descriptors” node. The descriptors are shown in Table 2-1.108 Principle component analysis 
(PCA) was then performed to compare the variation of chemical properties between 
databases, using the ‘fviz’ function on normalised data from the ‘factoextra’ package109 in R, 
version 3.5.1.110 
The chemical structures in each of the databases were compared using ‘extended 
connectivity fingerprints’ (ECFP), a circular, topological fingerprint, with radius = 4. The 
Tanimoto similarity of ECFP4 fingerprints between every compound in each database and its 
5 nearest neighbours in all databases was calculated using Python (version 3), in the same 
method as previous papers.111–113 In short, SMILES were converted to binary fingerprints. 
Tanimoto similarity is the determined using the overlap of matching bits. The Mann-
Whitney, Kolmogorov–Smirnov and t-tests were then performed to determine the 
significance of the resultant distribution using the ‘stats’ package in R.110 
 
Table 2-1 2D physico-chemical descriptors calculated used RDKit that build the basis for 
further analysis 
2D descriptor Description 
SlogP logP (partition coefficient) using surface area contributions 
SMR molecular refractivity 
LabuteASA Labute's Approximate Surface Area 
TPSA topological polar surface area 
AMW atomic molecular weight 
ExactMW exact molecular weight 
NumLipinskiHBA number of Lipinski hydrogen bond acceptors 
NumLipinskiHBD number of Lipinski hydrogen bond donors 
NumRotatableBonds number of rotatable bonds 
NumHBD number of hydrogen bond donors 
NumHBA number of hydrogen bond acceptors 
NumAmideBonds number of amide bonds 
NumHeteroAtoms number of heteroatoms 
NumHeavyAtoms number of heavy atoms 
NumAtoms number of atoms 
NumRings number of rings 
NumAromaticRings number of aromatic rings 
NumSaturatedRings number of saturated rings 
NumAliphaticRings number of aliphatic rings 
NumAromaticHeterocycles number of aromatic heterocycles 
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NumSaturatedHeterocycles number of saturated heterocycles 
NumAliphaticHeterocycles number of aliphatic heterocycles 
NumAromaticCarbocycles number of aromatic carbocycles 
NumSaturatedCarbocycles number of saturated carbocycles 
NumAliphaticCarbocycles number of aliphatic carbocycles 
FractionCSP3 fraction of sp3 hybridised carbon atoms 
Chi[1v-4v] and Chi[1n-4n] graphical parameters representing the "complexity" of a 
molecule 
HallKierAlpha Hall and Kier Alpha value (representing connectivity of a 
molecule) 
kappa[1-3] Hall and kier Kappa values 
slogp_VSA[1..12] logP using virtual surface area (subdivided surface area) 
smr_VSA[1..10] molecular refractivity (subdivided surface area) 
peoe_VSA[1..14] total partial charges of heavy atoms 
MQN[1..42] molecular quantum numbers 
 
 
 
2.1.2 Gene expression methods 
 
The DrugMatrix114 data was accessed via Gene Expression Omnibus (GSE57822).115 
Only Affymetrix whole genome GeneChip Rat Genome 230 2.0 Array data, from liver at 1 
and 5 days of daily dosing was selected using R, as these time points had the highest amount 
of histopathology observations (477 individual histopathology observations at 5 day and 188 
at 1 day (the next highest)).110 This process gave a total of 1004 CEL files, covering 129 
unique compounds and 159 compound-dose instances which also possessed histopathology 
data in DrugMatrix. Compound-dose pairs were considered as separate instances as they 
result in different histopathology profiles. Open TG-GATEs45 was accessed via 
ArrayExpress51 (E-MTAB-800) and liver data from the 1 and 4 day stage of daily dosing 
were selected, giving a total of 714 CEL files, covering 67 compounds and 109 compound-
dose instances.  
All CEL files for DrugMatrix and Open TG-GATEs were pre-processed using the Robust 
Microarray analysis (RMA)116 functions and quartile normalisation in the ‘affy’ package in R 
(version 1.62).117 Differentially expressed genes were determined using the ‘limma’ 
package69 as follows: Linear models were fitted (lmfit) to the distribution of probe intensities 
for each compound -dose-time point instance and controls. A moderated T-test was 
performed to determine the significance of the overlap of the distribution. The cut-off for the 
Benjamini-Hochberg corrected p-value was 0.05 and the log2(fold change) cut-off was 2. 
Probes were matched to genes using ‘AnnotationDbi’ and ‘Rat2302.db’.118 When multiple 
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probes matched to a single gene , the probe with the smallest p-value was used.119 When a 
probe matched to multiple genes, the log fold change and the p-value from the probe was 
used for each. 
Principle component analysis (PCA) was then performed to compare the variation of 
chemical properties between databases, using the ‘fviz’ function on the RMA adjusted data 
from the ‘factoextra’ package109 in R, version 3.5.1.110 Multidimensional scaling was 
performed using the ‘cmdscale’ function.  
To determine the consistency of compound induced gene expression, each compound-
dose-time-point instance was correlated internally (against each biological repeat) and 
externally (against other compound-dose-time-points). The RMA pre-processed gene 
expression data from DrugMatrix was linearly correlated (Pearson’s product-moment 
coefficient) in R, using the base package. 110 Gaussian kernel smoothing was used for ease of 
visualization, within the same R package.110 The two distributions can be seen in Figure 2-1. 
A Kolmogorov–Smirnov test (KS) test was applied to determine if the distributions were 
significantly different. 
 
 
Figure 2-1 Gaussian kernel density plots showing the correlation of gene expression data, 
when correlations are calculated for the same compound-dose-timepoint (red, n = 109) and 
not (black, n = 187889) for the DrugMatrix database. A KS test was performed, to test for the 
independence of each data. The null hypothesis (that both samples are from a larger 
distribution) was rejected with a p value = 0.0456, and the test statistic, D = 0.130. This 
means that whilst the size effect is small, compound-dose-timepoint gene expression profiles 
are more internally correlated.  
 36 
The results of this showed a small (size) but statistically significant differentiation 
between instances with the same compound and dose, to those without. This shows that there 
is a compound, dose, and time point signal within the gene expression data.  
 
2.1.3 Histopathology methods 
 
Histopathology data were downloaded from DrugMatrix.120 Each histopathology 
observation was mapped to the Histopathology Ontology, HPATH, which was created by the 
eTox consortium.27 The full list of mappings can be seen in Supplementary Table 1. 
Histopathology data for Open TG-GATEs were downloaded.121 In this case no mapping to 
HPATH could be performed due to the lack of meta data for each observation. However, 
matches of histopathology terms between DrugMatrix and Open TG-GATEs could still be 
determined by manual comparison. 
The histopathology data distributions over organ, time point, database and severity were 
plotted in Knime and R. Histopathology observations were treated as vectors, and their 
independence were tested using the Fisher’s exact test. The p value was corrected using the 
Benjamini-Hochberg correction. This was performed using the ‘stats’ package in R.  
In order to consider all measured histopathology readouts simultaneously histopathology 
signatures were created, which is represented in Figure 2-2. The histopathological assays 
from DrugMatrix mapped to HPATH were binarized using a cut-off ≥ 1 (slight) (see Figure 
2-2 for the severity score levels) for each rat, as in previous studies.97 These were 
summarized per compound-dose condition as a signature and identical signatures (in binary 
space) grouped together. This created sets of compound-dose instances at the 5 day stage that 
had identical observed histopathology profiles (in binary representation of readouts). While 
the time element of readouts is also scientifically relevant, this is considered in Chapter 3. 86 
signatures were determined in total, however only 6 signatures consisted of more than 4 
compound-dose instances. Histopathology signatures were created from Open TG-GATEs 
directly, without mapping to HPATH due to a lack of available information on the 
observations in English. 30 signatures were determined in total, 20 of which were larger than 
4 compound-dose instances (Supplementary Table 2). 
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Figure 2-2 Visualisation of the histopathology mapping to derive a histopathology signature. 
The heatmap above represents the data as available in DrugMatrix, using a scoring scheme 
from 0-5 (observation not present to severe). Each histopathology assay was mapped to a 
base HPATH term, resulting in many-to-one mappings or near synonyms. The score was 
binarized using a cut-off of minimal or above. The number of histopathology observations is 
therefore reduced and, as a result, more compound-dose instances could be mapped to the 
same histopathological signature (as indicated by the blue arrows). 
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2.2 Results and discussion 
 
2.2.1 Chemical space 
 
DrugMatrix contains around 600 unique compounds and Open TG-GATEs contains 170 
(of which 154 have publicly available structures). It has already been mentioned that the 
choice here reflects two different perspectives: a wide selection of therapeutic chemical space 
was selected for DrugMatrix, whereas Open TG-GATEs contains compounds that were 
previously annotated with either hepatoxicity or nephrotoxicity.  
The full list of compounds in each are readily available from their respective 
sources.120,121 There are 104 unique therapeutic classes in DrugMatrix, as shown in Table 2-2, 
out of a comprehensive list of 120 (according to the 2007 DrugMatrix Calculations White 
paper).120 From this, the wide coverage of therapeutic space can observed. 
 
Table 2-2 Therapeutic classes of DrugMatrix compounds, showing the wide therapeutic 
space from which compounds were selected for DrugMatrix. 
 
Therapeutic class of DrugMatrix Compounds 
Acidifying Agents Corticosteroids 
Acne Preparations Corticosteroids, Systemic 
Alkalinizing Agents Corticosteroids, Topical 
Amino acid metabolism Disorders Dental Agents 
Analgesics, Non-Opioid Diuretics 
Analgesics, Opioid Drug Delivery Systems 
Analgesics, Topical Drug Dependence Therapy 
Anorexiants General Anesthetics, Inhaled 
Antianginals General Anesthetics, Intravenous 
Antiarrhythmic Agents Gonadal Hormones 
Antibacterials Gout-Related Agents 
Antibacterials, Systemic Hematopoietic Agents 
Antibacterials, Topical Hemorrheologic Agents 
Anticoagulants Hemostatic Agents 
Antidepressants Hypolipidemic Agents 
Antidiabetic Agents Hypothalamic Hormones 
Antidiarrhea Agents Immunomodulants 
Antidotes Immunostimulants 
Antiemetics Immunosuppressants 
Antiepileptics / Anticonvulsants Insecticides / Pesticides 
 39 
Antifungals Irrigating Solutions 
Antifungals, Systemic Laxatives 
Antifungals, Topical Local Anesthetics 
Antiglaucoma Agents Miscellaneous Anti-Asthmatic Agents 
Antihistamines Miscellaneous Anti-Inflammatory 
Agents 
Antihypertensive Agents Miscellaneous Cardiac Agents 
Antimanic Agents Miscellaneous Dermatological Agents 
Antimigraines Miscellaneous Gastrointestinal 
Agents 
Antineoplastics Miscellaneous Ophthamological 
Agents 
Antiparasitics Movement Disorders 
Antiplatelets Mydriatics 
Antipruritic Agents Neurodegenerative Disorders 
Antipsychotics Nonsteroidal Anti-Inflammatories 
(NSAIDs) 
Antirheumatic Disease Modifying Agents Opiate Antagonists 
Antiseptics / Disinfectants Oxytocic 
Antispasmodic Agents Parasympatholytic Agents 
Antitussives, Expectorants and Mucolytic Agents Parasympathomimetic Agents 
Antiulcers Pituitary Hormones 
Antivirals Prokinetic Agents 
Antivirals, Systemic Psoralens 
Antivirals, Topical Radioactive Agents 
Anxiolytics Respiratory Stimulants 
Appetite Stimulants Sedatives/Hypnotics 
Astringents Skeletal Muscle Relaxants 
Bone Mineral Homeostasis Sympatholytic Agents 
Bronchodilators Sympathomimetic Agents 
Central Stimulants Thrombolytic Agents 
Cerebral Vascular Disorders Thyroid and Antithyroid Agents 
Chelating Agents / Heavy Metal Antagonists Uricosuric Agents 
Chemoprophylactics / Preventives / Protectives Vasodilators 
Congestive Heart Failure Vasopressors 
Contraceptive Hormones Vitamins / Minerals / Nutrients 
 
As Open TG-GATEs does not solely contain therapeutics, such annotations are not 
available. However, its selection criteria of nephro- or hepato- toxic annotation limits its 
coverage of therapeutic space.  To compare the chemical space, physico-chemical descriptors 
and compound descriptors from both databases and two external databases (ChEMBL and 
DrugBank) are compared. It is expected that DrugMatrix and Open TG-GATEs cover 
 40 
different chemical subspace to each other, and less varied chemical space compared to 
ChEMBL and DrugBank. ChEMBL and DrugBank are larger databases and the likelihood of 
finding more similar compounds is higher. To combat this, a subsample of 50,000 of each is 
used. 
Physico-chemical descriptors are used to capture the structural and physical properties of 
compounds. Figure 2-3 shows the result of the PCA analysis. The first three dimensions 
cover 57.5% of the total variance within the dataset. The subsets of ChEMBL and DrugBank 
cover DrugMatrix and Open TG-GATEs, indicate that the latter two do not cover novel 
chemical descriptor space. This indication is not proof as the total variance captured was 
57.5%. 
Structural comparisons of the databases show the diversity of both DrugMatrix and Open 
TG-GATEs. Each set of box plots in Figure 2-4 represent the tanimoto similarity the five 
most similar compounds in each of the databases, measured against all (or, in the case of 
ChEMBL and DrugBank, a subset) the compounds of the database of interest. In each case, 
ChEMBL and DrugBank have higher average similarity (~0.5 and ~0.4). This may reflect the 
larger size of these databases; each contain 50,000 compounds and so there is a higher chance 
of more similar compounds being measured. The dissimilarity of DrugMatrix and Open TG-
GATEs (~0.3 and ~0.2 respectively) shows that both DrugMatrix and Open TG-GATEs 
contain a wide variety of chemical structural space.  
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Figure 2-3 Principle Component Analysis (PCA) of the physico-chemical descriptors of the 
compounds in DrugMatrix, Open TG-GATEs, and a random subsection of ChEMBL and 
DrugBank. Each compound from the databases projected onto the first three dimensions. 
DrugMatrix and Open TG-GATEs are within the areas of ChEMBL and DrugBank, reflecting 
a less varied chemical space. 
 
To determine whether DrugMatrix and Open TG-GATEs contain diverse compound 
structure, the distributions of their five most similar compounds were tested using three 
methods: Mann-Whitney, t-test and the Kolmogorov–Smirnov (KS) test. The results of these 
are shown in 
 
 
 
Table 2-3. The distributions for similarity of the 5 closest neighbours were found to 
be significantly different in every case, except between DrugBank and ChEMBL. As 
DrugBank is a subset is a subset of ChEMBL (although the random sub-samples do not 
overlap here). The subsetting is to account for the difference in size of database. The T-test 
assumes a normal distribution of the test distributions, and these are plotted in Supplementary 
Figure 1. 
 42 
 
 
Figure 2-4 Distributions of ECFP4 similarity (Tanimoto) for each database. Across all 
boxplots, ChEMBL and DrugBank show higher amounts of similarity between compounds. 
DrugMatrix and Open TG-GATEs show low levels of similarity within themselves, showing 
the diversity in their structures. CH = ChEMBL, DB = DrugBank, DM = DrugMatrix, TG = 
Open TG-GATEs 
 
 
 
 
Table 2-3 Results of chemical structural similarity distribution testing. 0 represents a p value 
less that 1.6E-180. KS is the Kolmogorov–Smirnov test. This analysis helps to visualise the 
boxplots in Figure 2-4 to determine the significance between the distributions. It quantises 
that when using the DrugMatrix and Open TG-GATEs compounds, there is no observed 
difference between ChEMBL and DrugBank. DrugMatrix and Open TG-GATEs are 
consistently significantly distinct from each other, representing their different selection 
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criteria. Such differences mean each are outside the applicability domain of models built one 
the other, in chemical space. 
   
Test (p value) 
Compound 
database 
distribution comparison 
databases 
Mann-
Whitney 
KS t 
ChEMBL ChEMBL DrugBank 0 0 0 
ChEMBL DrugMatrix 0 0 0 
ChEMBL Open TG-
GATEs 
0 0 0 
DrugBank DrugMatrix 0 0 0 
DrugBank Open TG-
GATEs 
0 0 0 
DrugMatrix Open TG-
GATEs 
0 0 0 
DrugBank ChEMBL DrugBank 1.70E-11 0 4.09E-24 
ChEMBL DrugMatrix 0 0 0 
ChEMBL Open TG-
GATEs 
0 0 0 
DrugBank DrugMatrix 0 0 0 
DrugBank Open TG-
GATEs 
0 0 0 
DrugMatrix Open TG-
GATEs 
2.06E-138 0 1.74E-146 
DrugMatrix ChEMBL DrugBank 4.15E-01 4.32E-01 3.89E-01 
ChEMBL DrugMatrix 5.63E-53 0 2.16E-60 
ChEMBL Open TG-
GATEs 
6.59E-82 0 3.42E-98 
DrugBank DrugMatrix 6.89E-48 0 9.07E-55 
DrugBank Open TG-
GATEs 
1.54E-77 0 7.64E-92 
DrugMatrix Open TG-
GATEs 
8.20E-11 4.16E-08 2.73E-14 
Open TG-
GATEs 
ChEMBL DrugBank 2.19E-01 2.03E-01 2.83E-01 
ChEMBL DrugMatrix 3.00E-28 0 2.21E-32 
ChEMBL Open TG-
GATEs 
1.05E-40 0 2.86E-48 
DrugBank DrugMatrix 2.51E-24 0 4.24E-27 
DrugBank Open TG-
GATEs 
1.18E-37 0 2.62E-42 
DrugMatrix Open TG-
GATEs 
2.88E-05 5.48E-04 1.67E-06 
 
Compound structures and their physicochemical descriptors have been used for the 
prediction of toxicity (and more specifically drug-induced liver injury)122, and when in large 
enough sample sizes and closely defined endpoints, this has achieved high levels of success, 
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with that study showing correct classification rates up to 89%. However, more complicated 
end points are no so easily modelled. Compound structure does not correlate well with 
systems level data – for gene expression, for example, compounds with a Tanimoto similarity 
greater that 0.85 only have a one in five chance of a similar gene expression profile when 
under identical conditions.123 
 
2.2.2  Gene expression results 
 
The effects of time, dose and database on gene expression data was determined using 
principle component analysis, multi-dimensional scaling and hierarchical clustering, which 
are shown in Figure 2-5, Figure 2-6 and Figure 2-7 respectively. In the first instance (Figure 
2-5) very little can be concluded about the time dependency of DrugMatrix as only 24.4% of 
the variance is covered by the two dimensions. For Open TG-GATEs, 75.5% of the variance 
is covered and no distinguishable clusters of time and dose (low, medium and high) were 
formed. From this, it can be concluded that the individual compound-dose instance plays a 
more significant role than dose and time. Therefore, grouping of compound-dose instances to 
form a toxic set must be taken on data domain that is not purely gene expression data. 
To determine the differences between the databases, the multidimensional scaling 
(Figure 2-6) shows DrugMatrix and Open TG-GATEs distinction. This result was copied in 
the hierarchical clustering of instances (Figure 2-7) (using Euclidean distance). Additionally, 
this showed that, within a database, instances were a similar distance from each other (they 
merged at heights 30-50). This is promising as, within a database, it shows that the instances 
have a similar behaviour (in relationship to each other). This allows hypotheses that are 
developed in one to be tested in another. 
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Figure 2-5 Principle component analysis (PCA) of the DrugMatrix and Open TG-GATEs 
gene expression data at 1 and 4/5 days to show the effect of time and dose (for Open TG-
GATEs). A) PCA of DrugMatrix showing the overlap of 1 and 5 day data, 24.4% of variance 
was covered the two dimensions shown and so little can be concluded in this plot. B) PCA of 
Open TG-GATEs at 3 dose levels and 2 time points, showing a lack of distinction between 
variables, 75.5% of variance was covered the two dimensions shown. No obvious clusters 
can be seen. DM = DrugMatrix, TG = Open TG-GATEs. 
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Figure 2-6 Multi-dimensional scaling of DrugMatrix and Open TG-GATEs gene expression 
data, showing the database differentiation. From this, differentiation between the databases 
can be seen using MDS. 
 
Figure 2-7 Hierarchical clustering of gene expression data from DrugMatrix and Open TG-
GATEs at multiple time points. The two databases are separately clustered. Both databases 
have trees joining at similar heights (between 30 and 50) showing similar distances between 
the compound-dose instances. This means that the differences between samples with a 
database is similar regardless of database, and so the databases can be used to validate 
hypotheses generated in the other. 
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2.2.3  Histopathology results 
 
Histopathology observations, as previously noted, form the basis of toxicity and 
disease phenotypes. Herein, their distribution across organs, databases and scores were 
displayed, setting the background for any future study based on this work. 
 For DrugMatrix, Figure 2-8 shows the distributions of distinct histopathology 
observations across all organs (liver, kidney, mesentery, heart, thigh muscle, spleen and 
intestine). These reflect all observed phenotypes that occur at least once. The liver and kidney 
contain the largest number of observations. For Open TG-GATEs, observations were only 
made of the liver and kidney. It can be seen that Open TG-GATEs has a higher number of 
histopathology observation, despite the smaller number of samples. Across both, the liver has 
a higher cumulative number of observations. Therefore, the liver is more likely to be of 
interest in this work. 
 Histopathology observations are quantised into ordinal data types, consisting of a rank 
but no quantitative comparison between each rank. The ranks are not present (no observation 
was seen), present, minimal, slight, moderate and severe. Figure 2-9 shows the distribution of 
these scores for both databases. It can be seen that the highest number of observations are not 
present, representing a large imbalance in class sizes. Both databases tail off at higher 
severity levels. This creates a problem when modelling and grouping instances together. As 
such, binarization occurs, usually at the ‘minimal’ score.100,102 This cut off is used in further 
work. 
 
 
Figure 2-8 Histopathology observations in DrugMatrix (A) and Open TG-GATEs (B). These 
show the organs that were viewed microscopically for toxicity phenotypes. 
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Figure 2-9 Distribution of severity scores in DrugMatrix (DM) and Open TG-GATEs (TG) 
for both the liver and kidney. Most observations are negative, and so create a biased dataset. 
 
 In the introduction, it was suggested that modelling single observations is not 
reflective of the systems-level, in vivo response to a stimulus. This hypothesis was tested via 
determining the independence of each histopathology observation. This was performed using  
Fisher’s Exact Test in a pairwise fashion. The results can be seen in  
Figure 2-10. The significant terms shows both inter- and intra- organ histopathology 
observation dependency in a data-driven manner for all organs. Interestingly, the organ 
groups are reflected in the significance: observations tend to be dependent on others within 
the same organ. An interpretation of this is based on cell type. Within an organ, the cell types 
are the same and so the response is similar on a histopathology observation level. Between 
tissues, cell types are more different and so the response is different. Inter-organ dependency 
suggests either failure in experiment (i.e. mixed/contaminated tissues) or a systematic 
response. This could suggest an inflammatory response that affects the whole organism. 
Either way, models of histopathology observations should take such relationships into 
account. Here, this is done using histopathology signatures, created across all observations. 
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Figure 2-10 Significance of dependency between histopathology observations. Each 
histopathology observations in DrugMatrix was tested for dependency against all other, 
using the Fisher exact test. The FDR corrected p-value was defined to be significant if less 
than 0.05. Each red square represents a significant p value, meaning the two observations 
cannot be considered independent. For ease of visualisation, these have been grouped by 
organ. Inter- and intra- organ dependency can be seen, with higher levels for the latter. 
Therefore, each observation must be considered with the others when binning to create 
groups to model, especially those within the same organ.   
 
In DrugMatrix, 6 groups were found to have a minimum of 5 compound-dose 
instances, resulting in at least 15 gene expression profiles. The histopathology signatures of 
these groups are shown in Table 2-4. These 6 groups are non-distinct and share a total of 5 
mapped histopathology terms between all of them. All of these are from the liver, which is 
expected from the distribution of the observations between assays. The compounds 
comprising this groups are shown in  
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Table 2-5. As can be seen, compounds with a wide range of therapeutic purposes are 
found to cause identical responses, on a histopathology level, in rats. 
The appearance of inflammatory cells and infiltration reflects their co-occurrence 
previously found in this dataset.102 The groups of compounds associated with different 
histopathology profiles range in size from 5 to 10 instances and are made up of 
therapeutically diverse compounds, and there is no link between annotated mode of action 
class and assigned histopathology group apparent.  
The histopathological signatures are defined by only five histopathological 
observations in total, namely lymphocytic inflammatory cell infiltration, mixed infiltration, 
lipidic vacuolation (fatty change), glycogen accumulation, and hepatocellular necrosis (Table 
2-4), out of 146 possible observations pre-mapping. The many remaining assays are hence 
too rare, on either an individual or a combined level, to achieve sufficiently large groups for 
network correlation analysis. Lymphocytic inflammatory cell infiltration is characterised by 
the recruitment of lymphocytes (white blood cells) by the liver124 and is associated with the 
beginning and progression of inflammatory liver diseases.125 Mixed infiltration, however, 
covers a wide range of cells that may infiltrate the liver. Both of those processes are 
commonly occurring phenotypes after exposure to bioactive compounds, especially within 
the liver where the majority of metabolism occurs.97,126 As the term “inflammatory” is not 
present, the cells are non-leukocytes, and so may include other cells such as mast cells.28 
Lipidic vacuolation (fatty change), is a form of steatosis and is characterised by lipids 
accumulating as vacuoles within cells. 127 Glycogen accumulation is characterised by a 
distinctive morphologic appearance and it frequently co-occurs with fatty change or 
cytoplasmic vacuolization.128 Hepatocellular necrosis, the premature death of liver cells, is a 
major biomarker of liver injury. It is a frequent finding in chronic and acute liver injury, and 
if the injury is sustained, leads to fibrosis.129 
Open TG-GATEs formed 13 groups, with overlapping histopathology observations. 
These can be seen in Supplementary Table 2 and have a wider selection of histopathology 
observation. These groups are used in the later chapters of this thesis to probe the biological 
signal within gene expression data. 
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Table 2-4 Histopathology signatures defining 6 toxic groups from DrugMatrix at the 5 day 
stage Only assays that contain a non-zero score for at least one of the groups are shown, 
values represent averaged non-binarised values for each group. Each group now will be 
considered as reflective of their respective combinations of histopathology scores. The 
terminology of these DrugMatrix observations are in the Histopathology Ontology. 
 
 
 
Table 2-5 Compound-dose instances in each toxic group. Two compounds (imatinib(*) and 
bithionol(**)) occur in different doses in two groups (Group 2 and 5, and Group 5 and 6, 
respectively) 
Group Compound DrugMatrix 
Dose 
(mg/kg) 
class/type 
Group 1 Chlorambucil 0.6 chemotherapy, lymphoma 
Ethinylestradiol 10 estrogen medication 
Fluocinolone 
Acetonide 
2.5 corticosteroid 
Fluvastatin 5 statin 
Ketoconazole 114 antifungal 
Mitomycin C 0.5 chemotherapy, gastro-intestinal/breast 
Spironolactone 300 treats fluid build up (heart failure, liver 
scarring, kidney disease)/steroid 
Group 2 Allyl alcohol 16 Former herbicide 
Imatinib* 15 Antineoplastic agent 
Megestrol Acetate 132 Progestin medication 
N-
Nitrosodiethylamine 
100 carcinogen 
Pantoprazole 1100 Proton pump inhibitor for stomach ulcer 
treatment 
Group 3 Altretamine 13 Antineoplastic agent 
Clonazepam 2500 Treatment for epilepsy and seizures 
Clotrimazole 52 antifungal 
Toxic 
group 
Size 
(number of 
compound-
dose pairs) 
Mixed 
Infiltration 
Lipidic 
vacuolation 
(fatty 
change) 
Glycogen 
accumulation 
hepatocellular 
necrosis 
lymphocytic 
inflammatory 
cell 
infiltration 
Group 1 7 0.33 0.0 1.33 0.0 0.33 
Group 2 5 1.0 0.0 1.0 0.0 0.0 
Group 3 10 0.33 0.0 1.33 0.0 0.83 
Group 4 6 0.66 0.33 0.17 0.0 1.0 
Group 5 10 0.83 0.0 1.0 0.33 0.83 
Group 6 5 1.0 0.0 1.33 0.67 1.0 
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Cortisone 206 Steroid hormone 
Diethylstilbestrol 2.8 Former estrogen medication 
Lomustine 4.2 Alkylating antineoplastic agent 
Methyl Salicylate 444 Analgesic 
Mifepristone 3 Treatment for Cushing’s syndrome and 
emergency contraception 
Nimetazepam 122 Hypnotic and anticonvulsant 
Salicylic Acid 223 Analgesic and anti-inflammitory 
Group 4 Artemisinin 2000 Treatment for malaria 
Bis(2-
ethylhexyl)phthalate 
1000 Medical devices, endocrine disruptor, 
cardiotoxicity 
Carmustine 4 Alkylating antineoplastic agent 
Raloxifene 650 Selective estrogen receptor modulator 
Tamoxifen 2.5 Selective estrogen receptor modulator 
Tosufloxacin 2000 Fluoroquinolone antibiotic 
Group 5 17-Methyl 
testosterone 
2000 Androgen and anabolic steroid 
Acetaminophen 100 Analgesic 
Balsalazide 1100 Anti-inflammatory 
Bithionol** 59 anthelmintic 
Carbamazepine 490 Treatment for epilepsy and seizures 
Econazole 43 antifungal 
Ethisterone 1500 Progestin medication 
Imatinib* 150 Antineoplastic agent 
Olanzapine 23 Antipsychotic medication 
Progesterone 11.3 Endogenous hormone 
Group 6 1,1-Dichloroethene 600 Carcinogen 
Atorvastatin 2.5 statin 
Bithionol** 333 anthelmintic 
Isoeugenol 1560 Sensitiser and allergen 
Oxytetracycline 1500 antibiotic 
 
 
2.3 Conclusions 
 
This chapter summarised the chemical, gene expression and histopathology data available 
within DrugMatrix and Open TG-GATEs, with a view to categorising compound-dose 
instances for use in modelling and understanding biological mechanisms of action. 
Chemical space analysis, when compared to ChEMBL and DrugBank, showed that both 
DrugMatrix and Open TG-GATEs contain a wide variety of chemical structure and physico-
chemical descriptors. It has previously been shown that two highly similar compounds 
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(Tanimoto similarity > 0.85) only have a one in five change of having similar gene 
expression profiles.123 Due to this, the number of compounds and the dissimilar structures 
within the databases, chemical structure will not be considered in detail for future chapters of 
this thesis. 
Gene expression data analysis showed the high amount of data that is internally consistent 
(within a database). Therefore each database can be used separately, as in the next two 
chapters of this thesis. Gene expression data is used from one database to determine 
histopathology – gene expression associations. These associations can then be tested in the 
other database for consistency/validation.  
Analysis of histopathology observations showed the largest occurrence of observations to 
be in the liver, Open TG-GATEs has wider ranging histopathologies, and that the 
observations are dependent on each other. As such, the next chapters of this work use the 
histopathology signatures and groups of compound-dose instances to ensure that a systems-
level approach is considered. The DrugMatrix database is used to generate histopathology – 
gene associations and these are tested in Open TG-GATEs, as the range of histopathologies 
from DrugMatrix is captured in this. 
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3. Consistency evaluation of mechanistic hypotheses for rat liver 
histopathology readouts from DrugMatrix and Open TG-GATEs 
considering co-dependency of observations 
 
This work considers co-occurring histopathology observations as signatures and aims to 
determine novel and known associations between the transcriptomics and histopathology 
level. Associations were furthermore derived from the DrugMatrix database and validated 
against Open TG-GATEs and histopathology signatures for conserved associations 
compared. Hence, for the domain of rat in vivo liver injury, we aimed to investigate the extent 
to which complex histopathology signatures are conserved between both databases (and 
hence more generally for such data from different sources), what those conserved signatures 
are, and how they are mechanistically driven on the gene expression level. This is based on 
using data driven approaches to compliment known biological associations. 
Initial work based on DrugMatrix and Open TG-GATEs included the determination of 
predictive models for carcinogens. Using labels from 2 year rat carcinogenicity studies, a 37 
gene-set signature was determined from gene expression data taken at day 5 with daily 
exposure.130 Whilst carcinogenicity is outside the focus of this work, the high performance of 
the models (sensitivity and specificity of 86% and 81% respectively on a validation set) 
shows that there is a signal from microarrays readouts that translates to in vivo toxicity. On 
the mechanistic level, only 27 of the 37 signature genes were annotated in Gene Ontology, 
which represent various aspects of antiapoptotic effects and proliferation. However, when the 
gene signatures were tested on non-DrugMatrix data, it was found that “the decreased level of 
test sensitivity and specificity are not likely sufficient to justify routine use of the signatures 
as tested outside their laboratory of origin”.131 This finding makes the importance of 
generating consistent data, with enough coverage, clear to be able to arrive at truly predictive 
toxicity models. Subsequently, using Principle Component Analysis and prediction of mode-
of-action on gene expression data (cytotoxicant, enzyme inducer, PPARa agonist or “other”), 
Kanki et al. determined a 106 gene-set that accurately classified carcinogens with respect to 
time, dose and mode-of-action.132 Biological interpretation of this gene set via Ingenuity 
Pathway Analysis elucidated known associations to cancers, such as the geneset’s connection 
to regulated gene markers (MAPKs and PI3/AKT signalling) with downstream perturbation 
of hepatic system development and function, lipid metabolism, and organ morphology.65 This 
model was not externally validated, meaning its prospective predictive power remains 
unclear. 
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Both DrugMatrix and Open TG-GATEs data have also been used in the non-cancer field 
to model and predict specific organ histopathology readouts. This included modelling 
presence or absence of histopathology observations, their severity, and using ensemble 
models of the observations to predict a general “toxic” label.133,134 In one study, the severity 
of four different histopathology observations (necrosis, hypertrophy, cell infiltration and 
leukocytic change) was determined using the Random Forest algorithm, based on genes 
selected via sparse Linear Discriminant Analysis.133 Subsequently, the biological relevance of 
the selected genes was determined via enrichment of Gene Ontology (GO) terms, which were 
taken from the top level of GO and not mechanism focused (e.g. “response to xenobiotic 
stimulus”). In a separate study, an ensemble model was built on 21 histopathology endpoints 
from Open TG-GATEs, employing a k-nearest neighbour approach based on compound-
induced gene expression data and resulting in an AUC of 88% (sensitivity 0.84, specificity 
0.83).134 Whilst these approaches produced relatively accurate models, they do not provide 
in-depth biological interpretations for the histopathology observations. This study aims to 
explain the associations between gene expression data and histopathologies.  
The workflow of the current work is shown in Figure 3-1. Histopathology phenotypes 
from DrugMatrix and Open TG-GATEs were expressed as signatures to define toxic sets (a). 
In order to obtain unique signatures with a sufficient number of associated data points, 
histopathology observations from DrugMatrix were mapped to the HPATH histopathology 
ontology (b).27 This ontology, created by the eTox consortium, classifies and categorises 
histopathology observations and morphologies from animal studies. The created signatures 
defined toxic groups of compounds, whose differentially expressed genes after treatment (c), 
and resulting enriched pathways, and pharmacological profile were determined (d). Co-
expression networks were created for each toxic group using the WGCNA approach 
discussed above, which revealed known and novel associations that were consistent between 
DrugMatrix and Open TG-GATEs databases (e). These associations were determined on a 
gene, pathway, GO term, disease and transcription factor level, and hence to the best of 
knowledge of the author this represents the first study that establishes consistency between 
the two major toxicogenomics databases available on a large scale for liver toxicity readouts, 
while also considering multi-endpoint histopathology definitions. Throughout this work, a 
histopathology signature is defined as the group of observed histopathologies whereas the 
toxic group defines the compound-dose instances and their gene expression that make up 
each histopathology signature. 
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Figure 3-1 Workflow of this study. Compound-dose groups are segregated by their 
histopathology observation and the resultant gene-histopathology associations are tested for 
conservation between databases and biological meaning. Histopathology observations (a) 
are mapped to HPATH and define toxic groups (b). Differentially expressed genes and 
compound bioactivity profiles are determined (c) and co-expression networks created (d). 
The resultant networks are tested between databases (e) and their biological meaning 
determined by enrichment testing from gene-disease (the Comparative Toxicogenomics 
Database), gene-transcription factor (DoRothEA), gene-pathway (Rat Genome Database), 
and gene-GO term (Gene Ontology) data. 
An important confirmation of gene-gene associations is whether their behaviours are 
mirrored at the protein level. To this end, module (groups of genes) associations can be 
compared to known gene products (protein) interactions. Numerous databases of protein-
protein interactions (PPIs) are within the public domain.59 Within this study, it is key to use 
data from rat models, and as such, the String database was used.178 
 
3.1 Methods 
 
The histopathology signatures and toxic groups were used as generated in Chapter 2. 
 
3.1.1 Bioactivity 
 
The matrix of 79 bioactivities for all compounds was downloaded from the DrugMatrix 
database.120 This matrix contains activity (or inactivity) values for all the compounds. The 
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matrix was clustered using Euclidean distances and complete linkage in R (version 3.5) with 
package ‘ComplexHeatmap’.135 
 
3.1.2 Weighted Gene Coexpression Network Analysis (WGCNA) 
Coexpression network analysis was performed using the WGCNA package (version 1.66) 
in R (version 3.5.1). All gene expression CEL files from each histopathology signature were 
used to generate a network, (Groups 1-6 defined in Table 2-4 and controls for DrugMatrix, 
and the Open TG-GATEs groups). Raw RMA-adjusted gene expression values (as previously 
generated in Chapter 2) were used to generate the correlation matrix. The softpower was 
determined by comparing the scale-free topology and mean connectivity and was 
subsequently set to be 10 in each case. Unsigned networks were created for all groups (as 
default). Modules were formed using the FlastClust function with average linkage. The tree 
was cut at height = 0.99 for tighter module formation, and the remaining parameters were 
used as their default values. 
Module conservation was determined by permutation testing of mean densities and 
correlations, both inter- and intra- modular, of connectivity, adjacency matrices and 
eigengene values.83 30 permutations were performed, with a maximum module size of 1,000 
genes. Zsummary scores are used as a proxy for conservation. Zsummary scores greater than 
ten were taken to show significant conservation, and those less than 2 to show no evidence of 
conservation.83 A module of randomly selected genes (n=1,000) was created 30 times and the 
same permutation test was applied to determine the false discovery rate of conservation 
scores. This was performed in line with the WGCNA protocol to create and test coexpression 
network modules. 
 
3.1.3 Pathway enrichment 
Gene Ontology biological processes and pathway ontologies were downloaded from the 
Rat Genome Database.62 Differentially expressed genes and genes in modules were tested for 
enrichment using the ‘Enrichr’ package.21 Significance of enrichment was determined using 
Fisher’s exact test as implemented in Enrichr, with all measured genes (from the original 
microarray) used as a background. A Benjamini-Hochberg multiple testing correction was 
applied in R and an adjusted p-value cut-off of 0.05 defined significance. Significant GO 
terms were visualised with RamiGO.136 Pathway ontologies were visualised with 
OntologyX.137 
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3.1.4 Disease enrichment  
All disease-gene associations were retrieved from the Chemical Toxicogenomics 
Database (CTD)48 and the distribution of the  inference scores of these disease-gene 
associations is shown in Figure 3-2. As can be seen, the distribution has a long tail, meaning 
that very few disease-gene inferences have scores above 200. Three cut-offs of the inference 
score (50, 100, and the top 5%) were used to decide whether genes and diseases were 
associated. Gene sets for each disease instance were created and filtered to remove those with 
fewer than 10 genes. Disease enrichment for each module was performed using the same 
statistical approach as described above for the pathway enrichment. Diseases-module 
associations were considered significant if they were present at both the 100 and 5% 
inference score cut-offs. 
  
Figure 3-2 Distribution of interference score of gene-disease association from the 
comparative toxicogenomics database. The y axis is a logarithmic scale (base 10) and so 
there is a long tail.  
 
3.1.5 Transcription factor enrichment 
Transcription-gene associations were downloaded from DoRothEA138 using the 
confidence limits of A-C, as recommended to obtain higher confidence associations.139 Gene 
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sets for each transcription factor were created, filtered and tested for significant enrichment 
using the same statistical approach as in the disease enrichment. This step was performed 
mainly to determine module specificity – genes form modules if they are co-expressed and 
therefore are likely to share transcription factors. The incomplete nature of the database 
allows for positive enrichments to be found, though without being able to draw conclusions 
from the absence of enrichment. 
 
3.1.6 Protein – Protein interaction significance 
Protein – protein interactions were downloaded from the String database.178 Specifically, 
22,763 interactions that occur within rats were downloaded. Random subsets of proteins were 
selected, with sample sizes the same those in the defined modules. Each sample was 
permuted to determine all pairwise interactions. The number of known interactions (as 
defined by the String database) was compared to the number of true interactions from the 
each module. The random sub-setting was repeated 500 times to determine significance, 
against each module from each toxic group. A KS test was performed in R, to determine 
whether the edges in the module subgraphs (between genes) were reflected in the biological 
interactions (PPI network). 
 
 
 
 
3.2 Results 
 
 
3.2.1 Using Bioactivities, Differentially Expressed Genes and Pathway Enrichment to 
Discriminate between Histopathological Signatures  
 
We firstly analysed annotated protein activities, differentially expressed genes, and 
pathway enrichments for their ability to discriminate between toxic compound groups.  
We found when clustering based on annotated bioactivities that this did not discriminate 
between the toxic groups (Figure 3-3), where members of different toxic groups can be found 
spread out widely in bioactivity space. Hence, protein target activity alone is an insufficient 
predictor of particular histopathology readout profiles. 
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Figure 3-3 the bioactivity profiles of the compounds across 79 assays. It fails to discriminate 
between the toxic and non toxic instances. The red colour represents no activity and was 
defined in DrugMatrix. 
 
Similarly, differentially expressed genes by themselves failed to group between the 
different toxic compound classes with each other, and separately from non-toxic instances 
(Figure 3-4). It can be observed that individual genes were in most cases either up- or 
downregulated across compound-dose instances, but not upregulated in some compound-dose 
instances, and downregulated in others. This finding has previously been observed by 
Gusenleitner et al.140 when predicting the long term carcinogenicity of compounds using the 
DrugMatrix database. Their analysis noted that this effect was strongest when in response to 
carcinogens. Whilst this behaviour can be rationalized for genes that have low expression 
levels (reaching the detection limit of the microarray in case of no compound treatment and 
upregulation after treatment), there is no obvious explanation for commonly expressed genes. 
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Figure 3-4 the differentially expressed genes for each compound-dose instance at the five-
day stage. As the black bar on the righthand side shows, there is very little differentiation 
between toxic and non-toxic instances. The enrichment of these genes can be seen in the 
supplementary information (Supplementary Table 3). Similarly to the clustering in bioactivity 
space, gene expression does not clarify the distinction between the toxic and non-toxic sets. 
Note, genes that were not differentially expressed in any compound-dose-time point instance 
and those with zero variance were filtered out for ease of representation 
 
The differentially expressed genes per toxic group were next tested for GO pathway 
enrichment. This resulted in 166 enriched pathways over each group (see Supplementary 
Table 3). These pathways are compound-specific and their applicability to each group is not 
clear. The large number of enriched pathways prevent deconvolution of the signal. 
Hence we can conclude that neither protein activities, not clustering based on gene 
expression, or pathway enrichments were able to provide mechanistic hypotheses for the 
groups of toxic compounds defined by histopathology profiles in this work.  
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3.2.2 WGCNA analysis 
 
Co-expression networks were then made to investigate how gene-gene relationships vary 
within and between different toxic groups. This created module-histopathology associations 
on the gene and pathways level. 
We generated co-expression networks for each of the six toxic compound groups 
compared to control. Each network forms hierarchical clusters of genes, which are highly co-
expressed, and are named after colours for ease of reference. The modules defined in each 
network were then tested against each other (all against all) and against the Open TG-GATEs 
groups to determine their conservation (i.e. if the module genes have similar behaviour 
compared to each other and all other measured genes, in different networks). These results of 
which are shown in Figure 3-5 for compound group 1, and Supplementary Figure 2 for 
groups 2-6, respectively. High conservation (Zsummary score) indicates that inter- and intra- 
modular network characteristics are similar in different networks. Complete segregation 
between DrugMatrix and Open TG-GATEs networks can be seen. This is to be expected due 
to the differences (in time, location and exact experimental protocol) of the experiments. 
Similarly, there were more conserved modules within all six of the DrugMatrix groups. An 
average of 49% of modules were conserved with DrugMatrix compared to 6% with Open 
TG-GATEs. Additionally, there were more histopathology endpoints in Open TG-GATEs 
(13 compared to 6) which cover a larger range of observed histopathology. Hence, we can 
conclude that the two databases are distinct but there is shared gene expression signal 
between them (conserved modules). 
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Figure 3-5 Results of permutation testing of modules for Group 1, representing which 
modules defined by Group 1 are conserved with different histopathology groups in both 
DrugMatrix and Open TG-GATES. The separation of DrugMatrix and Open TG-GATES is 
apparent, and the conservation of particular modules between databases shown. The Open 
TG-GATEs group representing “fatty degeneration, cellular infiltration, hydropic 
degeneration” shows the highest inter-database concordance. SRI and Ricera represent 
different external controls that were included in the DrugMatrix database. 
 
3.2.2.1 Conservation of compound group 1, represented by mixed infiltration, glycogen 
accumulation and lymphocytic inflammatory cell infiltration 
 
We next analysed compound group 1 in detail to determine and understand the 
associations between group 1, the controls, and the other toxic groups. These associations are 
on the gene, pathway and histopathology level. 
The histopathology signature of Group 1 is defined by the original DM observations of 
mixed infiltration (average score of 0.33), glycogen accumulation (average score of 1.33) and 
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lymphocytic inflammatory cell infiltration (average score of 0.33). Its coexpression network 
formed 25 modules in total.  
 
Comparison of generated modules of Group 1 with modules of the control group 
First, we tested the modules defined by group one to see what was not conserved with 
the controls (no compound perturbation). These modules were tested for their biological 
meaning, disease association and transcription factor enrichment. 
Table 3-1 shows all modules that are either not-conserved with control (i.e. represent 
perturbations from the non-compound-induced state) and the modules that are conserved in 
networks from Open TG-GATEs (i.e. genes act the same way in relation to each other in the 
external database). Three modules are not conserved between Group 1 and the control: 
lightgreen, darkgreen, and cyan. Lightgreen had no significantly enriched pathways. 
However, there were 11 significantly enriched diseases for this module (shown in Table 3-2) 
seven of which are directly related to the definition of Group 1: ‘chemical and drug-induced 
liver injury’, ‘hepatomegaly’, ‘liver diseases’, ‘fatty liver’, ‘inflammation’, ‘necrosis’, and 
‘hypertrophy’. Hence, we can conclude that disease enrichment can be a useful analysis 
method to associate modules to general toxicity terms. 
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Table 3-1 Conserved modules between Group 1 (from DrugMatrix), control group and Open 
TG-GATEs histopathology groups. High Zsummary scores (>10) indicate module 
conservation between databases, while low scores indicate no conservation and so modules 
not conserved with the control are shown. Each Open TG-GATEs group is annotated with its 
histopathology signature. There are 3 modules not conserved with control (cyan, darkgreen 
and lightgreen) and 4 modules that are conserved between Group 1 and Open TG-GATEs 
groups, to varying degrees. The signature that is conserved in the highest number of modules 
is ‘fatty degeneration, cellular infiltration and hydropic degeneration’. This shows clear 
parallels with histopathology signature of group 1, and hence we can conclude that 
coexpression network module comparison shows concordance of gene expression and 
histopathology signature. 
Module Zsummary 
score 
Histopathology signature from Open TG-GATEs group 
cyan 8.02 Not-conserved with DrugMatrix Control 
darkgreen 7.10 Not-conserved with DrugMatrix Control 
lightgreen 8.51 Not-conserved with DrugMatrix Control 
brown 10.90 Increased mitosis, and granular eosinophilic Degeneration 
magenta 16.00 Fatty Degeneration, Cellular infiltration, and hydropic Degeneration 
turquoise 26.83 Microgranuloma 
35.11 Hypertrophy 
12.14 Cytoplasmic Vacuolization 
13.29 Fatty Degeneration, Cellular infiltration, and hydropic Degeneration 
21.61 Necrosis 
20.30 Eosinophilic Change 
11.78 Glycogen deposit 
28.28 Increased mitosis 
yellow 10.72 Hypertrophy 
16.34 Fatty Degeneration, Cellular infiltration, and hydropic Degeneration 
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Table 3-2 Disease enrichment of the lightgreen module, seven of which (chemical and drug 
induced liver injury, hepatomegaly, necrosis, fatty liver, hyperplasia, liver diseases and 
hypertrophy) are directly related to group 1’s histopathology signature. 
Disease term Number of  
genes in 
module 
Number of  
genes in 
pathway 
p value Adjusted p 
value 
Chemical and Drug Induced Liver 
Injury 
35 3645 3.80 x10-8 9.25x10-6 
Hepatomegaly 21 1366 5.41 x10-8 9.25 x10-6 
Inflammation 27 2443 3.07 x10-7 3.49 x10-5 
Necrosis 35 4048 6.41 x10-7 5.48 x10-5 
Weight Loss 24 2525 3.07 x10-5 2.10 x10-3 
Kidney Diseases 17 1410 3.94 x10-5 2.24 x10-3 
Fatty Liver 14 1009 5.06 x10-5 2.47 x10-3 
Hyperplasia 20 1938 6.22 x10-5 2.66 x10-3 
Prenatal Exposure Delayed Effects 24 2675 8.12 x10-5 3.08 x10-3 
Liver Diseases 11 814 4.68 x10-4 1.60 x10-2 
Hypertrophy 9 631 1.12 x10-3 3.48 x10-2 
 
We furthermore analysed hub genes (genes with highest degree of connectivity) for 
each module, i.e. those genes which are thought to be influential drivers of the function of 
one part of a network. Figure 3-6 shows the hub genes for the lightgreen module, which are 
associated with lipid binding, tubulin binding, proteolysis and ion transport. Despite no 
pathways being significantly enriched, its hub genes hence show a connection to the toxic 
definition in Group 1, also showing that network analysis can provide insight into gene 
modules beyond pathway enrichment alone.58 
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Figure 3-6 Lightgreen module for the Group 1 case study, based on visualising the sub-graph 
of the coexpression network (to show the gene in the module). The five genes with highest 
degree (‘hub genes’, displayed in red) are associated with lipid binding, tubulin binding, 
proteolysis and ion transport. 
The darkgreen module has five significantly enriched pathways, as shown in Figure 
3-7, namely the ‘fructose and mannose’, ‘pentose phosphate’, and ‘gluconeogenesis’ 
metabolic pathways, and the ‘hereditary fructose intolerance syndrome’ and ‘fructosuria’ 
disease pathways. Of these, there is literature evidence to support that the pentose phosphate 
and gluconeogenesis pathways have roles in chemical- and drug- induced liver injury, and 
promoting hepatic steatosis (fatty liver).141 Specifically, the pentose phosphate pathway 
parallels lipogenesis since it is a major source of NADPH (and pentoses) and NADPH is 
consumed for reductive biosynthesis.142 The importance of fructose metabolism is a known 
cause of liver diseases.143 However, the specific pathway of ‘fructose and mannose metabolic 
pathway’ may play a more significant role in the manifestation of the phenotype. The 
enriched disease pathways are fructose intolerance and fructosuria. The significance of 
fructose in hepatotoxicity is its alteration of the concentration of metabolites which promotes 
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intrahepatic fat deposition and hyperuricemia.144,145 These two pathways help to provide a 
mechanistic background with the observed glycogen accumulation which was part of the 
definition of compound Group 1.  
 
Figure 3-7 Ontology of enriched pathways in the darkgreen module of compound Group 1, 
which was conserved within the compound group, but different from control. The Pentose 
phosphate pathway is linked to ‘chemical and drug induced liver injury’ via the four genes 
ALDOB, PGM1, RGN, and TALDO1. Gluconeogenesis has been shown, via mouse knock out 
studies, to promote hepatic steatosis (fatty liver). Fructose can enter liver hepatic cells 
without the prescence of insulin (the rate limiting step for glucose). This provokes the change 
in concentration of several metabolites, ultimately being linked to intrahepatic fat deposition 
and hyperuricemia.144,145 Given that the histopathology readout of compound Group 1 is 
partly defined by glycogen accumulation, this module provides a mechanistic hypothesis of 
steps leading to this effect. 
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The two remaining histopathology observations that define the histopathology 
signature of Group 1 are ‘mixed cell cellular infiltration’ and ‘lymphocytic inflammatory cell 
infiltration’. We have next analysed the cyan module in order to explain this, as shown in 
Table 3-3, which shows the Gene Ontology enrichment for the cyan module. The one 
enriched pathway is “cellular response to corticotropin-releasing hormone stimulus”. 
Corticotropin-releasing hormone is a peptide hormone involved in stress response. This, 
alongside the more generic ‘inflammatory response’ GO term, demonstrates the resulting 
stress response to the compound exposure. There are 180 unique and significant disease 
associations for this module, reflecting the generic stress response from a system when 
changing to a disease state. Additionally, there are 7 enriched transcription factors, namely 
GATA2, RELA, NFKB1, STAT3, ATF2, STAT1, and CREB1, in the cyan modules. This 
supports the biological interpretation of the data driven approach – namely that there is 
evidence that specific transcription factors modulate genes that form part of particular 
modules. Additionally, NFKB1 is central to the role of liver homeostasis, and regulation of 
inflammation, fibrosis and carcinogenesis.146 Hence, the enriched pathways from these 
modules show biological signal for the observed histopathology. Similar to its enriched 
pathways, the cyan module’s hub genes are highly connected to stress response via 
interleukin-1 and 10 (Supplementary Table 4), showing that the systems stress response has 
been activated. The top hub gene, Cxcl2 is involved in ‘response to lipopolysaccharide’. This 
is highly associated with chemical- and drug- induced liver injury, and inflammation (over 
250 references in the Chemical Toxicogenomic Database).48 
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Table 3-3 All enriched GO terms in the cyan module of Group 1, which not conserved with 
the control. Corticotropin-releasing hormone is a peptide hormone involved in stress 
response, as is that of inflammatory response. This parallels the stress response seen in 
Group 1’s definition (inflammatory cell infiltration). TermID is the GO term ID and the 
multiple hypothesis adjustment is Benjamini-Hochberg. 
TermID Number of 
genes in module 
and pathway 
Total number of 
genes in 
pathway 
p value Adjusted p 
value 
GO:0006954 
inflammatory response 
10 215 3.77 x 10-7 0.005 
GO:0071376 cellular 
response to corticotropin-
releasing hormone 
stimulus 
3 5 1.78 x 10-6 0.011 
GO:0070098 chemokine-
mediated signalling 
pathway 
5 46 6.11 x 10-6 0.025 
 
In this section we found three modules for the first histopathological signature (Group 
1) which were not conserved with the control group and which hence would form hypotheses 
for the mechanistic basis of the observed toxicity signature. Whilst the histopathology 
observations have been discussed individually, they are only formed when generating a group 
of compounds with identical signatures. These three modules reveal known and novel 
associations, namely the specific involvement of fructose and mannose metabolic pathways 
and a systemic stress reaction.  
However, the robustness of these associations next needs to be confirmed in 
comparison to other databases to confirm the consistency of modules derived for compound 
Group 1 with external histopathology observations, to show the general applicability and 
validate the prospective value of the approach.  
 
Comparison of modules for Group 1 with groups from Open TG-GATEs 
We next analysed the conservations of Group 1’s modules with those from Open TG-GATEs 
in order to determine whether the histopathology observations are conserved on a gene level 
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between databases. The results are shown in Figure 3-8. It can be seen that each toxic group 
is conserved to differing extents with those from Open TG-GATEs. Most commonly, ‘fatty 
degeneration, cellular infiltration and hydropic degeneration’ is conserved with DrugMatrix 
groups, which broadly match their definition. 
 
Figure 3-8 Distribution of conserved modules across Open TG-GATEs histopathology 
signatures for Groups 1-6. ‘hypertrophy’ and ‘fatty degeneration, cellular infiltration, and 
hydropic degeneration’ both consistently show the highest amount of conservation, reflecting 
concordance of histpathology via co-expression networks between database 
The cyan, lightgreen and darkgreen modules are not externally confirmed with other 
toxic groups (Figure 3-5), even though these have overlapping toxic definitions (Table 2-4). 
Whilst these are the only modules not conserved with the control group, the inter-database 
conservations are still important, as these reflect the behaviour of the genes, not their absolute 
expression.  
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Histopathology-specific gene expression network concordance between database was 
determined, through conserved modules. These modules are, as shown in Table 3-1, namely 
the brown, yellow, magenta and turquoise modules.  Figure 3-9 show their enriched pathways 
and GO terms. As is clearly visible, there is a wide range of functional biology within these 
modules, which we assume to represent the underlying/background biology present within 
similar toxic groups (and, indeed, between databases). 
Conservation between databases is quantified as the fraction of modules that are 
conserved by histopathology signatures from different databases, and the signatures are 
compared. Figure 3-8 shows this frequency of conserved modules between Group 1 and those 
from Open TG-GATES. Groups representing “Fatty Degeneration, Cellular infiltration, and 
Hydropic Degeneration”, and hypertrophy are the most frequently conserved. Group 1 
represents cellular infiltrate (mixed cell and lymphocytic inflammatory cell) and glycogen 
accumulation. The amount of conservation on a module level is reflected by the joint 
histopathology meanings.  
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Figure 3-9 Gene Ontology and Pathway ontology terms enriched in the yellow, magenta and 
turquoise modules (the brown module had no significantly enriched terms). It can be seen 
that these enriched terms show that a wide range of functional biological space is covered. 
PW means pathway. 
Open TG-GATEs contains histopathology observations that are not included in the 
definition of groups 1-6, and their biological meaning for “hypertrophy” and “hydropic 
degeneration” are briefly summarised. The former is the enlargement of an organ (liver in 
this case), that is caused by an increase in size of cells. When this is compound or drug-
induced, fundamental cellular process have been shown to play a role.147 These include 
“altered oxidative status, fatty acid metabolism, energy production and utilization, cell 
turnover and altered hepatocellular cytoplasmic, and nuclear morphology”.147–151 Of crucial 
importance, in this case, is the fatty acid metabolism. The method presented above clearly 
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shows its importance in Group 1. The latter, hydropic degeneration, is the ballooning in the 
size of a cell due an increase in the amount of water, as is similarly associated with other 
forms of hepatic degeneration. These histopathology observations are highly related between 
databases when considering gene expression space.  
Group 1 is most conserved with histopathology signature definitions from Open TG-
GATEs that show concordant meaning. This analysis was then performed over all the 
remaining signatures to determine the applicability of these across different groups. 
 
3.2.2.2 Summary of Groups 2-6 
The same analysis on database concordance was performed for the remaining groups 
(groups 2-6). This concordance is expressed as the frequency of module conservation and is 
shown in Figure 3-8. It should be noted that Open TG-GATEs histopathology signature 
definitions are only represented here if they have at least one conserved module with one of 
the 6 toxic groups. The remaining groups represent a wider variation in histopathology and 
are not shown. 
Group 2 (mixed infiltration and glycogen accumulation) is conserved with the 
signatures ‘Fatty Degeneration, Cellular infiltration, and hydropic Degeneration’ and 
‘hypertrophy’. There is no conservation with “glycogen deposit”, as this is different from 
glycogen accumulation.128,152,153 
 Group 3 (mixed infiltration, glycogen accumulation and lymphocytic inflammatory 
cell infiltration) is defined by the same terms as Group 1, albeit a more severe finding. As 
such, it’s conservation mirrors that of Group 1. The main difference, in terms of module 
conservation, between Groups 1 and 3 is the latter’s conservation with ‘cellular infiltration’ 
and ‘increased mitosis and eosinophilic granular degeneration’ signatures. The former 
suggests that the increased amount of cellular infiltration observed in Group 3 (compared to 
Group 1), produces a signal that could be less dependent on the entire histopathology 
signature. 
Group 4 (mixed infiltration, fatty change, glycogen accumulation, lymphocytic 
inflammatory cell infiltration) modules are most highly conserved with ‘microgranuloma’ 
and ‘hypertrophy’ signatures. Lipidic vacuolation (fatty change) frequently accompanies cell 
death but the mechanism of its role when induced by low molecular weight compounds is not 
known.154 This method provides hypotheses on what might be occurring: Within Group 4’s 
conserved modules, one has ‘G protein-coupled receptor signalling pathway’ (GO:0007186) 
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enrichment. It has been previously hypothesised that the local lipid environment plays a role 
in the signalling pathway, with some evidence to support this.155 Further enquiry into this 
specific modules’ hub genes may provide an insight into the lipidic vacuolation observation. 
Group 5 (mixed infiltration, glycogen accumulation, lymphocytic cell infiltration and 
hepatocellular necrosis) uniquely has conserved modules with ‘swelling’. Swelling is a key 
part of necrosis, and occurs after mitochondrial impairment, ATP deletion and the resultant 
failure of ion pumps.156 It is not, however, conserved with the ‘necrosis’ group from Open 
TG-GATEs. 
Group 6 (mixed infiltration, glycogen accumulation, lymphocytic cell infiltration and 
hepatocellular necrosis) is defined by the same terms as Group 5, with more severe terms in 
every observation. This, however, is not reflected entirely in their conservation with Open 
TG-GATEs groups. Only ‘hypertrophy’ (which is the most conserved term for Group 6 and 
second most for Group 5) and ‘cellular infiltration’ are conserved for both groups.  Group 6 is 
additionally conserved with ‘microgranuloma’, ‘increased mitosis and granular eosinophilic 
degeneration’, ‘increased mitosis’ and ‘necrosis’ groups. The latter of these is within its 
definition, and therefore expected. Microgranuloma are a small collection of macrophages 
that occur typically with inflammatory cells (it is estimated that 13-33% have no discoverable 
aetiology in humans).157–159  
The conservation of each Group’s modules with TG histopathology signatures show 
direct and indirect associations. Direct associations are clear mappings of histopathology 
groups (e.g. cellular infiltration). Indirect associations, on the other hand, occur when the 
mappings are not as apparent, but these suggest the underlying relationship on a 
gene/molecular level as demonstrated with enrichments in ontology terms such as swelling 
and necrosis. Overall, we can conclude that unsupervised analysis of histopathology groups 
via co-expression networks enables their mapping to molecular processes that are DILI 
relevant. 
 
3.2.3 PPI comparison 
 
The interactions of genes within modules were compared to known interactions of the gene 
products. The size and significance of the resultant KS test can be seen in Table 3-4. From 
this, it can be concluded that the umber of interactions of gene products defined by modules 
is significantly more than that of random. This has accounted for the size effect of each 
module that was defined.  
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Table 3-4 The results of the Kolmogorov-Smirnov test, used to determine if randomly selected 
proteins have the same distribution of interactions as the gene products of genes in all 
calculated modules. The test statistic and significant p value reveals they do not share the 
same distribution. This furthers a weight of evidence that there is biological value in the 
WGCNA approach to define modules. 
Test statistic (D) P value 
0.480 3.42 x10-5 
 
 
 
 
3.3 Discussion 
 
It is well known that gene expression data is often noisy, with batch effects from 
different laboratories, ambient conditions and a low number of biological and technical 
repeats. As such, external validation is crucial to assess the biological interpretation of 
individual microarrays. One common method to overcome this is normalisation with respect 
to housekeeping genes.160 This is based on the assumption (and limitation) of there being 
genes who’s expression is constant in a cell. This analyse is often performed with reverse 
transcription polymerase chain reaction experiments, but is rarely done in microarray 
technologies.161 Research on applying this form of normalisation on microarray platforms 
found that it was most applicable where the expression/fold change are close to significance 
cut-offs.161 As such, it is not suitable for the co-expression method used here. 
This method of considering all the histopathological observations gives a holistic 
view of effects that compounds have. This is in direct contrast to previous work that chooses 
a specific histopathological assay of interest to determine its drivers.98 Indeed, this view of 
using histopathology observations to guide and determine ‘disease state’ has recently shown 
to determine novel and known mechanisms of liver injury.25 This histopathology-led 
approach, as taken in this work, treated in vivo toxicity as a systems biology problem. Here, 
this determined associations between databases that had not previously be found. 
Following on from this systems approach, this investigation enabled the consistency 
evaluation of liver-specific histopathology signatures between DrugMatrix and Open TG-
GATEs on the gene expression level. The signatures covered glycogen accumulation, cellular 
infiltration, necrosis and fatty change. The compounds within DrugMatrix were selected to 
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represent a wide area of therapeutic space. As such, they have fewer, less wide-ranging 
histopathology observations, compared to the toxicity-annotated compounds from Open TG-
GATEs. Creating co-expression networks and determining gene-histopathology associations 
within DrugMatrix is more useful, as these can be validated in the wider-ranging 
histopathologies in Open TG-GATEs. The unique approach of using module conservation 
found large numbers of known associations to liver injury. Known pathways and GO terms 
have been found, however novel importance of particular genes (from hub genes) helps to 
widen hypotheses.  
However, this method is not without its limitations. Firstly, it assumes that all of the 
histopathological observations are complete, with no other phenotype occurring. This is an 
inherent limitation of the data. Secondly, it suffers from the same limitations of a small 
sample size, which is exacerbated when considering samples’ full histopathology profile. 
Here, the histopathology ontology (HPATH) was implemented to counter this hurdle, but it 
does require a balance to determine where on the ontology the grouping is made (as shown in 
Chapter 2). The balance is between the number of compound-dose-timepoint instances that 
allow for statistical significance to be reached and how specific the resultant 
histopathological profile is. The number of modules that are conserved between toxic groups 
that share one histopathology is small. This reflects the stated systems view that all 
histopathology observations must be considered together. 
Pharmacological profiles from bioactivity clustering fail to discriminate toxicity. 
These profiles do not consider the absorption, distribution, metabolism and excretion 
(ADME) properties of the compounds, nor consider the exposures at the in vivo level. 
Additionally, they are limited in number and are not specific to rats. Thus, their failure is 
unsurprising. Determining differentially expressed genes and their pathway enrichments is 
one such method that is based directly upon the measured values. As such, and as shown 
above, these methods fail to discriminate between the toxic and non-toxic cases 
(Supplementary Figures 2 and 3). 
Despite these limitations, there is much more biological information that is captured 
by framing the question more appropriately. WGCNA does not directly use the values 
measured in a microarray experiment, but instead, uses the correlation of these values 
between genes (or probes) to make use of the relationship between them. Based off the 
assumption that highly correlating genes are biologically related, its data driven approach acts 
to reduce the dimensionality of the dataset from ~14,000 genes to ~30 modules. The ability to 
compare and contrast different networks identifies the modules that are conserved or not 
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conserved between them in an unbiased manner. Interpreting these modules can be performed 
using gene, pathway, GO term, transcription factor and disease annotations, which confirm 
known associations and provide suggestions for further research. 
The method goes on to suggest potential hypotheses for phenotypes: the involvement 
of lipid in G protein couple receptor pathways for efficient signalling, for example. It also 
suggests genes (from hub gene analysis) that have been annotated for specific functions, 
which concur with the defined histopathologies.  
This work confirms previous, smaller studies: a case study on the toxic effect of carbon 
tetrachloride on liver.162 Lipid binding and stress response at the gene expression level were 
associated with fatty degeneration and other histopathologies. This work widens the scope from 
specific compounds (with well characterised modes-of-action) to connecting signals between 
gene expression (from a wide range of compounds) to histopathologies. These associations 
help build up a set of “toxic modes-of-action”, combining what is already known and 
suggesting previously unknown hypotheses.  
 
 
3.4 Conclusion 
 
Histopathological assays were used to create a systems view of toxicity. More traditional 
methods, determining differentially expressed genes and their enrichment, and 
pharmacological profile, failed to discriminate between the toxic and non toxic cases. 
Weighted gene co-expression network analysis revealed the transcriptomic level changes on a 
range of histopathology signatures. For example, glycogen accumulation, mixed infiltration 
and lymphocytic inflammatory cell infiltration is associated with fructose metabolism, 
gluconeogenesis and chemokine response pathways.  
Conservation of modules between databases showed correlation of specific phenotypes, 
through the behaviour of groups of genes. Additional hypotheses were suggested for the 
presence of microgranuloma and lipidic vacuolation. 
 4. Concordance of transcriptomics data at different time points 
between similar and distinct rat liver histopathology 
observations based on the DrugMatrix and TG-GATEs 
databases 
 
The determination of earlier gene expression signatures which pre-empt the phenotype 
will provide value in predictive models. This chapter aims to determine if a biologically 
meaningful signal is conserved across time points (1 day and 4/5 days). If late stage toxicity 
end points can be predicted by early time points, fewer compounds will fail due to toxicity 
later in the drug development pipeline. This precise question was asked using Open TG-
GATEs and one day vs 28 day toxicity assays.163 High levels of similarity were found in the 
gene expression profiles at both stages, based on the overlap of the top and bottom ranked 
genes. Specific histopathology observations and their occurrence and development were not 
the focus of any enquiry here. 
The use of laser microdissection was used to determine the development of Helicobacter-
induced mucosa-associated lymphoid tissue lymphoma in the gene expression domain.164 In 
this study, the gene expression profiles of various histopathology stages of disease were 
determined. The time analysis determined genes coding for the immunoglobulins and the 
small proline-rich protein Sprr 2A to be critical for the initiation of reactive lymphocytes into 
the stomach. The subsequent step is characterized histologically by the antigen-driven 
proliferation and aggregation of B cells and the gradual appearance of lymphoepithelial 
lesions, in which the laminin receptor 1 and multidrug resistant channel MDR-1 are over 
expressed. This time-dependent analysis showed how the disease progressed on the gene 
expression level and this can equally be applied to toxicity. For example, the progression of 
disease (due to chronic dietary TCDD (a known toxicant) exposure) in zebra fish has been 
studied to determine the growth and development of histopathology at a gene expression 
level has been performed.165 This work found dysregulated genes involved in pathways 
associated with cardiac necrosis/cell death, cardiac fibrosis, renal necrosis/cell death and liver 
necrosis/cell death , which are relevant to the endpoints discussed so far. 
Time course, gene expression data are not easily modelled. A study that determined genes 
predictive of “DILI most concern” using Open TG-GATEs data found Time-series work has 
been performed modelling “did not perform well on directly measured gene expression 
values”.166 To improve the situation, co-expression network methods have subsequently been 
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employed in this work to determine how networks change over time, in a novel manner. One 
such method used weighted gene co-expression network analysis across the entirety of 
DrugMatrix and Open TG-GATEs to determined gene – anchoring phenotype associations.102 
Time series analysis of 3 hour through to 14 hour gene expression data identified modules 
associated bile duct hyperplasia varying over time. Whilst this does allow for co-occurance of 
histopathology observations (necrosis, inflammation and fibrosis, in this case), it uses 
modules that were created in a network covering all time points and exposures. In this work, 
networks are built on separate histopathology signatures to allow the creation (or lack 
thereof) of specific modules in case. Separating out time, dose and histopathology signatures 
allows (as performed in this work) allows for both background biology and toxicity specific 
functions to be examined directly. 
This work uses weighted gene co-expression network analysis (WGCNA) to 
determine the conservation between supervised clusters of histopathologies.  Histopathology 
observations are not considered independent of each other and so signatures created across all 
observations. These map to toxic groups that consist of compound-dose-time point 
expression profiles. It goes on to introduce a metric, W, that can be used to address the 
similarities between networks, showing where and what the biological meaning of the 
similarity occurs (step 1 in Figure 4-1). Toxicity specific and generic conserved biological 
pathways were determined and examined in a data driven manor (step 2 in Figure 4-1). This 
was then validated against TG (step 3 in Figure 4-1), to test whether the network similarity 
value, W, connects matched histopathology observations on the gene expression level, 
between databases. 
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Figure 4-1 The workflow for this study. Coexpression networks were created for six toxic 
compound groups (each of which caused identical histopathology phenotypes) based on the 
DrugMatrix data at both 1 and 5 days (12 networks in total). Their network modules were (1) 
tested to determine module conservations across time points. These were then (2) enriched 
with pathway and GO terms, allowing determination of time-independent biological 
conservation within the DrugMatrix data. The modules were (3) furthermore validated 
against two different sets of toxic groups from Open TG-GATEs (at 1 and 4 days). 
4.1 Methods 
 
The histopathology signatures, toxic groups and gene expression profiles from the 
previous chapters were used in this one also, and their determination was identical. The 1 day 
time point data has not been until this point. 
 
4.1.1 Weighted Gene Coexpression Network Analysis (WGCNA) 
 
Weighted Gene Coexpression Network Analysis (WGCNA) was performed using the 
‘wgcna’ package (version 1.66) in R.80,110 Networks were created with softpower = 10, for 
each toxic group (Groups 1-6  at 5 day, Group1 1-6 at 1day, control and TG groups) on their 
raw, RMA-adjusted gene expression values. Modules were formed in each network using 
flashClust167 and average linkage and a cut height = 0.99 for smaller modules. The remaining 
parameters were set as default. 
Module conservation was determined by permutation testing of mean densities and 
correlations, both inter- and intra- modular, of connectivity, adjacency matrices and 
eigengene values.83 30 permutations were performed, with a maximum module size of 1,000 
genes. Zsummary scores greater 10 were taken to show significant conservation, and less 
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than 2 shows no evidence of conservation.83 A module consisting of randomly selected genes 
(n=1,000) was created 30 times and the same permutation test was applied to determine the 
false discovery rate of conservation scores. It has been shown both here and previously83 that 
Zsummary score correlates linearly with modules size (Figure 4-2): the larger the module, the 
higher the chances of significant overlap. However, the median rank of the modules does not 
suffer from the same size dependency (Figure 4-2). The median rank is comparative between 
all of the modules within a network, and so is insufficient to solely determine whether a 
module is conserved or not. As such, a module can be considered significantly conserved if 
Zsummary >10 (as recommended83) and median rank < k * number of modules (to be 
determined). To determine a suitable value of k, values of k between 0 and 1 were selected at 
0.1 intervals.  
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Figure 4-2 Analysis of the effect that module size (number of genes) plays on the median rank 
(the average of the median module rank for 6 network characteristics 83) and Zsummary 
score. (a) Correlation of median rank with modules size, with associated Pearson product 
moment correlation p value. A linear relationship cannot be seen. (b) Correlation of 
Zsummary with module size, which shows a linear relationship. (c) Shows the Pearson 
product moment correlation values for all tested modules for Group 1 between median rank 
and modules size. No strong relationship can be observed. (d) Correlation between 
Zsummary and module size, showing a positive correlation across the tested values. The 
Zsummary score, therefore, is not appropriate when determining if a module is conserved 
between networks. We conclude that joint cut-offs of median rank and Zsummary score can 
be used to determine is a module is conserved between networks, as it is in this work. 
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In order to determine a suitable median rank cut off for networks with differing 
numbers of modules, the fraction of median rank is used. The total number of module 
conservations with a Zsummary score greater than 10 (the suggested significance cut off83) 
are shown in Figure 4-3. As shown, varying the median rank fraction changes the number of 
associations considered conserved. At high values (greater than 0.8), there is relatively little 
change, indicating that there are few modules with significant Zsummary scores and near the 
bottom of ranked conservations. In order to minimise false conservations, a value of 0.5 for a 
median rank cut off was selected. 
 
 
Figure 4-3 (a) the relationship between a median rank cut-off and the number of associations 
(modules defined in one network being tested in another), and (b) between median rank cut-
off and Zsummary score. All associations with high fraction value (i.e. are low in median 
rank list) represent false positives if only considering a Zsummary cut-off. Hence, in this 
analysis we chose to use a cut off of 0.5 
 
4.1.2 Network Conservation 
 
The similarity and conservation of each network, W, was calculated using the fraction of 
the conserved number of modules against all modules: 
 @	 = 	 34)#56	78	$79:56;5%	)7%4<5:=7>!<	94)#56	78	)7%4<5:  (1) 
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As each network defined a set of modules, W is therefore directed. As such, the 
similarities of each group can be treated as the nodes and W as the directed edge weight. This 
was determined and viewed in Cytoscape.168 K-medoids clustering was performed using 
ClusterMaker169 with k = 6, using W as edge value.169 Six clusters were formed, three of 
which contained “self transformations”. Self transformations are defined as toxic groups from 
1 day going to the same toxic group at 5 day (e.g. Group 1 1day -> Group 1 5 day, Table 
4-1), whereas non-self transformations occur between different group labels.  
 
Table 4-1 definitions of self transformations within DrugMatrix. 
Transformation  self transformations 
T1 Group 1 1day -> Group 1 5 day 
T2 Group 2 1day -> Group 2 5 day 
T3 Group 3 1day -> Group 3 5 day 
T4 Group 4 1day -> Group 4 5 day 
T5 Group 5 1day -> Group 5 5 day 
T6 Group 6 1day -> Group 6 5 day 
 
4.1.3 Module Enrichment and biological function overlap 
 
Gene Ontology62 terms and pathway annotations were downloaded from the Rat Genome 
Database.58 Overrepresentation analysis was performed on each module using the Fisher 
exact test from the ‘enrichr’ package170 against a background of all measured genes.170 The 
FDR (Benjamini-Hochberg) multiple hypothesis correction171 was applied on the resultant p-
value and a corrected cutoff < 0.05 determined significance.  
To determine the asymmetric biological overlap of two networks, each comparison was 
considered as a transformation (e.g. Group 1 1day data -> Group 1 5 day data). Each 
transformation had associated GO and pathway terms, defined as those enriched from the 
conserved modules. A Fisher’s Exact Test was performed in R on the overlap of these terms 
when comparing two transformations (Table 4-2). The test results were visualised using 
heatmap.2 from the ‘gplots’ package in R.172 Overlaps of enriched terms determined 
consensus toxic groups and time points, and unique terms were calculated using overlapper 
from the ‘systemPipeR’ package.173 
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Table 4-2 Confusion matrix used to calculate the significance of overlap between two 
transformations on GO and pathway term levels. The Fisher’s Exact Test, with FDR 
(Benjamini-Hochberg) corrected p value, was used to determine significance 
  Confusion matrix Terms conserved in 
Transformation-1 
Terms not conserved 
in transformation-1 
Terms conserved in 
Transformation-2 
GO/pathway terms enriched 
in both transformations  
(i.e. enriched GO terms 
from conserved modules) 
terms enriched in 
transformation-2 but 
not in transformation-1 
Terms not conserved 
in transformation-2 
terms enriched in 
transformation-1 but not in 
transformation-2 
Remaining 
GO/pathway terms 
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4.2 Results and Discussion 
 
4.2.1 Network comparison: time and histopathology signature dependence 
 
We firstly analysed the concordance of co-expression networks in order to understand the 
relative influence of time and histopathology signature. This was performed by considering a 
“network of networks”, to examine the networks relationships. Such a network consists of 
each toxic group as a node and the directed, weighted edge as the network conservation 
value, W (Figure 4-4). It can be seen that three of the six clusters (Groups 1, 3, and 4) form 
self transformation clusters. This implies that the histopathology signature which defines 
each toxic group has a greater effect on gene expression than the time at which the gene 
expression was measured. 
 
 
 
Figure 4-4 Network of networks representation. Each node represents the co-expression 
network of a toxic group at a particular time point, and GX is Group X. Edges represent the 
directed weight, W. This shows that three out of the six clusters prioritise the toxicity label, 
over the time point. Two of the six prioritise the time point and one is (Group 6 at 5 day) is 
dissimilar to all. 
To investigate this further, we next analysed the importance of “self transformations” 
in each node, going from 1 day groups to 5 day groups. These distributions are shown in 
Figure 4-5. Four of the six of these weights are in the top 75th percentile. This observation, 
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and the clustering of the networks, was somewhat unexpected but implies the significance of 
toxic group membership when compared to time point of measurement, for the 
histopathology signatures studied here. As such, the biological overlap of this conservation 
was considered to determine the time independent facets of the underlying biology and toxic 
group specific terms. 
 
Figure 4-5 the outgoing weight edge distribution for each group, at two time points. The red 
line is the weight edge for the same toxic group at a different time point. When considering 
the forward transformation (1 day to 5 day), this edge is in at least the 75th percentile of 
edges for 4 out of 6 cases. This means that there is significantly more conservation within a 
group of compounds with a shared histopathology definition across time points, than between 
compounds with distinct histopathology annotations. 
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We next analysed the biological meaning of the similarity between networks in order 
to determine which pathways are conserved in each transformation (and so which pathways 
are time/label independent). Calculated using Fisher’s Exact Test and the confusion matrix 
(Table 4-2), the results are shown in Figure 4-6. This shows the adjusted p value and that all 
transformations (except Group 2 1 day -> Group 2 5 five day (T2) GO terms) contain a 
statistically significant number of overlapping enriched terms. We conclude that the 
biological terms significantly conserved in each transformation are consistent across 
transformations. The precise values of these terms are shown in Supplementary Table 5 
 
Figure 4-6 the significance of overlapping pathway (PW; a) and GO terms (b) for the self 
transformations. The scale is represented as the -log(adjusted p value). T1 refers to 
Transformation 1 (i.e. Group 1 1day -> Group 1 5day). This shows that the pathway and GO 
terms that are significant in each transformation are statistically significant across the other 
transformations. Therefore, biological meaning in a transformation is significantly conserved 
across other transformations and so these are not label specific (the same terms are 
conserved in nearly each case). Only transformation 2 (Group 2 1 day -> Group 2 5 day) is 
not significant with the others. 
We next analysed the specific meaning of these terms, to determine their nature 
(background biology or toxicity specific). Significant pathway and GO term overlap showed 
some terms were conserved over the majority of transformations (Figure 4-7). “RNA 
transport pathway” was indeed conserved in each case. This is a regulatory pathway and only 
one of 93 associated diseases in the CTD refer to liver injury.48 “translation” and “ribosome 
biogenesis” pathways are conserved in all except one transformation, and so these support the 
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hypothesis of underlying regulatory biology being most conserved. Similarly, for metabolic 
pathways, pyrimidine metabolism, is conserved in four of six. The remaining conserved 
pathway terms are related to background cell regulation biology, but terms with smaller 
overlap (e.g. in two transformation) include toxicity specific relationships. We conclude that 
the overlapped pathways conserved in each transformation represent more basic biological 
functions. 
 
Figure 4-7 Enriched pathways which overlap in at least 3 self-transformations. This shows 
the range of pathways that are conserved in the transformations; from S Aureus to general 
‘translation pathway’ terms. This reflects the background biology which is not toxic group 
specific. The more specific terms are showed in the individual transformations 
(Supplementary Table 5) The colour represents which self transformations are included: blue 
is all transformations,  green is Groups 1, 3, 4, 5, and 6,  yellow is Groups 1, 4, 5 and 6,  red 
is Groups 1, 3 and 6, and orange is Groups 2, 3, and 5. The pathway hierarchy comes from 
the Rat Genome Database.. 
Groups 1 and 3 contain the same histopathology observations (mixed infiltration, 
lymphocytic inflammatory cell infiltration and glycogen accumulation), albeit with different 
severity scores. Their equivalent self-transformations (Group 1 1day -> Group 1 5 day, Group 
3 1day -> Group 3 5 day) both contain the aminoacyl-tRNA biosynthetic pathway 
(Supplementary Table 5). This pathway consists of 38 genes, each coding for t-RNA 
synthetases. These are vital for the metabolic processes within cells. These are connected to 
various diseases, including cancers and metabolic diseases.174 The connection between the 
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gene expression of Group 1, its defining histopathology and its relationship to cancers and 
metabolic diseases have been studied in detail.(Chapter 3) 131 Such a relationship could 
become vital in determining both the formation of histopathologies and their development to 
later stage toxicity read outs. We conclude the usefulness of this data led association, albeit 
with known relevance. 
Similar relationships, however, do not exist within other groups; Groups 5 and 6 
contain the same histopathology observations (hepatocellular necrosis, mixed infiltration, 
lymphocytic inflammatory cell infiltration and glycogen accumulation) but do not hold 
unique conserved pathways in their self-transformation. This is not easily explainable, 
however it is also not a finding in itself. From this we conclude that not all expected 
observations are shown in the gene expression data. 
GO terms reflect the same biological conservations with “translation” and “ribosomal 
large subunit biogenesis” conserved across all transformations (Supplementary Table 5). 
Additionally, “biological process” is conserved in half of the self-transformations. This 
generic term confirms that the conserved signal represents basic biology. Groups 1 and 3 
share the “liver regeneration” term, which is associated with the toxicity being considered in 
this study. These are fairly generic observations and do not add any biological meaning. 
From this, we can conclude that the method generates related pathways, but those that 
overlap in all transformations are non-specific. 
 
4.2.2 Network Validation: internal DrugMatrix 
 
We next analysed the internal validation with DrugMatrix to determine the 
significance of the pathway terms conserved in self transformations. Their significance must 
be determined otherwise their inclusion be an artefact of the data. The significance of these 
transformations were firstly determined against all non-self-transformations. 
Significance within DrugMatrix between self transformations and all other 
transformations was determined by comparing enriched GO and pathways terms that were 
conserved between conserved modules from different toxic group networks. This is 
visualised (Figure 4-8) and the relative proportion of significant terms compared (Table 4-3). 
For pathways, there is a significant difference in the proportion of conserved terms between 
self-transformations, ranging between 16-45%.  There are, therefore, a greater number of 
conserved pathways in the self transformations, adding support to the evidence that the toxic 
group definition plays a greater role in determining similarity than the time effects. From this, 
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we conclude the greater significance of histopathology signature (compared to time) in co-
expression networks. 
 
Figure 4-8 significance of overlapping pathways (a) and GO terms (b) in pairwise 
comparison of self-transformations vs all possible transformation.  This shows the relative 
importance of significant overlap between self-transformations and all possible 
transformations. There is a difference with enriched pathways, but this is not seen with GO 
terms. T1 is transformation one (Group 1 1 day -> Group 1 5 day). 
On the other hand, there is no significant difference in GO term conservations 
between transformations. This may reflect the lack of specificity and proportionately high 
number of GO terms (6,000 GO terms compared to 2,635 pathway terms). This redundancy 
in GO terms has previously been studied.175,176 This analysis does not clarify the utility of 
using co-expression networks. 
Table 4-3 the proportion of terms conserved in comparing pathway (a) and GO (b) terms. The relative number show a large difference between 
self and all transformations for Pathway terms. There is no difference between the proportion of enriched GO terms between the self and all 
transformations. This analysis shows that the self-transformations have a disproportionate percentage of enriched and conserved pathways, 
compared to all other transformations. However, the same is not see with GO terms 
 A Pathway 
 
# significant of 
overlap 
between self-
transformations 
total # self 
transformation 
Proportion 
(significant self 
transformations 
/ total number) 
# significant of 
overlap between all 
transformations 
total # all 
transformations 
Proportion 
(significant in 
all 
transformations 
/ total number) 
difference 
between 
proportions 
G1 1 day->G1 5 day 4 5 0.8 73 132 0.55 0.25 
G2 1 day->G2 5 day 2 5 0.4 22 132 0.17 0.23 
G3 1 day->G3 5 day 4 5 0.8 84 132 0.64 0.16 
G4 1 day->G4 5 day 3 5 0.6 48 132 0.36 0.24 
G5 1 day->G5 5 day 5 5 1 97 132 0.73 0.27 
G6 1 day->G6 5 day  4 5 0.8 46 132 0.35 0.45 
  
      
 B GO term 
  
# significant of 
overlap 
between self-
transformations 
total # self 
transformation 
Proportion 
(significant self 
transformations 
/ total number) 
# significant of 
overlap between all 
transformations 
total # all 
transformations 
Proportion 
(significant in 
all 
transformations 
/ total number) 
difference 
between 
proportions 
G1_1day->G1 5 day 4 5 0.8 101 132 0.77 0.03 
G2_1day->G2 5 day 0 5 0 11 132 0.08 -0.08 
G3_1day->G3 5 day 4 5 0.8 102 132 0.77 0.03 
G4_1day->G4 5 day 4 5 0.8 90 132 0.68 0.12 
G5_1day->G5 5 day 4 5 0.8 103 132 0.78 0.02 
G6_1day->G6 5 day 4 5 0.8 105 132 0.80 0.00 
 
4.2.3 Network Validation: Open TG GATEs 
 
We next investigated how well the co-expression network comparison works on 
external data, using the Open TG-GATEs database.  For any gene expression-based work, the 
practical value depends on whether the signal found can be replicated across datasets and 
databases.177 This external validation investigated three main points: total amount of 
conservation, group similarity, and comparison of similar histopathologies between 
databases. 
Firstly, 1 day networks had a higher amount of conservation with the 1 day networks 
from TG compared to the 4 day networks from Open TG-GATEs ( 
Figure 4-9). This implies that, when comparing databases, gene expression data at 1 
day is more similar to other 1 day data, at the network level. This is in line with expectations, 
as TG does not contain identical groups to those determined from DrugMatrix. 
  Secondly, there are significant similarities between Groups 5 and 6 at the 1 day stage 
( 
Figure 4-9), with conservation with identical Open TG-GATEs histopathology groups. Both 
of these are defined by ‘mixed infiltration’, ‘glycogen accumulation’, ‘necrosis’ and 
‘lymphocytic inflammatory cell infiltration’. Likewise, they are both solely conserved with 
the same 6 groups from Open TG-GATEs. These concern ‘mixed infiltration’, ‘glycogen 
deposition’, ‘fatty degeneration’ and ‘hypertrophy’. Clearly, these are related to Groups 5 and 
6 and so their conservation is expected. However, the TG group ‘necrosis’ was not 
conserved, despite it being present in Groups 5 and 6. This is unexpected but may be due to 
the Open TG-GATEs ‘necrosis’ observation occurring in insolation, compared to the 
signature of terms in the other groups. This may support the use of histopathology signatures.  
Thirdly, of all the possible histopathology groups in TG, only those similar 
observations to Groups 1-6 have any conservation ( 
Figure 4-9 and Supplementary Table 1). This is encouraging, concerning the 
concordance of gene expression data across databases in the efforts towards creating 
predictive models of later stage toxicity. 
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Figure 4-9 The network similarity value, W, for the DrugMatrix toxic groups (Groups 1-6 at 1 day) compared to Open TG-GATEs groups at 1 and 4 days. This 
crucially shows higher W for the 1 day groups (the same time point as the comparison) and the similarity on a histopathology level, determined from a co-expression 
network level. Groups 1 and 3 and Groups 5 and 6 show very similar behaviour at 1 day, reflecting their similar histopathology signature. This figure shows the co-
expression validation across databases, and that co-expression network similarity captures gene expression signal for phenotype conservation. 
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4 day Open TG-GATEs groups 
 
4.3 Conclusions 
This work determined differences in the effect that time and toxicity group definition 
have on gene expression data. Using DM, a systems level view of histopathology 
observations was used to determine histopathology signature, creating toxic groups. 
Networks built on these were compared to each other, using a novel metric based on 
conserved modules. These revealed that toxicity group membership has a more significant 
role in affecting gene expression than time point of measurement within a database. This 
encourages the development of predictive models from earlier data, modelling later stage 
data, in particular, it confirms the Sutherland et al. work that predicted later stage 
histopathology observations from earlier time point gene expression.102 This analysis also 
leads to a greater understanding about what biology is conserved, and how specific it is to 
toxicity and underlying biology for compound-induced liver injury – specially glycogen 
accumulation, cellular infiltration, hepatocellular necrosis, and fatty change. Underlying 
terms include RNA transport, ribosome biogenesis, pyrimidine metabolism and translation. 
Toxicity specific terms suggest the role that aminoacyl tRNA synthesis has in metabolic 
processes, leading to glycogen accumulation and cellular infiltration. These network methods 
were confirmed using Open TG-GATEs, whose histopathology groups matched those from 
DM. Between databases, higher levels of concordance were found for networks built on gene 
expression data from the same time. 
This work lays the groundwork for predictive modelling, by including biological 
knowledge-based information for supervised and semi-supervised methods. Additionally, it 
provides data-driven information about the precise role of tRNA in hepatoxicity and provides 
a metric for co-expression network comparisons to determine the effect of toxic group and 
time on conservation. 
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5. Conclusions 
 
In conclusion, data-driven analysis of DrugMatrix and Open TG-GATEs led to the 
creation of novel histopathology signatures which define toxic groups (Chapter 2). The gene 
expression data measured concurrently to the histopathology phenotype revealed known and 
novel gene-phenotype associations (Chapter 3). The significance of these labels was 
determined in time-series analysis where the label was shown to be more significant than the 
time point of measurement on affecting gene co-expression networks (Chapter 4). These 
conclusions are valid for the five main histopathology observations: glycogen accumulation, 
mixed infiltration, lymphocytic inflammatory cell infiltration, hepatocellular necrosis and 
fatty change. 
This work determined the concordance between these forms of data. It is, however, not 
without limitations. These include the noise within microarray platforms, dose dependency, 
and species specificity. The co-expression network methods used here (WGCNA) is 
weighted and so the relative impact of the noise is reduced. Biological noise (such as a stress 
reaction within the cell) was observed and cannot be discounted. 
A key draw back here, and more generally in gene expression data, is the requirement of 
a priori knowledge in order to understand the gene expression. Known biological pathways, 
gene – disease relationships, and gene – transcription factor associations were required to 
determine the meaning of the data driven modules that were formed here. Key genes (e.g. 
hub genes) were suggested by the methodology and do provide a hypothesis for further 
experimentation. The results presented here do not offer a direct causation or proven 
biological pathway as output. 
Dose dependency is the fundamental principle in toxicology and gene expression profiles 
of the same compound at different dose levels highly variable. As such, care must be taken 
when determining gene-phenotype associations and determining conservation between 
differing toxic groups. As was the case here where imatinib and bithionol was both present to 
two different groups each: imatinib was in group 2 (at 15 mg/kg) and group 5 (at 150 mg/kg), 
bithionol was in group 5 (at 59 mg/kg) and group 6 (at 333 mg/kg). It was shown that groups 
5 and 6 were similar at the histopathological and gene expression level. However, group 2 
was distinct from group 5 (and 6). The role of dose is clearly important. Future work with co-
expression networks could determine which modules were dose dependent and to what 
degree, in a manner similar to the timepoint dependency in Chapter 4. However, this does 
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depend on the amount of data available, as the co-expression networks are more robust and 
reliable the higher the number of gene expression profiles that the networks are built upon.  
Model species are also an obstacle in the field of toxicogenomics. This work has been 
based on rats but the manner in which a rat liver responds to compound exposure is not 
necessarily the same as the way that a human liver would respond. The same is true when 
considering the in vivo/in vitro comparison. However, an obvious extension to this work is to 
determine the network similarities and differences between gene expression from rats to rat 
and human in vitro hepatocytes.  
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7. Supplementary Information 
 
 
Supplementary Figure 1 distribution of compound similarities from ChEMBL (CH), 
DrugBank (DB), DrugMatrix (DM) and Open TG-GATEs (TG). All follow an approximate 
normal distribution. 
 
Supplementary Table 1 Full mapping between DrugMatrix and HPATH histopathology terms 
DrugMatrix Term HPATH term Term ID 
HEART_ENDOCARDIUM, CELLULAR INFILTRATE, 
MONONUCLEAR CELL 
mononuclear cell infiltrate MC_0000850 
HEART_EPICARDIUM, CELLULAR INFILTRATE, MIXED CELL mixed infiltration MC_0000008 
HEART_EPICARDIUM, CELLULAR INFILTRATE, 
MONONUCLEAR CELL 
mononuclear cell infiltrate MC_0000850 
HEART_EPICARDIUM, HYPERPLASIA hyperplasia\mesothelial\epicardium 
or pericardium 
MC_0000467 
HEART_INTERVENTRICULAR SEPTUM, CELLULAR 
INFILTRATE, MIXED CELL 
mixed infiltration MC_0000008 
HEART_INTERVENTRICULAR SEPTUM, CELLULAR 
INFILTRATE, MONONUCLEAR CELL 
mononuclear cell infiltrate MC_0000850 
HEART_INTERVENTRICULAR SEPTUM, FIBROSIS lenticular fibrosis MC_0000402 
HEART_INTERVENTRICULAR SEPTUM, MYOCYTE, 
DEGENERATION 
muscle degeneration/necrosis MC_2000691 
HEART_INTRAMYOCARDIAL ARTERIES, CELLULAR 
INFILTRATE, MIXED CELL 
mixed infiltration MC_0000008 
HEART_INTRAMYOCARDIAL ARTERIES, CELLULAR 
INFILTRATE, MONONUCLEAR CELL 
mononuclear cell 
infiltrate/fibrosis\myocardium 
MC_0000850 
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HEART_INTRAMYOCARDIAL ARTERIES, DEGENERATION cardiomyocyte degeneration MC_2000711 
HEART_INTRAMYOCARDIAL ARTERIES, NECROSIS, 
FIBRINOID 
myocardium fibrosis MC_0000935 
HEART_INTRAMYOCARDIAL ARTERIES, PERIVASCULAR 
EDEMA 
myocardium edema MC_2000713 
HEART_INTRAMYOCARDIAL ARTERIES, PERIVASCULAR 
FIBROSIS 
myocardium fibrosis MC_0000935 
HEART_INTRAMYOCARDIAL ARTERIES, TUNICA MEDIA, 
HYPERTROPHY 
cardiomyocyte hypertrophy MC_0000468 
HEART_LEFT ATRIUM, CELLULAR INFILTRATE, 
MONONUCLEAR CELL 
mononuclear cell infiltrate/fibrosis 
myocardium 
MC_0000850 
HEART_LEFT ATRIUM, FIBROSIS myocardium fibrosis MC_0000935 
HEART_LEFT ATRIUM, MYOCYTE, DEGENERATION cardiomyocyte degeneration MC_2000711 
HEART_LEFT VENTRICLE, CELLULAR INFILTRATE, MIXED 
CELL 
mixed infiltration MC_0000008 
HEART_LEFT VENTRICLE, CELLULAR INFILTRATE, 
MONONUCLEAR CELL 
mononuclear cell infiltrate/fibrosis 
myocardium 
MC_0000850 
HEART_LEFT VENTRICLE, FIBROSIS myocardium fibrosis MC_0000935 
HEART_LEFT VENTRICLE, MYOCYTE, DEGENERATION cardiomyocyte degeneration MC_2000711 
HEART_PAPILLARY MUSCLE, CELLULAR INFILTRATE, 
MIXED CELL 
mixed infiltration MC_0000008 
HEART_PAPILLARY MUSCLE, CELLULAR INFILTRATE, 
MONONUCLEAR CELL 
mononuclear cell infiltrate/fibrosis 
myocardium 
MC_0000850 
HEART_PAPILLARY MUSCLE, MYOCYTE, DEGENERATION cardiomyocyte degeneration MC_2000711 
HEART_RIGHT ATRIUM, CELLULAR INFILTRATE, MIXED 
CELL 
mixed infiltration MC_0000008 
HEART_RIGHT ATRIUM, CELLULAR INFILTRATE, 
MONONUCLEAR CELL 
mononuclear cell infiltrate/fibrosis 
myocardium 
MC_0000850 
HEART_RIGHT ATRIUM, MYOCYTE, DEGENERATION cardiomyocyte degeneration MC_2000711 
HEART_RIGHT VENTRICLE, CELLULAR INFILTRATE, MIXED 
CELL 
mixed infiltration MC_0000008 
HEART_RIGHT VENTRICLE, CELLULAR INFILTRATE, 
MONONUCLEAR CELL 
mononuclear cell infiltrate/fibrosis 
myocardium 
MC_0000850 
HEART_RIGHT VENTRICLE, FIBROSIS myocardium fibrosis MC_0000935 
HEART_RIGHT VENTRICLE, MINERALIZATION mineralization\cardiomyocyte or 
myocardium 
MC_2000715 
HEART_RIGHT VENTRICLE, MYOCYTE, DEGENERATION cardiomyocyte degeneration MC_2000711 
HEART_RIGHT VENTRICLE, MYOCYTE, LIPID 
ACCUMULATION 
cardiomyocyte vacuolation MC_0000476 
INTESTINE_EPITHELIAL ATROPHY mucosa atrophy MC_0000325 
INTESTINE_VILLUS TIP FUSION Villus fusing MC_0000356 
KIDNEY_AUTOLYSIS autolysis MC_2000081 
KIDNEY_CORTEX, CYST(S) cyst MC_2000164 
KIDNEY_CORTEX, MINERALIZATION mineralization MC_2000168 
KIDNEY_CORTEX, TUBULE, DEGENERATION tubule degeneration MC_0000867 
KIDNEY_CORTEX, TUBULE, DILATATION tubule dilation MC_0000483 
KIDNEY_CORTEX, TUBULE, INCREASED MITOSES increased mitoses MC_0000407 
KIDNEY_CORTEX, TUBULE, NECROSIS renal tubules necrosis MC_0000836 
KIDNEY_CORTEX, TUBULE, VACUOLATION tubular vacuolation MC_0000872 
KIDNEY_INFILTRATIVE CELL, POLYMORPHONUCLEAR CELL granulocytic inflammatory cell 
infiltration 
MC_2000145 
KIDNEY_INTERSTITIUM, FIBROSIS interstitial fibrosis MC_0000934 
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KIDNEY_INTERSTITIUM, INFLAMMATION, CHRONIC lymphohistioplasmacytic 
inflammation 
MC_2000159 
KIDNEY_MEDULLA, CYST(S) cyst MC_2000164 
KIDNEY_MEDULLA, MINERALIZATION mineralization MC_2000168 
KIDNEY_MEDULLA, TUBULE, DILATATION tubule dilation MC_0000483 
KIDNEY_NEPHROPATHY nephropathy MC_0000857 
KIDNEY_PAPILLA, CYST(S) cystic/papillary hyperplasia MC_0000648 
KIDNEY_PAPILLA, MINERALIZATION mineralization MC_2000168 
KIDNEY_PAPILLA, NECROSIS papillary necrosis MC_0000835 
KIDNEY_PAPILLA, TUBULE, REGENERATION tubule regeneration MC_0000988 
KIDNEY_PELVIS, DILATATION pelvis dilation MC_0000482 
KIDNEY_PELVIS, INFLAMMATION, SUBACUTE lymphocytic inflammation MC_0000011 
KIDNEY_PELVIS, UROTHELIAL HYPERPLASIA urothelium hyperplasia MC_0000822 
KIDNEY_PERIVASCULAR EDEMA pericascular inflammatory cell 
infiltrate 
MC_2000165 
KIDNEY_TUBULE, CAST, GRANULAR granular casts MC_2000487 
KIDNEY_TUBULE, CAST, PROTEINACEOUS casts MC_0000502 
KIDNEY_TUBULE, HYALINE DROPLETS hyaline droplets accumulation MC_0000503 
KIDNEY_TUBULE, REGENERATION tubule regeneration MC_0000988 
LIVER_AUTOLYSIS autolysis MC_2000081 
LIVER_BILE DUCT DILATATION ductal dilation MC_0000365 
LIVER_BILE DUCT HYPERPLASIA bile duct hyperplasia MC_0000541 
LIVER_BILE DUCT, NECROSIS, ONCOCYTIC squamous epithelium necrosis MC_0000839 
LIVER_CAPSULE, HEMORRHAGE hemorrhage MC_0000126 
LIVER_CAPSULE, INFLAMMATORY CELL INFILTRATE, 
LYMPHOID 
lymphocytic inflammatory cell 
infiltration 
MC_2000151 
LIVER_CAPSULE, INFLAMMATORY CELL INFILTRATE, 
MIXED CELL 
mixed infiltration MC_0000008 
LIVER_CAPSULE, INFLAMMATORY CELL INFILTRATE, 
NEUTROPHILIC 
neutrophil infiltration MC_2000147 
LIVER_CAPSULE, MESOTHELIAL CELL, HYPERPLASIA mesothelium hyperplasia MC_0000199 
LIVER_CAPSULE, THROMBUS thrombosis MC_2000400 
LIVER_CENTRILOBULAR FIBROSIS regeneration fibrosis MC_0000528 
LIVER_CENTRILOBULAR, INFLAMMATORY CELL 
INFILTRATE, LYMPHOID 
lymphocytic inflammatory cell 
infiltration 
MC_2000151 
LIVER_CENTRILOBULAR, INFLAMMATORY CELL 
INFILTRATE, MIXED CELL 
mixed infiltration MC_0000008 
LIVER_CENTRILOBULAR, INFLAMMATORY CELL 
INFILTRATE, NEUTROPHILIC 
neutrophil infiltration MC_2000147 
LIVER_CLEAR CELL FOCUS clear cell cellular alteration MC_0000538 
LIVER_HEPATOCYTE, CENTRILOBULAR, ATROPHY hepatocyte atrophy MC_0000532 
LIVER_HEPATOCYTE, CENTRILOBULAR, CYTOPLASM, 
EOSINOPHILIA 
cytoplasmic alteration MC_2000255 
LIVER_HEPATOCYTE, CENTRILOBULAR, DEGENERATION degeneration MC_0000101 
LIVER_HEPATOCYTE, CENTRILOBULAR, GLYCOGEN 
ACCUMULATION 
glycogen accumulation MC_0000551 
LIVER_HEPATOCYTE, CENTRILOBULAR, HYPERTROPHY hepatocyte hypertrophy MC_0000533 
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LIVER_HEPATOCYTE, CENTRILOBULAR, LIPID 
ACCUMULATION, MACROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, CENTRILOBULAR, LIPID 
ACCUMULATION, MICROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, CENTRILOBULAR, NECROSIS, 
APOPTOTIC 
zonal centrilobular necrosis MC_0000844 
LIVER_HEPATOCYTE, CENTRILOBULAR, NECROSIS, 
ONCOCYTIC 
zonal centrilobular necrosis MC_0000844 
LIVER_HEPATOCYTE, DIFFUSE, CYTOPLASM, EOSINOPHILIA cytoplasmic alteration MC_2000255 
LIVER_HEPATOCYTE, DIFFUSE, HYPERTROPHY hepatocyte hypertrophy MC_0000533 
LIVER_HEPATOCYTE, MIDZONAL, LIPID ACCUMULATION, 
MACROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, MIDZONAL, LIPID ACCUMULATION, 
MICROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, MIDZONAL, NECROSIS, APOPTOTIC zonal\midzonal necrosis MC_0000846 
LIVER_HEPATOCYTE, MIDZONAL, NECROSIS, ONCOCYTIC zonal\midzonal necrosis MC_0000846 
LIVER_HEPATOCYTE, NONZONAL, DEGENERATION degeneration MC_0000101 
LIVER_HEPATOCYTE, NONZONAL, 
ERYTHROPHAGOCYTOSIS 
erythrophagocytosis MC_0000239 
LIVER_HEPATOCYTE, NONZONAL, GLYCOGEN 
ACCUMULATION 
glycogen accumulation MC_0000551 
LIVER_HEPATOCYTE, NONZONAL, INCREASED MITOSES Increased mitoses MC_0000407 
LIVER_HEPATOCYTE, NONZONAL, LIPID ACCUMULATION, 
MACROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, NONZONAL, LIPID ACCUMULATION, 
MICROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, NONZONAL, MINERALIZATION mineralization MC_2000168 
LIVER_HEPATOCYTE, NONZONAL, MULTINUCLEATED hepatic karyocytomegaly and/or 
multinucleated hepatocytes 
MC_2000291 
LIVER_HEPATOCYTE, NONZONAL, NECROSIS, APOPTOTIC hepatocellular necrosis MC_0000831 
LIVER_HEPATOCYTE, NONZONAL, NECROSIS, ONCOCYTIC hepatocellular necrosis MC_0000831 
LIVER_HEPATOCYTE, PERIPORTAL, CYTOPLASM, 
EOSINOPHILIA 
eosinophil inflammatory cell 
infiltration 
MC_2000149 
LIVER_HEPATOCYTE, PERIPORTAL, GLYCOGEN 
ACCUMULATION 
glycogen accumulation MC_0000551 
LIVER_HEPATOCYTE, PERIPORTAL, HYPERTROPHY hepatocyte hypertrophy MC_0000533 
LIVER_HEPATOCYTE, PERIPORTAL, LIPID ACCUMULATION, 
MACROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, PERIPORTAL, LIPID ACCUMULATION, 
MICROVESICULAR 
lipidic vacuolation (fatty change) MC_0000515 
LIVER_HEPATOCYTE, PERIPORTAL, NECROSIS, APOPTOTIC zonal/periportal necrosis MC_0000847 
LIVER_HEPATOCYTE, PERIPORTAL, NECROSIS, ONCOCYTIC zonal/periportal necrosis MC_0000847 
LIVER_HEPATOCYTE, SUBCAPSULAR, MINERALIZATION mineralization MC_2000168 
LIVER_HEPATOCYTE, SUBCAPSULAR, NECROSIS, 
ONCOCYTIC 
hepatocellular necrosis MC_0000831 
LIVER_MALIGNANT LYMPHOMA malignant lymphoma MC_0000130 
LIVER_MIDZONAL, INFLAMMATORY CELL INFILTRATE, 
MIXED CELL 
mixed infiltration MC_0000008 
LIVER_NONZONAL, EXTRAMEDULLARY HEMATOPOIESIS Extramedullary hematopoiesis MC_0000082 
LIVER_NONZONAL, INFLAMMATORY CELL INFILTRATE, 
GRANULOMATOUS 
granulomatous inflammation MC_2000161 
LIVER_NONZONAL, INFLAMMATORY CELL INFILTRATE, 
LYMPHOID 
lymphocytic inflammatory cell 
infiltration 
MC_2000151 
LIVER_NONZONAL, INFLAMMATORY CELL INFILTRATE, 
MIXED CELL 
mixed infiltration MC_0000008 
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LIVER_NUCLEAR CYTOPLASMIC CONDENSATION tubular degeneration MC_0000742 
LIVER_OVAL CELL, HYPERPLASIA oval cell hyperplasia MC_0000544 
LIVER_PERIPORTAL, EDEMA edema MC_2000376 
LIVER_PERIPORTAL, FIBROSIS regeneration fibrosis MC_0000528 
LIVER_PERIPORTAL, INFLAMMATORY CELL INFILTRATE, 
LYMPHOID 
lymphocytic inflammatory cell 
infiltration 
MC_2000151 
LIVER_PERIPORTAL, INFLAMMATORY CELL INFILTRATE, 
MIXED CELL 
mixed infiltration MC_0000008 
LIVER_PERIPORTAL, INFLAMMATORY CELL INFILTRATE, 
NEUTROPHILIC 
neutrophil infiltration MC_2000147 
LIVER_PERIPORTAL, MINERALIZATION mineralization MC_2000168 
LIVER_SINGLE HEPATOCYTE NECROSIS hepatocellular necrosis MC_0000831 
LIVER_SUBCAPSULAR, FIBROSIS regeneration fibrosis MC_0000528 
LIVER_SUBCAPSULAR, INFLAMMATORY CELL INFILTRATE, 
MIXED CELL 
mixed infiltration MC_0000008 
LIVER_SUBCAPSULAR, MINERALIZATION mineralization MC_2000168 
MESENTERY_INTESTINE AUTOLYSIS autolysis MC_2000081 
MESENTERY_LYMPH NODE EDEMA edema MC_2000376 
MESENTERY_LYMPH NODE HEMORRHAGE hemorrhage MC_0000126 
MESENTERY_LYMPH NODE PROLIFERATION Lymphocyte proliferation MC_0000175 
MESENTERY_VASCULITIS vascular/perivascular inflammation MC_2000167 
SPLEEN_EXTRAMEDULLARY HEMATOPOIESIS INCREASED Extramedullary hematopoiesis MC_0000082 
SPLEEN_LYMPHOID DEPLETION lymphoid depletion MC_0000173 
THIGH MUSCLE_RIGHT BICEPS FEMORIS, MYOCYTE, 
DEGENERATION 
muscle degeneration/necrosis MC_2000691 
THIGH MUSCLE_RIGHT BICEPS FEMORIS, MYOCYTE, 
INFLAMMATION 
inflammation MC_0000010 
THIGH MUSCLE_RIGHT BICEPS FEMORIS, MYOCYTE, 
REGENERATION 
regeneration MC_0000893 
THIGH MUSCLE_RIGHT GASTROCNEMIUS, MYOCYTE, 
DEGENERATION 
muscle degeneration/necrosis MC_2000691 
THIGH MUSCLE_RIGHT GASTROCNEMIUS, MYOCYTE, 
INFLAMMATION 
inflammation MC_0000010 
THIGH MUSCLE_RIGHT GASTROCNEMIUS, MYOCYTE, 
REGENERATION 
regeneration MC_0000893 
THIGH MUSCLE_RIGHT SOLEUS, MYOCYTE, DEGENERATION muscle degeneration/necrosis MC_2000691 
THIGH MUSCLE_RIGHT SOLEUS, MYOCYTE, INFLAMMATION inflammation MC_0000010 
THIGH MUSCLE_RIGHT SOLEUS, MYOCYTE, REGENERATION regeneration MC_0000893 
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Supplementary Table 2: The compound-dose instances that make up the histopathology 
signatures from Open TG-GATEs. 
Compound Dose (mg/kg) Histopathology signature 
benziodarone 300 Increased mitosis, hypertrophy 
bendazac 300 
phenobarbital 100 
ciprofloxacin 1000 Microgranuloma 
simvastatin 120 
simvastatin 400 
ajmaline 300 
dantrolene 25 
dantrolene 75 
dantrolene 250 
acarbose 100 
acarbose 300 
etoposide 3 
nimesulide 10 
nimesulide 30 
ethanol 1200 
cyclophosphamide 1.5 
cyclophosphamide 5 
cyclophosphamide 15 
desmopressin acetate 200 
methimazole 100 hypertrophy 
flutamide 150 
chlormezanone 500 
imipramine 100 
hydroxyzine 100 
diltiazem 240 
diltiazem 800 
chlorpropamide 300 
bendazac 100 
phenacetin 1000 
ticlopidine 100 
ticlopidine 300 
nimesulide 100 
phenobarbital 30 
omeprazole 1000 
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benzbromarone 60 
benzbromarone 200 
diazepam 250 
bromobenzene 100 
bromobenzene 300 
ketoconazole 100 cytoplasmic vacuolization 
disulfiram 600 
ethionamide 100 
carbon tetrachloride 30 fatty degeneration 
carbon tetrachloride 100 fatty degeneration, cellular 
infiltration, hydropic 
degeneration 
carbon tetrachloride 300 
acetamidofluorene 30 swelling 
acetamidofluorene 100 
acetamidofluorene 300 
sulfasalazine 1000 
fluphenazine 20 necrosis 
chlormezanone 150 
ethinylestradiol 3 
methyldopa 60 
tetracycline 100 
amitriptyline 15 
ranitidine 300 
enalapril 600 
simvastatin 40 
promethazine 20 
lornoxicam 1 
etoposide 10 
ethionamide 30 
omeprazole 100 
fluoxetine hydrochloride 3 
fluoxetine hydrochloride 10 
tamoxifen 60 eosinophilic change 
bucetin 1000 
aspirin 450 
metformin 300  glycogen deposit  
metformin 1000 
valproic acid 45 cellular infiltration 
 115 
 
ethionine 25 
amiodarone 20 
amiodarone 200 
allyl alcohol 3 
carbamazepine 300 
nitrofurantoin 30 
nitrofurantoin 100 
griseofulvin 300 increased mitosis 
griseofulvin 1000 
colchicine 1.5 
benziodarone 30 
benziodarone 100 
bendazac 30 
hexachlorobenzene 30 
hexachlorobenzene 100 
hexachlorobenzene 300 
gemfibrozil 30 
gemfibrozil 100 
gemfibrozil 300 
phenylbutazone 200 
fenofibrate 100 increased mitosis, granular 
eosinophilic degeneration 
fenofibrate 1000 
WY-14643 10 
WY-14643 
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Supplementary Table 3 Enriched pathways from differentially expressed genes for each toxic group. Only significantly enriched pathways are 
shown (FDR p value > 0.05) 
TermID Number DEGs in 
pathway 
All genes in 
pathway 
p value FDR corrected 
p value 
compound and dose toxic 
group 
PW:0002106 
desmosterolosis 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0000728 statin 
pharmacodynamics 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0001586 Wolman 
disease pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0001933 
hypercholesterolemia 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0002270 
zoledronate 
pharmacodynamics 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0002177 
pamidronate 
pharmacodynamics 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0001624 
nitrogenous 
bisphosphonate 
pharmacodynamics 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
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PW:0001812 
mevalonic aciduria 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0002591 X-
linked dominant 
chondrodysplasia 
punctata 2 pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0001650 Smith-
Lemli-Opitz 
Syndrome pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0002347 
cholesterol ester 
storage disease 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0002002 
ibandronate 
pharmacodynamics 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0001838 
risedronate 
pharmacodynamics 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0002174 
alendronate 
pharmacodynamics 
pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
PW:0002439 
congenital 
hemidysplasia with 
ichthyosiform 
erythroderma and 
limb defects pathway 
8 21 1.49E-17 9.94E-16 fluvastatin 5 mg/kg Group 1 
 118 
PW:0000454 
cholesterol 
biosynthetic pathway 
8 23 3.58E-17 2.24E-15 fluvastatin 5 mg/kg Group 1 
PW:0000184 
terpenoid biosynthetic 
pathway 
4 13 8.57E-09 5.05E-07 fluvastatin 5 mg/kg Group 1 
PW:0001152 steroid 
biosynthetic pathway 
4 14 1.20E-08 6.66E-07 fluvastatin 5 mg/kg Group 1 
PW:0000069 ketone 
bodies metabolic 
pathway 
2 10 1.68E-04 8.84E-03 fluvastatin 5 mg/kg Group 1 
PW:0000834 bile acid 
transport pathway 
3 62 2.41E-04 1.21E-02 fluvastatin 5 mg/kg Group 1 
GO:0006695 
cholesterol 
biosynthetic process 
6 27 9.49E-12 1.18E-07 fluvastatin 5 mg/kg Group 1 
GO:0007584 response 
to nutrient 
6 126 1.39E-07 8.62E-04 fluvastatin 5 mg/kg Group 1 
GO:0008299 
isoprenoid 
biosynthetic process 
3 13 1.95E-06 7.81E-03 fluvastatin 5 mg/kg Group 1 
GO:0016126 sterol 
biosynthetic process 
3 15 3.09E-06 7.81E-03 fluvastatin 5 mg/kg Group 1 
GO:0010949 negative 
regulation of 
intestinal phytosterol 
absorption 
2 2 3.77E-06 7.81E-03 fluvastatin 5 mg/kg Group 1 
GO:0045796 negative 
regulation of 
2 2 3.77E-06 7.81E-03 fluvastatin 5 mg/kg Group 1 
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intestinal cholesterol 
absorption 
PW:0000375 phase I 
biotransformation 
pathway via 
cytochrome P450 
12 70 1.03E-10 1.03E-07 fluocinolone acetonide 2.5 mg/kg Group 1 
PW:0000523 linoleic 
acid metabolic 
pathway 
7 33 1.95E-07 9.76E-05 fluocinolone acetonide 2.5 mg/kg Group 1 
PW:0000054 
tryptophan metabolic 
pathway 
7 38 5.45E-07 1.82E-04 fluocinolone acetonide 2.5 mg/kg Group 1 
PW:0000141 retinol 
metabolic pathway 
8 66 2.31E-06 5.78E-04 fluocinolone acetonide 2.5 mg/kg Group 1 
PW:0000062 
ascorbate and aldarate 
metabolic pathway 
4 16 4.67E-05 9.35E-03 fluocinolone acetonide 2.5 mg/kg Group 1 
PW:0001158 alpha-
linoleic acid 
metabolic pathway 
4 17 6.04E-05 1.01E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
PW:0000460 
arachidonic acid 
metabolic pathway 
6 62 1.60E-04 2.28E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0009617 response 
to bacterium 
13 129 1.44E-08 1.79E-04 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0060700 
regulation of 
ribonuclease activity 
4 5 1.44E-07 8.94E-04 fluocinolone acetonide 2.5 mg/kg Group 1 
 120 
GO:0055114 
oxidation-reduction 
process 
21 454 5.63E-07 2.33E-03 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0006805 
xenobiotic metabolic 
process 
7 49 3.28E-06 1.02E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0006082 organic 
acid metabolic 
process 
6 35 5.66E-06 1.41E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0051412 response 
to corticosterone 
6 37 7.93E-06 1.64E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0017144 drug 
metabolic process 
5 23 1.04E-05 1.84E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0051085 
chaperone cofactor-
dependent protein 
refolding 
5 27 2.39E-05 3.71E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
GO:0016064 
immunoglobulin 
mediated immune 
response 
4 15 3.54E-05 4.89E-02 fluocinolone acetonide 2.5 mg/kg Group 1 
PW:0000040 steroid 
hormone biosynthetic 
pathway 
6 44 8.39E-07 8.40E-04 ethinylestradiol 10 mg/kg Group 1 
PW:0000523 linoleic 
acid metabolic 
pathway 
5 33 4.23E-06 2.12E-03 ethinylestradiol 10 mg/kg Group 1 
PW:0000834 bile acid 
transport pathway 
5 62 9.72E-05 3.24E-02 ethinylestradiol 10 mg/kg Group 1 
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PW:0000141 retinol 
metabolic pathway 
5 66 1.31E-04 3.24E-02 ethinylestradiol 10 mg/kg Group 1 
PW:0000375 phase I 
biotransformation 
pathway via 
cytochrome P450 
5 69 1.62E-04 3.24E-02 ethinylestradiol 10 mg/kg Group 1 
PW:0000062 
ascorbate and aldarate 
metabolic pathway 
3 16 2.11E-04 3.52E-02 ethinylestradiol 10 mg/kg Group 1 
PW:0001158 alpha-
linoleic acid 
metabolic pathway 
3 17 2.55E-04 3.64E-02 ethinylestradiol 10 mg/kg Group 1 
GO:0055114 
oxidation-reduction 
process 
20 455 1.25E-10 1.55E-06 ethinylestradiol 10 mg/kg Group 1 
PW:0000054 
tryptophan metabolic 
pathway 
4 38 4.35E-07 4.35E-04 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000062 
ascorbate and aldarate 
metabolic pathway 
3 16 2.31E-06 1.15E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000188 pentose 
and glucuronate 
interconversion 
pathway 
3 19 3.98E-06 1.33E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000077 beta-
alanine metabolic 
pathway 
3 26 1.06E-05 2.38E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000051 histidine 
metabolic pathway 
3 27 1.19E-05 2.38E-03 n nitrosodiethylamine 100 mg/kg Group 2 
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PW:0000064 
propanoate metabolic 
pathway 
3 36 2.88E-05 4.75E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000073 lysine 
degradation pathway 
3 38 3.39E-05 4.75E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000058 fatty 
acid metabolic 
pathway 
3 41 4.27E-05 4.75E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0001156 
glycerolipid 
metabolic pathway 
3 41 4.27E-05 4.75E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000043 
pyruvate metabolic 
pathway 
3 46 6.05E-05 5.50E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000071 valine, 
leucine and isoleucine 
degradation pathway 
3 46 6.05E-05 5.50E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000050 arginine 
and proline metabolic 
pathway 
3 51 8.25E-05 6.88E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000025 
glycolysis/gluconeoge
nesis pathway 
3 55 1.03E-04 7.97E-03 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000640 
glycolysis pathway 
3 61 1.41E-04 1.01E-02 n nitrosodiethylamine 100 mg/kg Group 2 
PW:0000641 
gluconeogenesis 
pathway 
3 65 1.70E-04 1.14E-02 n nitrosodiethylamine 100 mg/kg Group 2 
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PW:0000375 phase I 
biotransformation 
pathway via 
cytochrome P450 
5 69 2.11E-07 2.11E-04 pantoprazole 1100 mg/kg Group 2 
PW:0000054 
tryptophan metabolic 
pathway 
4 38 8.55E-07 4.28E-04 pantoprazole 1100 mg/kg Group 2 
PW:0000141 retinol 
metabolic pathway 
4 66 8.04E-06 2.68E-03 pantoprazole 1100 mg/kg Group 2 
PW:0000134 
glutathione metabolic 
pathway 
3 47 1.06E-04 2.64E-02 pantoprazole 1100 mg/kg Group 2 
PW:0000050 arginine 
and proline metabolic 
pathway 
3 51 1.35E-04 2.70E-02 pantoprazole 1100 mg/kg Group 2 
PW:0000460 
arachidonic acid 
metabolic pathway 
3 62 2.41E-04 4.03E-02 pantoprazole 1100 mg/kg Group 2 
GO:0055114 
oxidation-reduction 
process 
9 454 1.26E-07 1.57E-03 pantoprazole 1100 mg/kg Group 2 
GO:0098869 cellular 
oxidant detoxification 
4 63 6.67E-06 2.96E-02 pantoprazole 1100 mg/kg Group 2 
GO:0042744 
hydrogen peroxide 
catabolic process 
3 21 8.96E-06 2.96E-02 pantoprazole 1100 mg/kg Group 2 
GO:0046223 
aflatoxin catabolic 
process 
2 3 1.13E-05 2.96E-02 pantoprazole 1100 mg/kg Group 2 
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GO:0017144 drug 
metabolic process 
3 23 1.19E-05 2.96E-02 pantoprazole 1100 mg/kg Group 2 
PW:0000058 fatty 
acid metabolic 
pathway 
5 43 6.16E-09 6.17E-06 methyl salicylate 444 mg/kg Group 3 
PW:0001137 
unsaturated fatty acid 
biosynthetic pathway 
4 20 2.41E-08 1.20E-05 methyl salicylate 444 mg/kg Group 3 
PW:0000071 valine, 
leucine and isoleucine 
degradation pathway 
4 47 8.61E-07 2.87E-04 methyl salicylate 444 mg/kg Group 3 
PW:0001147 
eicosanoid signaling 
pathway via 
peroxisome 
proliferator-activated 
receptor gamma 
4 68 3.85E-06 9.62E-04 methyl salicylate 444 mg/kg Group 3 
GO:0006635 fatty 
acid beta-oxidation 
4 45 7.21E-07 8.96E-03 methyl salicylate 444 mg/kg Group 3 
GO:1902380 positive 
regulation of 
endoribonuclease 
activity 
2 2 2.48E-06 1.54E-02 methyl salicylate 444 mg/kg Group 3 
GO:0010124 
phenylacetate 
catabolic process 
2 3 7.43E-06 3.08E-02 methyl salicylate 444 mg/kg Group 3 
GO:0070370 cellular 
heat acclimation 
2 4 1.48E-05 3.69E-02 methyl salicylate 444 mg/kg Group 3 
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GO:0070434 positive 
regulation of 
nucleotide-binding 
oligomerization 
domain containing 2 
signaling pathway 
2 4 1.48E-05 3.69E-02 methyl salicylate 444 mg/kg Group 3 
GO:0097201 negative 
regulation of 
transcription from 
RNA polymerase II 
promoter in response 
to stress 
2 5 2.47E-05 4.39E-02 methyl salicylate 444 mg/kg Group 3 
GO:0090063 positive 
regulation of 
microtubule 
nucleation 
2 5 2.47E-05 4.39E-02 methyl salicylate 444 mg/kg Group 3 
PW:0001026 graft-
versus-host disease 
pathway 
3 32 7.78E-06 4.05E-03 clotrimazole 52 mg/kg Group 3 
PW:0001025 allograft 
rejection pathway 
3 34 9.37E-06 4.05E-03 clotrimazole 52 mg/kg Group 3 
PW:0001024 
autoimmune 
thyroiditis pathway 
3 37 1.21E-05 4.05E-03 clotrimazole 52 mg/kg Group 3 
PW:0000239 type 1 
diabetes mellitus 
pathway 
3 42 1.79E-05 4.47E-03 clotrimazole 52 mg/kg Group 3 
PW:0000050 arginine 
and proline metabolic 
pathway 
3 51 3.22E-05 6.44E-03 clotrimazole 52 mg/kg Group 3 
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PW:0000825 antigen 
processing and 
presentation pathway 
3 56 4.27E-05 7.12E-03 clotrimazole 52 mg/kg Group 3 
PW:0001037 
myocarditis pathway 
3 62 5.80E-05 8.29E-03 clotrimazole 52 mg/kg Group 3 
PW:0000141 retinol 
metabolic pathway 
3 66 6.99E-05 8.75E-03 clotrimazole 52 mg/kg Group 3 
PW:0000375 phase I 
biotransformation 
pathway via 
cytochrome P450 
3 69 7.99E-05 8.88E-03 clotrimazole 52 mg/kg Group 3 
PW:0000062 
ascorbate and aldarate 
metabolic pathway 
2 16 1.73E-04 1.74E-02 clotrimazole 52 mg/kg Group 3 
PW:0000188 pentose 
and glucuronate 
interconversion 
pathway 
2 19 2.46E-04 2.24E-02 clotrimazole 52 mg/kg Group 3 
PW:0001145 
phagocytosis pathway 
3 120 4.12E-04 3.43E-02 clotrimazole 52 mg/kg Group 3 
PW:0000077 beta-
alanine metabolic 
pathway 
2 26 4.66E-04 3.59E-02 clotrimazole 52 mg/kg Group 3 
PW:0000051 histidine 
metabolic pathway 
2 27 5.03E-04 3.60E-02 clotrimazole 52 mg/kg Group 3 
PW:0000834 bile acid 
transport pathway 
5 62 6.93E-05 3.86E-02 diethylstilbestrol 2 8 mg/kg Group 3 
PW:0000523 linoleic 
acid metabolic 
pathway 
4 33 7.70E-05 3.86E-02 diethylstilbestrol 2 8 mg/kg Group 3 
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PW:0000062 
ascorbate and aldarate 
metabolic pathway 
3 16 1.71E-04 4.83E-02 diethylstilbestrol 2 8 mg/kg Group 3 
PW:0001158 alpha-
linoleic acid 
metabolic pathway 
3 17 2.07E-04 4.83E-02 diethylstilbestrol 2 8 mg/kg Group 3 
PW:0000040 steroid 
hormone biosynthetic 
pathway 
4 44 2.41E-04 4.83E-02 diethylstilbestrol 2 8 mg/kg Group 3 
GO:0055114 
oxidation-reduction 
process 
16 454 8.44E-08 1.05E-03 diethylstilbestrol 2 8 mg/kg Group 3 
PW:0001670 
sarcosinemia pathway 
3 25 8.87E-07 2.22E-04 lomustine 4 2 mg/kg Group 3 
PW:0002209 
dimethylglycine 
dehydrogenase 
deficiency pathway 
3 25 8.87E-07 2.22E-04 lomustine 4 2 mg/kg Group 3 
PW:0001808 
nonketotic 
hyperglycinemia 
pathway 
3 25 8.87E-07 2.22E-04 lomustine 4 2 mg/kg Group 3 
PW:0002210 
dihydropyrimidine 
dehydrogenase 
deficiency pathway 
3 25 8.87E-07 2.22E-04 lomustine 4 2 mg/kg Group 3 
PW:0000047 glycine, 
serine and threonine 
metabolic pathway 
3 30 1.56E-06 3.13E-04 lomustine 4 2 mg/kg Group 3 
GO:0031667 response 
to nutrient levels 
4 136 2.95E-06 2.20E-02 lomustine 4 2 mg/kg Group 3 
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GO:0006564 L-serine 
biosynthetic process 
2 4 3.54E-06 2.20E-02 lomustine 4 2 mg/kg Group 3 
PW:0000375 phase I 
biotransformation 
pathway via 
cytochrome P450 
5 69 7.42E-06 7.43E-03 clonazepam 2500 mg/kg Group 3 
PW:0001565 
doxorubicin 
pharmacokinetics 
pathway 
3 17 3.82E-05 1.91E-02 clonazepam 2500 mg/kg Group 3 
PW:0000141 retinol 
metabolic pathway 
4 66 1.31E-04 4.38E-02 clonazepam 2500 mg/kg Group 3 
GO:0055114 
oxidation-reduction 
process 
15 454 1.40E-10 1.74E-06 clonazepam 2500 mg/kg Group 3 
GO:0017144 drug 
metabolic process 
4 23 1.83E-06 1.14E-02 clonazepam 2500 mg/kg Group 3 
GO:0007568 aging 9 312 3.26E-06 1.35E-02 clonazepam 2500 mg/kg Group 3 
GO:0033993 response 
to lipid 
3 37 3.97E-06 3.13E-02 carmustine 4 mg/kg Group 4 
GO:0120163 negative 
regulation of cold-
induced 
thermogenesis 
3 40 5.03E-06 3.13E-02 carmustine 4 mg/kg Group 4 
GO:0042752 
regulation of 
circadian rhythm 
4 43 1.42E-06 1.49E-02 raloxifene 650 mg/kg Group 4 
GO:0007623 
circadian rhythm 
5 113 2.48E-06 1.49E-02 raloxifene 650 mg/kg Group 4 
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GO:0032922 
circadian regulation 
of gene expression 
4 54 3.59E-06 1.49E-02 raloxifene 650 mg/kg Group 4 
PW:0001147 
eicosanoid signaling 
pathway via 
peroxisome 
proliferator-activated 
receptor gamma 
3 67 1.81E-05 1.81E-02 bis(2 ethylhexyl)phthalate 1000 
mg/kg 
Group 4 
PW:0000141 retinol 
metabolic pathway 
4 66 5.84E-06 3.49E-03 artemisinin 2000 mg/kg Group 4 
PW:0000375 phase I 
biotransformation 
pathway via 
cytochrome P450 
4 69 6.98E-06 3.49E-03 artemisinin 2000 mg/kg Group 4 
GO:0014070 response 
to organic cyclic 
compound 
8 252 9.95E-09 1.24E-04 artemisinin 2000 mg/kg Group 4 
GO:0017144 drug 
metabolic process 
3 23 9.38E-06 3.82E-02 artemisinin 2000 mg/kg Group 4 
GO:0046223 
aflatoxin catabolic 
process 
2 3 9.65E-06 3.82E-02 artemisinin 2000 mg/kg Group 4 
GO:0055114 
oxidation-reduction 
process 
7 454 1.23E-05 3.82E-02 artemisinin 2000 mg/kg Group 4 
PW:0000007 mitogen 
activated protein 
kinase signaling 
pathway 
4 245 1.19E-05 1.19E-02 olanzapine 23 mg/kg Group 5 
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PW:0001054 
influenza A pathway 
3 127 6.34E-05 3.17E-02 olanzapine 23 mg/kg Group 5 
GO:1902380 positive 
regulation of 
endoribonuclease 
activity 
2 2 3.86E-07 4.81E-03 olanzapine 23 mg/kg Group 5 
GO:0070370 cellular 
heat acclimation 
2 4 2.32E-06 8.00E-03 olanzapine 23 mg/kg Group 5 
GO:0070434 positive 
regulation of 
nucleotide-binding 
oligomerization 
domain containing 2 
signaling pathway 
2 4 2.32E-06 8.00E-03 olanzapine 23 mg/kg Group 5 
GO:0060395 SMAD 
protein signal 
transduction 
3 49 3.60E-06 8.00E-03 olanzapine 23 mg/kg Group 5 
GO:0097201 negative 
regulation of 
transcription from 
RNA polymerase II 
promoter in response 
to stress 
2 5 3.86E-06 8.00E-03 olanzapine 23 mg/kg Group 5 
GO:0090063 positive 
regulation of 
microtubule 
nucleation 
2 5 3.86E-06 8.00E-03 olanzapine 23 mg/kg Group 5 
GO:0009408 response 
to heat 
3 70 1.06E-05 1.73E-02 olanzapine 23 mg/kg Group 5 
GO:0090084 negative 
regulation of 
2 9 1.39E-05 1.73E-02 olanzapine 23 mg/kg Group 5 
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inclusion body 
assembly 
GO:1901029 negative 
regulation of 
mitochondrial outer 
membrane 
permeabilization 
involved in apoptotic 
signaling pathway 
2 9 1.39E-05 1.73E-02 olanzapine 23 mg/kg Group 5 
GO:1903265 positive 
regulation of tumor 
necrosis factor-
mediated signaling 
pathway 
2 9 1.39E-05 1.73E-02 olanzapine 23 mg/kg Group 5 
GO:0010941 
regulation of cell 
death 
2 11 2.12E-05 2.40E-02 olanzapine 23 mg/kg Group 5 
GO:0009612 response 
to mechanical 
stimulus 
3 101 3.20E-05 3.31E-02 olanzapine 23 mg/kg Group 5 
GO:0051131 
chaperone-mediated 
protein complex 
assembly 
2 14 3.50E-05 3.35E-02 olanzapine 23 mg/kg Group 5 
GO:0033120 positive 
regulation of RNA 
splicing 
2 15 4.04E-05 3.35E-02 olanzapine 23 mg/kg Group 5 
GO:0006402 mRNA 
catabolic process 
2 15 4.04E-05 3.35E-02 olanzapine 23 mg/kg Group 5 
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GO:0031396 
regulation of protein 
ubiquitination 
2 17 5.23E-05 3.42E-02 olanzapine 23 mg/kg Group 5 
GO:0034620 cellular 
response to unfolded 
protein 
2 17 5.23E-05 3.42E-02 olanzapine 23 mg/kg Group 5 
GO:1902236 negative 
regulation of 
endoplasmic 
reticulum stress-
induced intrinsic 
apoptotic signaling 
pathway 
2 17 5.23E-05 3.42E-02 olanzapine 23 mg/kg Group 5 
GO:0042026 protein 
refolding 
2 17 5.23E-05 3.42E-02 olanzapine 23 mg/kg Group 5 
GO:0035994 response 
to muscle stretch 
2 20 7.30E-05 4.32E-02 olanzapine 23 mg/kg Group 5 
GO:1901673 
regulation of mitotic 
spindle assembly 
2 20 7.30E-05 4.32E-02 olanzapine 23 mg/kg Group 5 
GO:0042744 
hydrogen peroxide 
catabolic process 
4 21 1.15E-06 1.43E-02 17 methyltestosterone 2000 mg/kg Group 5 
GO:0015671 oxygen 
transport 
3 10 6.50E-06 3.29E-02 17 methyltestosterone 2000 mg/kg Group 5 
GO:0055114 
oxidation-reduction 
process 
10 453 7.94E-06 3.29E-02 17 methyltestosterone 2000 mg/kg Group 5 
GO:1902380 positive 
regulation of 
2 2 1.48E-05 4.60E-02 17 methyltestosterone 2000 mg/kg Group 5 
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endoribonuclease 
activity 
GO:0015671 oxygen 
transport 
2 10 2.90E-06 3.60E-02 imatinib 150 mg/kg Group 5 
PW:0000375 phase I 
biotransformation 
pathway via 
cytochrome P450 
6 69 1.60E-06 1.60E-03 carbamazepine 490 mg/kg Group 5 
PW:0000054 
tryptophan metabolic 
pathway 
4 38 4.57E-05 2.29E-02 carbamazepine 490 mg/kg Group 5 
PW:0000062 
ascorbate and aldarate 
metabolic pathway 
3 16 7.48E-05 2.50E-02 carbamazepine 490 mg/kg Group 5 
PW:0000134 
glutathione metabolic 
pathway 
4 47 1.07E-04 2.67E-02 carbamazepine 490 mg/kg Group 5 
GO:0055114 
oxidation-reduction 
process 
13 454 6.03E-07 7.50E-03 carbamazepine 490 mg/kg Group 5 
PW:0000054 
tryptophan metabolic 
pathway 
3 38 1.09E-05 1.09E-02 bithionol 333 mg/kg Group 6 
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Supplementary Figure 2 shows the network conservation of modules for groups 2-6. In each 
case, DrugMatrix and Open TG-GATEs are separated. Modules which are conserved (green) 
are those of interest for pathway enrichment and biological signal deconvolution. These 
figures are analogous to Figure 3-5
Group 6 
modules 
 
Supplementary Table 4 Rat genome database (RGD) definition of the hub genes for Group 1’s modules of interest. Hub genes were quantified 
using degree.  
Module name Degree RGD definition 
darkgreen Ftcd 26 ENCODES a protein that exhibits formimidoyltetrahydrofolate cyclodeaminase activity; formimidoyltransferase activity; microtubule 
binding; INVOLVED IN cytoskeleton organization; PARTICIPATES IN folate metabolic pathway; hereditary folate malabsorption 
pathway; histidine metabolic pathway; ASSOCIATED WITH Axenfeld-Rieger syndrome type 3 (ortholog); Bethlem myopathy 
(ortholog); Burkitt lymphoma (ortholog); FOUND IN endoplasmic reticulum; endoplasmic reticulum-Golgi intermediate 
compartment; Golgi apparatus; INTERACTS WITH 1,2-dimethylhydrazine; 1-benzylpiperazine; 1-naphthyl isothiocyanate 
darkgreen Ndufa5 20 ENCODES a protein that exhibits NADH dehydrogenase (ubiquinone) activity (ortholog); INVOLVED IN mitochondrial respiratory 
chain complex I assembly (ortholog); respiratory electron transport chain (ortholog); PARTICIPATES IN Alzheimer's disease 
pathway; Huntington's disease pathway; oxidative phosphorylation pathway; ASSOCIATED WITH Facial Nerve Injuries; 
Alzheimer's disease (ortholog); pleomorphic xanthoastrocytoma (ortholog); FOUND IN mitochondrion; protein-containing complex; 
mitochondrial respiratory chain complex I (ortholog); INTERACTS WITH 17alpha-ethynylestradiol; 3,3',5-triiodo-L-thyronine; 6-
propyl-2-thiouracil 
darkgreen Smarcd2 16 INVOLVED IN chromatin remodeling (ortholog); nucleosome disassembly (ortholog); PARTICIPATES IN SWI/SNF family 
mediated chromatin remodeling pathway; ASSOCIATED WITH myeloid leukemia (ortholog); neutropenia (ortholog); Smith-
Magenis syndrome (ortholog); FOUND IN nucleoplasm (ortholog); SWI/SNF complex (ortholog); INTERACTS WITH (S)-10-
[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-
3,14(4H,12H)-DIONE; 17alpha-ethynylestradiol; 17beta-estradiol 
darkgreen Ube2k 16 ENCODES a protein that exhibits ubiquitin protein ligase binding (ortholog); ubiquitin-protein transferase activity (ortholog); 
ubiquitin-ubiquitin ligase activity (ortholog); INVOLVED IN intrinsic apoptotic signaling pathway in response to endoplasmic 
reticulum stress; cellular response to interferon-beta (ortholog); free ubiquitin chain polymerization (ortholog); PARTICIPATES IN 
ubiquitin/proteasome degradation pathway; FOUND IN cytoplasm (ortholog); filopodium tip (ortholog); nucleus (ortholog); 
INTERACTS WITH 2,4-dinitrotoluene; 2,6-dinitrotoluene; bisphenol A 
darkgreen Ass1 11 ENCODES a protein that exhibits argininosuccinate synthase activity; toxic substance binding; amino acid binding (ortholog); 
INVOLVED IN acute-phase response; aging; arginine biosynthetic process; PARTICIPATES IN urea cycle pathway; AGAT 
deficiency pathway; arginine and proline metabolic pathway; ASSOCIATED WITH Acute-Phase Reaction; Diabetes Mellitus, 
Experimental ; Drug Toxicity; FOUND IN cell body fiber; cytoplasm; endoplasmic reticulum; INTERACTS WITH (S)-10-
[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-
3,14(4H,12H)-DIONE; 17alpha-ethynylestradiol; 2,2,2-tetramine 
cyan Cxcl2 12 ENCODES a protein that exhibits chemokine activity; INVOLVED IN cellular response to interleukin-1; cellular response to 
lipopolysaccharide; leukocyte chemotaxis; PARTICIPATES IN chemokine mediated signaling pathway; cytokine mediated signaling 
pathway; NOD-like receptor signaling pathway; ASSOCIATED WITH Acute Lung Injury; Acute Necrotizing Pancreatitis; Alcoholic 
Liver Diseases; FOUND IN extracellular space; INTERACTS WITH (+)-alpha-tocopherol; (S)-10-
[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-
3,14(4H,12H)-DIONE; 1,2,4-trimethylbenzene 
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cyan Il10 11 ENCODES a protein that exhibits interleukin-10 receptor binding; cytokine activity (ortholog); INVOLVED IN aging; cellular 
response to estradiol stimulus; immune response; PARTICIPATES IN Interleukin-10 signaling pathway; interleukin-4 signaling 
pathway; allograft rejection pathway; ASSOCIATED WITH Acute Lung Injury; adult respiratory distress syndrome; Alveolar Bone 
Loss; FOUND IN extracellular space; INTERACTS WITH (+)-alpha-tocopherol; (+)-pilocarpine; (-)-epigallocatechin 3-gallate 
cyan Nr4a2 8 ENCODES a protein that exhibits proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific; 
RNA polymerase II proximal promoter sequence-specific DNA binding; sequence-specific DNA binding; INVOLVED IN positive 
regulation of transcription by RNA polymerase II; response to inorganic substance; response to insecticide; PARTICIPATES IN 
Parkinson's disease pathway; ASSOCIATED WITH Arsenic Poisoning (ortholog); autism spectrum disorder (ortholog); autistic 
disorder (ortholog); FOUND IN cytoplasm; nucleus; nuclear speck (ortholog); INTERACTS WITH 1,2,4-trimethylbenzene; 3,7-
dihydropurine-6-thione; 6-propyl-2-thiouracil 
cyan Dusp2 5 ENCODES a protein that exhibits mitogen-activated protein kinase binding (ortholog); phosphoprotein phosphatase activity 
(ortholog); INVOLVED IN protein dephosphorylation (ortholog); PARTICIPATES IN mitogen activated protein kinase signaling 
pathway; ASSOCIATED WITH juvenile rheumatoid arthritis (ortholog); schizophrenia (ortholog); FOUND IN nuclear membrane 
(ortholog); nucleus (ortholog); INTERACTS WITH (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-
PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; 6-propyl-2-thiouracil; acrylamide 
cyan Il1r2 5 ENCODES a protein that exhibits interleukin-1 binding (ortholog); interleukin-1 receptor activity (ortholog); INVOLVED IN 
negative regulation of cytokine production involved in inflammatory response (ortholog); negative regulation of interleukin-1 alpha 
secretion (ortholog); negative regulation of interleukin-1-mediated signaling pathway (ortholog); PARTICIPATES IN interleukin-1 
signaling pathway; cytokine mediated signaling pathway; Entamoebiasis pathway; ASSOCIATED WITH aggressive periodontitis 
(ortholog); allergic hypersensitivity disease (ortholog); ankylosing spondylitis (ortholog); FOUND IN cytoplasm (ortholog); 
INTERACTS WITH (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-
PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; 1-benzylpiperazine; 2-amino-2-deoxy-D-
glucopyranose 
lightgreen Pcyt1a 52 ENCODES a protein that exhibits calmodulin binding; choline-phosphate cytidylyltransferase activity; lipid binding; INVOLVED IN 
CDP-choline pathway; phosphatidylcholine biosynthetic process; PARTICIPATES IN glycerophospholipid metabolic pathway; 
lamivudine pharmacokinetics pathway; ASSOCIATED WITH Chemical and Drug Induced Liver Injury (ortholog); genetic disease 
(ortholog); schizophrenia (ortholog); FOUND IN cytoplasm; endoplasmic reticulum; nuclear envelope; INTERACTS WITH (R)-
mevalonic acid; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-
B]-QUINOLINE-3,14(4H,12H)-DIONE; 2,4-dinitrotoluene 
lightgreen Map1lc3b 51 ENCODES a protein that exhibits microtubule binding; protein domain specific binding; tubulin binding; INVOLVED IN positive 
regulation of protein binding; autophagosome maturation (ortholog); autophagy (ortholog); PARTICIPATES IN autophagy pathway; 
ASSOCIATED WITH Myocardial Ischemia; 16Q24.3 Microdeletion Syndrome (ortholog); Chemical and Drug Induced Liver Injury 
(ortholog); FOUND IN autophagosome membrane; axon; cytoplasm; INTERACTS WITH 2,2',5,5'-tetrachlorobiphenyl; 2,3,7,8-
tetrachlorodibenzodioxine; 3-methyladenine 
lightgreen Rhbdd2 51 ENCODES a protein that exhibits serine-type endopeptidase activity (inferred); INVOLVED IN proteolysis (inferred); 
ASSOCIATED WITH pleomorphic xanthoastrocytoma (ortholog); FOUND IN Golgi apparatus (ortholog); Golgi membrane 
(ortholog); nucleoplasm (ortholog); INTERACTS WITH 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-
B:2',3'-E][1,4]DIAZEPIN-6-ONE; 2,3,7,8-tetrachlorodibenzodioxine; bisphenol A 
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lightgreen Fkbp5 49 ENCODES a protein that exhibits heat shock protein binding (ortholog); peptidyl-prolyl cis-trans isomerase activity (ortholog); 
INVOLVED IN chaperone-mediated protein folding (ortholog); response to bacterium (ortholog); PARTICIPATES IN aldosterone 
signaling pathway; cortisol signaling pathway; ASSOCIATED WITH endogenous depression (ortholog); endometriosis (ortholog); 
Infant, Newborn, Diseases (ortholog); FOUND IN nucleoplasm (ortholog); INTERACTS WITH (S)-10-
[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-
3,14(4H,12H)-DIONE; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 
2,3,7,8-tetrachlorodibenzodioxine 
lightgreen Tmem38b 44 ENCODES a protein that exhibits potassium channel activity (inferred); INVOLVED IN potassium ion transmembrane transport 
(inferred); ASSOCIATED WITH Chemical and Drug Induced Liver Injury (ortholog); osteogenesis imperfecta type 14 (ortholog); 
schizophrenia (ortholog); FOUND IN endoplasmic reticulum membrane (inferred); integral component of membrane (inferred); 
INTERACTS WITH 1,3-dinitrobenzene; 2,3,7,8-tetrachlorodibenzodioxine; acrylamide 
Brown Orc4 15 ENCODES a protein that exhibits DNA replication origin binding (ortholog); nucleotide binding (ortholog); INVOLVED IN DNA 
replication initiation (ortholog); ASSOCIATED WITH autosomal dominant non-syndromic intellectual disability 1 (ortholog); Meier-
Gorlin syndrome (ortholog); schizophrenia (ortholog); FOUND IN cytosol (ortholog); nuclear chromosome, telomeric region 
(ortholog); nuclear origin of replication recognition complex (ortholog); INTERACTS WITH 2,4-dinitrotoluene; 2,6-dinitrotoluene; 
bis(2-ethylhexyl) phthalate 
Brown Atp6v1h 11 ENCODES a protein that exhibits proton-transporting ATPase activity, rotational mechanism (inferred); INVOLVED IN endocytosis 
(ortholog); PARTICIPATES IN oxidative phosphorylation pathway; phagocytosis pathway; rheumatoid arthritis pathway; FOUND 
IN vacuolar proton-transporting V-type ATPase, V1 domain (inferred); INTERACTS WITH bisphenol A; cadmium dichloride; 
flutamide 
Brown Tbc1d15 10 ENCODES a protein that exhibits GTPase activator activity (ortholog); INVOLVED IN regulation of GTPase activity (ortholog); 
FOUND IN cytoplasm (ortholog); extracellular region (ortholog); INTERACTS WITH bisphenol A; cobalt dichloride; flutamide 
Brown Slc25a17 9 ENCODES a protein that exhibits ADP transmembrane transporter activity (ortholog); AMP transmembrane transporter activity 
(ortholog); ATP transmembrane transporter activity (ortholog); INVOLVED IN ATP transport (ortholog); fatty acid beta-oxidation 
(ortholog); fatty acid transport (ortholog); FOUND IN integral component of peroxisomal membrane (ortholog); peroxisomal 
membrane (ortholog); peroxisome (ortholog); INTERACTS WITH 2,6-dinitrotoluene; bisphenol A; buspirone 
Brown Lamtor3 8 ENCODES a protein that exhibits guanyl-nucleotide exchange factor activity (ortholog); kinase activator activity (ortholog); protein-
containing complex scaffold activity (ortholog); INVOLVED IN activation of MAPKK activity (ortholog); cellular protein 
localization (ortholog); cellular response to amino acid stimulus (ortholog); PARTICIPATES IN mTOR signaling pathway; FOUND 
IN late endosome (ortholog); Ragulator complex (ortholog); INTERACTS WITH 2,6-dinitrotoluene; dibutyl phthalate; flutamide 
magenta Rpl17 51 ENCODES a protein that exhibits large ribosomal subunit rRNA binding; INVOLVED IN cellular response to amino acid starvation; 
positive regulation of G1/S transition of mitotic cell cycle; response to amino acid starvation; PARTICIPATES IN ribosome 
biogenesis pathway; translation pathway; ASSOCIATED WITH Myocardial Ischemia (ortholog); FOUND IN A band; cytosolic large 
ribosomal subunit; nucleus; INTERACTS WITH 2,4-dinitrotoluene; 2,6-dinitrotoluene; 2-nitrofluorene 
magenta Rpl15 50 INVOLVED IN response to ethanol; PARTICIPATES IN ribosome biogenesis pathway; translation pathway; ASSOCIATED WITH 
Diamond-Blackfan anemia (ortholog); Diamond-Blackfan Anemia 12 (ortholog); Disease Progression (ortholog); FOUND IN A 
band; cytosolic large ribosomal subunit; nucleus (ortholog); INTERACTS WITH 17alpha-ethynylestradiol; 2,4-dinitrotoluene; 2,6-
dinitrotoluene 
 140 
magenta Rpl5 46 ENCODES a protein that exhibits 5S rRNA binding; mRNA binding; mRNA 3'-UTR binding (ortholog); INVOLVED IN cellular 
response to inorganic substance; positive regulation of isoleucine-tRNA ligase activity; positive regulation of methionine-tRNA ligase 
activity; PARTICIPATES IN ribosome biogenesis pathway; translation pathway; ASSOCIATED WITH aplastic anemia (ortholog); 
Diamond-Blackfan anemia (ortholog); Diamond-Blackfan Anemia 6 (ortholog); FOUND IN aminoacyl-tRNA synthetase 
multienzyme complex; cytosolic large ribosomal subunit; cytosolic ribosome; INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-
tetrachlorodibenzodioxine; ammonium chloride 
magenta Rps12 44 ENCODES a protein that exhibits structural constituent of ribosome (inferred); INVOLVED IN response to organonitrogen 
compound; PARTICIPATES IN ribosome biogenesis pathway; translation pathway; ASSOCIATED WITH Hypertriglyceridemia; 
FOUND IN cytosolic large ribosomal subunit; cytosolic small ribosomal subunit; cytosol (ortholog); INTERACTS WITH 2,6-
dinitrotoluene; 3H-1,2-dithiole-3-thione; ammonium chloride 
magenta Rps8 39 INVOLVED IN translation (inferred); PARTICIPATES IN ribosome biogenesis pathway; translation pathway; ASSOCIATED WITH 
Breast Neoplasms (ortholog); Charcot-Marie-Tooth disease dominant intermediate C (ortholog); Parkinson's disease (ortholog); 
FOUND IN cytosolic small ribosomal subunit; cytosol (ortholog); endoplasmic reticulum (ortholog); INTERACTS WITH 1,1,1-
Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1-naphthyl isothiocyanate; 17alpha-ethynylestradiol 
yellow Cdk1 56 ENCODES a protein that exhibits cyclin binding; cyclin-dependent protein serine/threonine kinase activity; histone kinase activity; 
INVOLVED IN animal organ regeneration; cell aging; cellular response to hydrogen peroxide; PARTICIPATES IN cell cycle 
pathway, mitotic; G1/S transition pathway; G2/M checkpoint pathway; ASSOCIATED WITH hepatocellular carcinoma; Spinal Cord 
Injuries; Thyroid Neoplasms; FOUND IN cytoplasm; nucleus; centrosome (ortholog); INTERACTS WITH (+)-catechin; (+)-
pilocarpine; (R)-mevalonic acid 
yellow Nusap1 56 ENCODES a protein that exhibits microtubule binding (ortholog); INVOLVED IN establishment of mitotic spindle localization 
(ortholog); mitotic chromosome condensation (ortholog); mitotic cytokinesis (ortholog); ASSOCIATED WITH Colorectal Neoplasms 
(ortholog); FOUND IN nucleolus (ortholog); spindle microtubule (ortholog); INTERACTS WITH (S)-10-
[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-
3,14(4H,12H)-DIONE; 2,3,7,8-tetrachlorodibenzodioxine; 2-acetamidofluorene 
yellow Spc25 53 INVOLVED IN chromosome segregation (ortholog); mitotic spindle organization (ortholog); FOUND IN condensed chromosome 
kinetochore (ortholog); cytosol (ortholog); Ndc80 complex (ortholog); INTERACTS WITH (S)-10-
[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-
3,14(4H,12H)-DIONE; 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine 
yellow Ube2c 52 ENCODES a protein that exhibits ubiquitin conjugating enzyme activity (ortholog); ubiquitin-like protein ligase binding (ortholog); 
ubiquitin-protein transferase activity (ortholog); INVOLVED IN anaphase-promoting complex-dependent catabolic process 
(ortholog); exit from mitosis (ortholog); free ubiquitin chain polymerization (ortholog); PARTICIPATES IN ubiquitin/proteasome 
degradation pathway; ASSOCIATED WITH Breast Neoplasms (ortholog); Chromosome Aberrations (ortholog); FOUND IN 
anaphase-promoting complex (ortholog); cytosol (ortholog); plasma membrane (ortholog); INTERACTS WITH (S)-10-
[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-
3,14(4H,12H)-DIONE; 1,3-dinitrobenzene; 2,3,7,8-tetrachlorodibenzodioxine 
yellow Ccnb1 49 ENCODES a protein that exhibits histone kinase activity; protein kinase binding; protein-containing complex binding; INVOLVED 
IN cellular response to fatty acid; cellular response to hypoxia; cellular response to iron(III) ion; PARTICIPATES IN cell cycle 
pathway, mitotic; G1/S transition pathway; G2/M checkpoint pathway; ASSOCIATED WITH Diabetes Mellitus, Experimental ; 
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Experimental Liver Neoplasms; Hyperplasia; FOUND IN cytoplasm; nucleus; centrosome (ortholog); INTERACTS WITH (-)-
citrinin; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-
QUINOLINE-3,14(4H,12H)-DIONE; 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane 
turquoise Relt 132 INVOLVED IN apoptotic process (ortholog); PARTICIPATES IN cytokine mediated signaling pathway; FOUND IN nucleus 
(ortholog); INTERACTS WITH 6-propyl-2-thiouracil; acrylamide; bisphenol A 
turquoise RGD1312005 109 #N/A 
turquoise Cnksr1 95 ENCODES a protein that exhibits protein binding, bridging (ortholog); INVOLVED IN Ras protein signal transduction (ortholog); 
Rho protein signal transduction (ortholog); PARTICIPATES IN angiotensin II signaling pathway via AT2 receptor; interleukin-3 
signaling pathway; ASSOCIATED WITH intellectual disability (ortholog); FOUND IN cell cortex (ortholog); INTERACTS WITH 
2,3,7,8-tetrachlorodibenzodioxine; 3-chloropropane-1,2-diol; 6-propyl-2-thiouracil 
turquoise Epb41l4a 51 ASSOCIATED WITH Failure to Thrive (ortholog); Hereditary Neoplastic Syndromes (ortholog); FOUND IN cytoskeleton (inferred); 
INTERACTS WITH aflatoxin B1; all-trans-retinoic acid; bisphenol A 
turquoise LOC56764 49 #N/A 
Supplementary Table 5:Enriched pathway and GO terms for each transformation and their 
overlap. All gene sets are significantly enriched with an FDR-adjusted p value < 0.05. 
                         Pathways                                                                   GO terms  
G1_1day->G1 
PW:0000015 Alzheimer's disease 
pathway 
GO:0000082 G1/S transition of mitotic cell cycle 
PW:0000017 Huntington's disease 
pathway 
GO:0006099 tricarboxylic acid cycle 
PW:0000018 Parkinson's disease 
pathway 
GO:0006103 2-oxoglutarate metabolic process 
PW:0000025 
glycolysis/gluconeogenesis pathway 
GO:0006260 DNA replication 
PW:0000026 citric acid cycle pathway GO:0006261 DNA-dependent DNA replication 
PW:0000034 electron transport chain 
pathway 
GO:0006270 DNA replication initiation 
PW:0000045 pentose phosphate 
pathway 
GO:0009060 aerobic respiration 
PW:0000398 homocysteine metabolic 
pathway 
GO:0009615 response to virus 
PW:0000640 glycolysis pathway GO:0009617 response to bacterium 
PW:0000641 gluconeogenesis 
pathway 
GO:0022900 electron transport chain 
PW:0000662 mismatch repair 
pathway 
GO:0032981 mitochondrial respiratory chain 
complex I assembly 
PW:0000718 p53 signaling pathway GO:0035458 cellular response to interferon-beta 
PW:0000817 NOD-like receptor 
signaling pathway 
GO:0045071 negative regulation of viral genome 
replication 
PW:0001059 oxidative 
phosphorylation pathway 
GO:0051321 meiotic cell cycle 
PW:0001078 cysteine and methionine 
metabolic pathway 
GO:0051607 defense response to virus 
PW:0001610 tyrosinemia type III 
pathway 
GO:2000059 negative regulation of ubiquitin-
dependent protein catabolic process 
PW:0001628 triosephosphate isomerase deficiency pathway 
PW:0001754 pyruvate dehydrogenase E2 deficiency pathway 
PW:0001755 pyruvate dehydrogenase E3 deficiency pathway 
PW:0001814 mitochondrial complex II deficiency pathway 
PW:0001992 glycogen storage disease  type Ia pathway 
PW:0001993 glycogen storage disease type Ib pathway 
PW:0002098 fumaric aciduria pathway 
PW:0002100 fructose-1,6-bisphosphatase deficiency pathway 
PW:0002617 phosphoenolpyruvate carboxykinase deficiency pathway   
G2_1day->G2 
PW:0000180 mTOR signaling 
pathway 
GO:0006955 immune response 
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G3_1day->G3 
PW:0000019 prion disease pathway GO:0001732 formation of cytoplasmic translation 
initiation complex 
PW:0000126 RNA polymerase I 
transcription pathway 
GO:0006749 glutathione metabolic process 
PW:0000134 glutathione metabolic 
pathway 
GO:0006954 inflammatory response 
PW:0000829 chemokine mediated 
signaling pathway 
GO:0007166 cell surface receptor signaling 
pathway 
PW:0001023 systemic lupus 
erythematosus pathway 
GO:0030593 neutrophil chemotaxis 
PW:0001146 Fc gamma receptor 
mediated signaling pathway 
GO:0042102 positive regulation of T cell 
proliferation  
GO:0042176 regulation of protein catabolic 
process  
GO:0042254 ribosome biogenesis  
GO:0042535 positive regulation of tumor necrosis 
factor biosynthetic process  
GO:0045454 cell redox homeostasis  
GO:0045727 positive regulation of translation  
GO:0045899 positive regulation of RNA 
polymerase II transcriptional preinitiation 
complex assembly  
GO:0050790 regulation of catalytic activity  
GO:0071222 cellular response to 
lipopolysaccharide  
GO:0071346 cellular response to interferon-
gamma  
GO:1901800 positive regulation of proteasomal 
protein catabolic process  
GO:2000249 regulation of actin cytoskeleton 
reorganization  
GO:2000406 positive regulation of T cell 
migration   
G4_1day->G4 
PW:0000127 RNA polymerase II 
transcription pathway 
GO:0000387 spliceosomal snRNP assembly 
PW:0000129 base excision repair 
pathway 
GO:0006606 protein import into nucleus 
PW:0000202 homologous 
recombination pathway of double-
strand break repair 
GO:0006913 nucleocytoplasmic transport 
PW:0001151 Fc epsilon receptor mediated signaling pathway 
PW:0001587 mRNA nuclear export pathway 
PW:0001626 CRM1 export pathway 
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G5_1day->G5 
PW:0000050 arginine and proline 
metabolic pathway 
GO:0006468 protein phosphorylation 
PW:0000088 G1/S transition pathway GO:0007019 microtubule depolymerization 
PW:0000214 polyamine metabolic 
pathway 
GO:0007080 mitotic metaphase plate congression 
PW:0000373 glutathione conjugation 
pathway 
GO:0007088 regulation of mitotic nuclear 
division 
PW:0000528 angiotensin II signaling 
pathway via AT2 receptor 
GO:0032465 regulation of cytokinesis 
PW:0000638 Endoplasmic Reticulum-
associated degradation pathway 
GO:0032467 positive regulation of cytokinesis 
  
G6_1day->G6 
PW:0000008 Wnt signaling pathway GO:0006360 transcription by RNA polymerase I 
PW:0000862 de novo pyrimidine 
biosynthetic pathway 
GO:0007030 Golgi organization 
PW:0001406 SWI/SNF family mediated chromatin remodeling pathway 
PW:0001944 mercaptopurine pharmacodynamics pathway 
PW:0002203 azathioprine pharmacodynamics pathway 
PW:0002394 tioguanine pharmacodynamics pathway   
G1_1day->G1 + G3_1day->G3 
PW:0001159 aminoacyl-tRNA 
biosynthetic pathway 
GO:0097421 liver regeneration 
  
G1_1day->G1 + G4_1day->G4 
PW:0000098 DNA replication 
pathway 
GO:0071897 DNA biosynthetic process 
PW:0000130 nucleotide excision repair pathway   
G1_1day->G1 + G5_1day->G5 
PW:0000086 cell cycle pathway, 
mitotic 
GO:0000070 mitotic sister chromatid segregation 
PW:0000759 gemcitabine 
pharmacokinetics pathway 
GO:0000278 mitotic cell cycle 
PW:0000760 gemcitabine 
pharmacodynamics pathway 
GO:0000281 mitotic cytokinesis 
 
GO:0006281 DNA repair  
GO:0007018 microtubule-based movement  
GO:0007051 spindle organization  
GO:0007052 mitotic spindle organization  
GO:0007059 chromosome segregation  
GO:0007094 mitotic spindle assembly checkpoint 
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GO:0008283 cell proliferation  
GO:0051301 cell division   
G1_1day->G1 + G6_1day->G6 
PW:0000048 methionine 
cycle/metabolic pathway 
GO:0000462 maturation of SSU-rRNA from 
tricistronic rRNA transcript (SSU-rRNA, 5.8S 
rRNA, LSU-rRNA) 
PW:0001073 spliceosome pathway   
G3_1day->G3 + G5_1day->G5 
PW:0000144 ubiquitin/proteasome 
degradation pathway 
GO:0010498 proteasomal protein catabolic 
process 
PW:0000375 phase I 
biotransformation pathway via 
cytochrome P450 
GO:0010499 proteasomal ubiquitin-independent 
protein catabolic process 
PW:0000474 coagulation cascade 
pathway 
GO:0043161 proteasome-mediated ubiquitin-
dependent protein catabolic process 
PW:0000502 complement system pathway   
G3_1day->G3 + G6_1day->G6  
GO:0006413 translational initiation   
G4_1day->G4 + G6_1day->G6 
PW:0000031 purine metabolic pathway 
PW:0000867 de novo purine biosynthetic pathway 
PW:0001590 xanthinuria pathway 
PW:0001591 xanthinuria  type I pathway 
PW:0001592 xanthinuria type II pathway 
PW:0001777 purine nucleoside phosphorylase deficiency pathway 
PW:0001779 adenosine monophosphate deaminase deficiency pathway 
PW:0001817 molybdenum cofactor deficiency pathway 
PW:0001879 Lesch-Nyhan syndrome pathway 
PW:0001938 Kelley-Seegmiller syndrome pathway 
PW:0002137 presequence pathway of mitochondrial protein import 
PW:0002140 beta-barrel pathway of mitochondrial protein import 
PW:0002276 adenylosuccinate lyase deficiency pathway 
PW:0002294 AICA-ribosuria pathway 
PW:0002566 adenine phoshoribosyltransferase deficiency pathway   
G1_1day->G1 + G3_1day->G3 + G5_1day->G5  
GO:0000028 ribosomal small subunit assembly  
GO:0002181 cytoplasmic translation  
GO:0042274 ribosomal small subunit biogenesis 
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GO:0045087 innate immune response   
  
G1_1day->G1 + G3_1day->G3 + G6_1day->G6 
PW:0000580 translation initiation 
pathway 
GO:0000463 maturation of LSU-rRNA from 
tricistronic rRNA transcript (SSU-rRNA, 5.8S 
rRNA, LSU-rRNA)   
G2_1day->G2 + G3_1day->G3 + G5_1day->G5 
PW:0001045 Staphylococcus aureus infection pathway   
G1_1day->G1 + G3_1day->G3 + G4_1day->G4 + G6_1day->G6  
GO:0008150 biological_process   
G1_1day->G1 + G3_1day->G3 + G5_1day->G5 + G6_1day->G6  
GO:0000027 ribosomal large subunit assembly  
GO:0006364 rRNA processing   
G1_1day->G1 + G4_1day->G4 + G5_1day->G5 + G6_1day->G6 
PW:0000032 pyrimidine metabolic pathway   
G1_1day->G1 + G3_1day->G3 + G4_1day->G4 + G5_1day->G5 + G6_1day->G6 
PW:0000101 translation pathway GO:0006412 translation 
PW:0001066 ribosome biogenesis 
pathway 
GO:0042273 ribosomal large subunit biogenesis 
  
G1_1day->G1 + G2_1day->G2 + G3_1day->G3 + G4_1day->G4 + G5_1day->G5 + 
G6_1day->G6 
PW:0001160 RNA transport pathway 
 
